Cell-associated secretion-enhancing fusion proteins
11390899 · 2022-07-19
Assignee
Inventors
Cpc classification
C07K2319/35
CHEMISTRY; METALLURGY
C07K14/705
CHEMISTRY; METALLURGY
C07K2317/14
CHEMISTRY; METALLURGY
A61K48/00
HUMAN NECESSITIES
C07K2319/30
CHEMISTRY; METALLURGY
C07K16/00
CHEMISTRY; METALLURGY
C07K2319/70
CHEMISTRY; METALLURGY
C07K14/755
CHEMISTRY; METALLURGY
C07K16/22
CHEMISTRY; METALLURGY
C07K14/70575
CHEMISTRY; METALLURGY
C12N2710/16622
CHEMISTRY; METALLURGY
C07K14/7151
CHEMISTRY; METALLURGY
International classification
C07K14/00
CHEMISTRY; METALLURGY
C07K16/00
CHEMISTRY; METALLURGY
C07K16/24
CHEMISTRY; METALLURGY
C07K16/22
CHEMISTRY; METALLURGY
C07K14/755
CHEMISTRY; METALLURGY
C07K14/715
CHEMISTRY; METALLURGY
C12P21/02
CHEMISTRY; METALLURGY
Abstract
Cell-associated secretion-enhancing fusion proteins are disclosed that comprise a target protein binding domain and a transmembrane retention domain. Co-expression in a host cell of a fusion protein and a target protein of interest that is temporarily bound by the fusion protein leads to an increased level of target protein secreted from the host cell. The fusion proteins are engineered to be retained with the producing host cell, thus eliminating a non-natural component from the extracellular media of the host cell and simplifying purification of the target protein. Nucleic acid molecules encoding such fusion proteins are also disclosed for use in expressing the fusion proteins in host cells, for use in restoring lost or diminished cell functions, and for use in treating diseases characterized by a lost or diminished cell function. Methods and compositions comprising fusion proteins of the invention are disclosed for use in enhancing the level of co-expressed target proteins secreted from host cells.
Claims
1. A cell-associated, secretion-enhancing (CASE) fusion protein comprising: (a) a target protein binding (TPB) domain, (b) a transmembrane retention (TMR) domain, and (c) optionally, a chaperone machinery peptide (CMP) domain; wherein co-expression in a host cell in culture of the CASE fusion protein and a target protein enhances the level of target protein secreted from the host cell in the culture media as compared to the level of target protein secreted from a host cell expressing the target protein in the absence of the CASE fusion protein.
2. The CASE fusion protein of claim 1, wherein the TPB domain comprises a polypeptide that binds a target protein of interest, wherein the polypeptide is selected from the group consisting of: an antibody, an antigen-binding fragment of an antibody, an antibody binding region of an antibody-binding protein, a polypeptide ligand of a receptor protein, a ligand-binding domain of a receptor protein, a polypeptide antigen, a polypeptide epitope, and a PDZ domain.
3. The CASE fusion protein of claim 1, wherein the TPB domain is an antigen-binding fragment of an antibody.
4. The CASE fusion protein of claim 1, wherein the TPB domain is a polypeptide that binds to an antibody.
5. The CASE fusion protein of claim 4, wherein the polypeptide comprises an antibody binding region of Protein L.
6. The CASE fusion protein of claim 1, wherein the TPB domain comprises a polypeptide that binds to an Fc region.
7. The CASE fusion protein of claim 6, wherein the polypeptide is an Fc-binding portion of a protein selected from the group consisting of: Protein A, Protein G, glycoprotein E, FcB6, GB919, and hFcR.
8. The CASE fusion protein of claim 1, wherein the TPB domain comprises a polypeptide ligand of a receptor protein.
9. The CASE fusion protein of claim 8, wherein the polypeptide ligand of a receptor protein is a cytokine.
10. The CASE fusion protein of claim 1, wherein the TPB domain comprises a ligand-binding domain of a receptor protein.
11. The CASE fusion protein of claim 10, wherein the ligand-binding domain of a receptor is a cytokine binding domain of a cytokine receptor.
12. The CASE fusion protein of claim 1, wherein the TPB domain comprises a single chain Fv.
13. The CASE fusion protein of claim 1, wherein the TPB domain comprises the antigen-binding site of a single domain antibody.
14. The CASE fusion protein of claim 1, wherein the TMR domain comprises a polypeptide that comprises at least a membrane-spanning region of a transmembrane protein.
15. The CASE fusion protein of claim 14, wherein the transmembrane protein is selected from the group consisting of: human CD4, human p23, human p24, human LAMP2, human LIMP2, cation dependent mannose-6-phosphate receptor, vesicular stomatitis virus glycoprotein (VSV-G), herpesvirus 1 envelope glycoprotein I, Borna disease virus gp84, and human KDEL receptor 1 protein.
16. The CASE fusion protein of claim 14, wherein the transmembrane protein is vesicular stomatitis virus glycoprotein (VSV-G), human p23, or human KDEL receptor 1 protein.
17. The CASE fusion protein of any one of claims 14-16, wherein the polypeptide comprising at least a membrane-spanning region of a transmembrane protein also comprises one or more amino acids flanking the membrane-spanning region.
18. The CASE fusion protein of claim 17, wherein the one or more amino acids flanking the transmembrane region are upstream and/or downstream from the membrane-spanning region.
19. The CASE fusion protein of claim 14, wherein the transmembrane protein is selected from the group consisting of: a Type I transmembrane protein, a Type II transmembrane protein, a Type III transmembrane protein, and a Type IV transmembrane protein.
20. The CASE fusion protein of claim 14, wherein the TMR domain comprises a polypeptide of any of SEQ ID NOS:62-82 or a portion thereof comprising at least a membrane-spanning region.
21. The CASE fusion protein of claim 19 or claim 20, wherein the polypeptide comprising at least a membrane-spanning region of a transmembrane protein also comprises one or more amino acids flanking the membrane-spanning region.
22. The CASE fusion protein of claim 21, wherein the one or more amino acids flanking the membrane-spanning region are upstream and/or downstream from the membrane-spanning region.
23. The CASE fusion protein according to claim 22, wherein the TMR domain is selected from the group of polypeptides consisting of: residues 459-522 of SEQ ID NO:156, residues 459-494 of SEQ ID NO:160, residues 459-495 of SEQ ID NO:162, residues 459-535 of SEQ ID NO:165, SEQ ID NO:193 and truncations of such polypeptides that retain the property of retaining the CASE fusion protein expressed by a host cell within the intracellular compartment.
24. The CASE fusion protein of claim 23, wherein the TMR domain comprises a C-terminal portion of p23, KDEL receptor 1, or VSV-G, which C-terminal portion includes the membrane-spanning region.
25. The CASE fusion protein of claim 1 comprising a CMP domain, wherein the CMP domain is selected from the group consisting of: (a) an isolated J domain of a J protein, or an active fragment of a J domain; or (b) an isolated polypeptide analog of a J domain, wherein said J domain analog polypeptide comprises the amino acid sequence of formula I: TABLE-US-00069 (I) (SEQ ID NO: 1) X1-X2-X3-X4-X5-X6-X7-X8-X9, wherein: X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M); X2 and X3 are each independently any amino acid with the proviso that one or both are K or R; X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present; X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F); X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present.
26. The CASE fusion protein according to claim 25, wherein said CMP domain comprises an amino acid sequence selected from the group consisting of: TABLE-US-00070 (SEQ ID NO: 2) IKKAYKLALQ, (SEQ ID NO: 3) IKKAYRLALQ, (SEQ ID NO: 4) IKKAYRKALQ, (SEQ ID NO: 5) IKKAYRKLLQ, (SEQ ID NO: 6) IKKAYRKLA, (SEQ ID NO: 7) IRKAYRKLSLTL, (SEQ ID NO: 8) IKKQYRLLSLKY, (SEQ ID NO: 9) IKKAFHKLAMKY, (SEQ ID NO: 10) IRQAFKKLALKL, (SEQ ID NO: 11) IIKAYRKLALQW, (SEQ ID NO: 12) IARAYRQLARRY, (SEQ ID NO: 13) IKRAYRRQALRY, (SEQ ID NO: 14) IKKSYRKLALKY, and (SEQ ID NO: 15) IKKAYKRLAMKY.
27. The CASE fusion protein according to claim 25, wherein said CMP domain comprises the amino acid sequence: IKKAFHKLAMKY (SEQ ID NO:9) or IKKAYRKLA (SEQ ID NO:6).
28. The fusion protein of claim 1 comprising a CMP domain, wherein the CMP domain comprises an amino acid sequence selected from the group consisting of: TABLE-US-00071 SEQ ID NO: 2 SEQ ID NO: 3 SEQ ID NO: 4 SEQ ID NO: 5 SEQ ID NO: 6 SEQ ID NO: 7 SEQ ID NO: 8 SEQ ID NO: 9 SEQ ID NO: 10 SEQ ID NO: 11 SEQ ID NO: 12 SEQ ID NO: 13 SEQ ID NO: 14 SEQ ID NO: 15 SEQ ID NO: 16 SEQ ID NO: 17 SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 20 SEQ ID NO: 21 SEQ ID NO: 22 SEQ ID NO: 23 SEQ ID NO: 24 SEQ ID NO: 25 SEQ ID NO: 26 SEQ ID NO: 27 SEQ ID NO: 28 SEQ ID NO: 29 SEQ ID NO: 30 SEQ ID NO: 31 SEQ ID NO: 32 SEQ ID NO: 33 SEQ ID NO: 34 SEQ ID NO: 35 SEQ ID NO: 36 SEQ ID NO: 37 SEQ ID NO: 38 SEQ ID NO: 39 SEQ ID NO: 40 SEQ ID NO: 41 SEQ ID NO: 42 SEQ ID NO: 43 SEQ ID NO: 44 SEQ ID NO: 45 SEQ ID NO: 46 SEQ ID NO: 47 SEQ ID NO: 48 SEQ ID NO: 49 SEQ ID NO: 50 SEQ ID NO: 51 SEQ ID NO: 52 SEQ ID NO: 53 SEQ ID NO: 54 SEQ ID NO: 55 SEQ ID NO: 56 SEQ ID NO: 57 SEQ ID NO: 58 SEQ ID NO: 59 SEQ ID NO: 60 and SEQ ID NO: 61.
29. The CASE fusion protein of claim 1 comprising a CMP domain, wherein the CMP domain comprises a fragment of a J protein or a fragment of a Hsp70 protein; wherein co-expression of the CASE fusion protein comprising the CMP domain and a target protein bound by the CASE fusion protein in a host cell enhances the level of target protein secreted from the host cell compared to the level of target protein secreted from a host cell co-expressing the target protein and a CASE fusion protein without the CMP domain.
30. The CASE fusion protein of claim 1, comprising a domain structure, N-terminal to C-terminal, selected from the group consisting of: (TPB domain)-L-(TMR domain), (CMP domain)-L-(TPB domain)-L-(TMR domain), and (TPB domain)-L-(CMP domain)-L-(TMR domain), wherein each L is, independently, a direct peptide bond or a linker of one or more amino acids.
31. The CASE fusion protein of claim 30, wherein said TMR domain comprises a membrane-spanning region of a Type I, a Type III, or a Type IV protein.
32. The CASE fusion protein of claim 30, wherein said TMR domain comprises a membrane-spanning region of a Type I transmembrane protein.
33. The CASE fusion protein of claim 30, wherein the TMR domain comprising an amino acid sequence selected from the group consisting of: TABLE-US-00072 SEQ ID NO: 62 SEQ ID NO: 63 SEQ ID NO: 64 SEQ ID NO: 65 SEQ ID NO: 66 SEQ ID NO: 67 SEQ ID NO: 71 SEQ ID NO: 73 SEQ ID NO: 74 SEQ ID NO: 75 SEQ ID NO: 76 SEQ ID NO: 77 SEQ ID NO: 80 and SEQ ID NO: 82.
34. The CASE fusion protein of claim 1, comprising a domain structure, N-terminal to C-terminal, selected from the group consisting of: (TMR domain)-L-(TPB domain), (TMR domain)-L-(CMP domain)-L-(TPB domain), or (TMR domain)-L-(TPB domain)-L-(CMP domain), wherein each L is, independently, a direct peptide bond or a linker of one or more amino acids.
35. The CASE fusion protein of claim 34, wherein said TMR domain comprises a membrane-spanning region of a Type II or a Type III transmembrane protein.
36. The CASE fusion protein of claim 1, comprising a domain structure, N-terminal to C-terminal, selected from the group consisting of: (TMR domain)-L-(TPB domain)-L-(TMR domain), or (TMR domain)-L-(CMP domain)-L-(TPB domain)-L-(TMR domain), wherein said TMR domains are the same or different, and wherein each L is, independently, a direct peptide bond or a linker of one or more amino acids.
37. The CASE fusion protein of claim 36, wherein said N-terminal TMR domain comprises a membrane-spanning region of a Type II or a Type III protein, and wherein said C-terminal TMR domain comprises a membrane-spanning region of a Type I, a Type III, or a Type IV protein.
38. The CASE fusion protein of claim 36, wherein said TMR domains may be the same or different and each comprises a membrane-spanning region of a Type III protein.
39. The CASE fusion protein of claim 38, wherein each of said TMR domains comprises one or more membrane-spanning regions of KDEL receptor 1 or LIMP2.
40. The CASE fusion protein of claim 38, wherein said TMR domains may be the same or different and each comprises a membrane-spanning region taken from the KDEL receptor 1 C-terminal fragment SEQ ID NO:71.
41. The CASE fusion protein of any one of claims 30-40, wherein each linker, L, if present, is independently an amino acid or is selected from the group consisting of: LE, SR, LEG, GSR, GTGSEFDIAAALE (SEQ ID NO:175); GTGSGEF (SEQ ID NO:176); DIAAA (SEQ ID NO:83); DIAAALE (SEQ ID NO:84); GTGSEF (SEQ ID NO:85); AS; TVA; ASTK (SEQ ID NO:86); GGGSGGSGGSGG (SEQ ID NO:87); DIGGGSGGSGGSGGAAA (SEQ ID NO:88); DIGGGGSGGGGSGGGGSAAA (SEQ ID NO:178); AKTTPKLEEGEFSEAR (SEQ ID NO:89); AKTTPKLEEGEFSEARV (SEQ ID NO:90); AKTTPKLGG (SEQ ID NO:91); SAKTTPKLGG (SEQ ID NO:92); SAKTTP (SEQ ID NO:93); RADAAP (SEQ ID NO:94); RADAAPTVS (SEQ ID NO:95); RADAAAAGGPGS (SEQ ID NO:96); RADAAAA(G.sub.4S).sub.4 (SEQ ID NO:97); SAKTTPKLEEGEFSEARV (SEQ ID NO:98); ADAAP (SEQ ID NO:99); ADAAPTVSIFPP (SEQ ID NO:100); TVAAP (SEQ ID NO:101); TVAAPSVFIFPP (SEQ ID NO:102); QPKAAP (SEQ ID NO:103); QPKAAPSVTLFPP (SEQ ID NO:104); AKTTPP (SEQ ID NO:105); AKTTPPSVTPLAP (SEQ ID NO:106); AKTTAP (SEQ ID NO:107); AKTTAPSVYPLAP (SEQ ID NO:108); ASTKGP (SEQ ID NO:109); ASTKGPSVFPLAP (SEQ ID NO:110); GGGGS (SEQ ID NO:181); GGGGSGGGGS (SEQ ID NO:180); GGGGSGGGGSGGGGS (SEQ ID NO:111); GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:179); GENKVEYAPALMALS (SEQ ID NO:112); GPAKELTPLKEAKVS (SEQ ID NO:113); GHEAAAVMQVQYPAS (SEQ ID NO:114); GGGGGGGP (SEQ ID NO:115); GGGGGGGGP (SEQ ID NO:116); PAPNLLGGP (SEQ ID NO:117); PNLLGGP (SEQ ID NO:118); GGGGGGP (SEQ ID NO:119); PAPELLGGP (SEQ ID NO:120); PTISPAPNLLGGP (SEQ ID NO:121); TVAADDDDKSVFIVPP (SEQ ID NO:122); TVDDDDKAAP (SEQ ID NO:123); LVPRGSAAP (SEQ ID NO:124); ASTKGPSV (SEQ ID NO:125); ASTKGPSVFP (SEQ ID NO:126); TVAAPSV (SEQ ID NO:127); TVAAPSVFI (SEQ ID NO:128).
42. The fusion protein of claim 1, further comprising: (d) an epitope tag.
43. The fusion protein of claim 42, wherein said epitope tag is selected from the group consisting of: a polyhistidine tag, V5 tag, Myc tag, Flag tag, and an influenza hemagglutinin tag.
44. The fusion protein of claim 43, wherein said epitope tag is selected from the group consisting of: GKPIPNPLLGLDST (SEQ ID NO:131), DYKDDDDK (SEQ ID NO:132), and HHHHHH (SEQ ID NO:177).
45. An isolated polynucleotide comprising a nucleic acid sequence encoding a CASE fusion protein according to any one of claims 1-44.
46. The isolated polynucleotide of claim 45, further comprising a nucleotide sequence encoding a signal sequence located in frame at the 5′ end of said polynucleotide.
47. The isolated polynucleotide of claim 46, wherein said signal sequence is a signal sequence that is native to the protein from which the N-terminal domain of the encoded fusion protein is derived.
48. The isolated polynucleotide of claim 46, wherein the signal sequence is the signal sequence of a J protein.
49. The isolated polynucleotide of claim 46, wherein the signal sequence is the signal sequence for human insulin.
50. A nucleic acid vector comprising the isolated nucleic acid molecule according to any one of claims 45-49.
51. The nucleic acid vector of claim 50 comprising a plasmid selected from the group consisting of: pcDNA, pcDNA3.3 TOPO, pTT3, and pEF-BOS.
52. A host cell comprising the nucleic acid vector molecule according to claim 50 or claim 51.
53. A method of expressing a fusion protein comprising culturing a host cell according to claim 52 under conditions sufficient to produce the encoded CASE fusion protein.
54. A method of enhancing the level of secretion of a target protein of interest that is expressed in a host cell comprising: (1) transfecting the host cell with an expression vector comprising a structural gene encoding a CASE fusion protein according to any one of claims 1-44 that exhibits a TPB domain capable of binding to said target protein of interest, and (2) culturing said transfected host cell under conditions for co-expression in said host cell of said CASE fusion protein and said target protein of interest.
55. The method of claim 54, wherein said CASE fusion protein dissociates from said target protein of interest under conditions found within the Golgi apparatus of said host cell.
56. The method of claim 54, wherein said CASE fusion protein dissociates from said target protein of interest under conditions of pH from pH 5.5 to pH 7.
57. The method of claim 54, wherein said CASE fusion protein dissociates from said target protein of interest under conditions of pH from pH 5.5 to pH 6.3.
58. The method of claim 54, wherein said CASE fusion protein dissociates from said target protein of interest under conditions of pH from pH 5.5 to pH 6.
59. A method of enhancing the level of a target protein of interest secreted from a host cell expressing said target protein, the method comprising the steps of: 1) constructing a recombinant gene encoding a CASE fusion protein according to any one of claims 1-44 having a target protein binding (TPB) domain capable of binding said target protein expressed by said host cell; 2) inserting the recombinant gene into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence; 3) transfecting said recombinant expression vector into host cells that are compatible with said promoter sequence; and 4) culturing said transfected host cells under conditions that permit co-expression of said CASE fusion protein encoded by said recombinant gene and of said target protein of interest.
60. A method of restoring a secreted protein function in cells of a mammalian subject that are deficient in the secretion of a native secreted protein that provides said secreted protein function comprising: inserting into cells of the subject an exogenous nucleic acid molecule encoding a CASE fusion protein according to any one of claims 1-44, wherein the target protein binding domain of the CASE fusion protein binds the native secreted protein, and wherein co-expression of the CASE fusion protein and the native secreted protein in the cells enhances the level of native secreted protein to provide said secreted protein function to the subject.
61. The method according to claim 60, wherein the subject has a disease associated with the deficient secretion of the native protein in the subject.
62. The method according to claim 61, wherein said disease is selected from the group consisting of a prion-associated disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, cystic fibrosis (CF), and α1-antitrypsin (AAT) deficiency.
63. The method according to claim 62, wherein the subject is a human subject deficient in the secretion of cystic fibrosis transmembrane conductance regulator protein and the disease is cystic fibrosis, and wherein expression of said CASE fusion protein in cells of said subject increases the level of circulating cystic fibrosis transmembrane conductance regulator protein in said subject.
64. The method according to claim 62, wherein the subject is a human subject deficient in secretion of AAT and the disease is AAT deficiency, and wherein expression of said CASE fusion protein in cells of said subject increases the level of circulating AAT in said subject.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)
(56)
(57)
(58)
DETAILED DESCRIPTION OF THE INVENTION
(59) A major advantage of secreting a protein of interest from cells in a production culture is that the purification of the protein species from the medium of a culture of largely intact cells is typically far more economical than if the protein species remained in the cells and required purification away from all of the other cellular components that are released upon disrupting the cells. Moreover, regulatory approval of a protein of interest as well as a production protocol for the protein of interest is generally more expedient when components of a production run are known and do not include new contaminating species that have not previously existed in previous production protocols. Accordingly, any effort to improve production yields of proteins that have recognized medical and commercial value preferably will comprise such features as described.
(60) This invention provides a new family of engineered fusion proteins, wherein the fusion protein binds to a target protein of interest that is co-expressed within a host cell and wherein the fusion protein also enhances the amount of target protein that is secreted from the host cell while also remaining associated with the host cell so as not to be co-secreted with the target protein of interest. Thus, a fusion protein of the invention provides a means of elevating the yield of a target protein of interest that can be secreted from a host cell into a culture medium, without also becoming a new contaminating component of the host cell culture medium. Accordingly, fusion proteins of the invention are referred to as cell-associated secretion-enhancing (“CASE”) fusion proteins. A CASE fusion protein described herein comprises: (a) a target protein binding (“TPB”) domain, (b) a transmembrane retention (“TMR”) domain, and (c) optionally, a chaperone machinery polypeptide (“CMP”) domain.
(61) The domains of a CASE fusion protein according to the invention are typically selected from different proteins, are derivatives of portions of different proteins, or may be polypeptides not previously known to exist in nature. The TPB domain comprises a polypeptide that is selected for its ability to bind to a particular target protein of interest, and the TMR domain comprises a polypeptide that is selected mainly to result in the CASE fusion protein being essentially completely retained within the expressing host cell. The CMP domain (“chaperone machinery polypeptide”, “chaperone machinery peptide”), when present in a CASE fusion protein, is selected mainly for its ability to improve target protein secretion, presumably by acting as a type of chaperone to a target protein bound by the CASE fusion protein to engage in some manner the cellular chaperone mechanisms involved with processing, folding, membrane-translocation, and/or secretion. Where two domains of a CASE fusion protein are selected from the same natural protein, they are not in the same orientation with respect to each other as found in the native protein from which they were derived. Thus, it will be understood that CASE fusion proteins of the invention are formed as the result of a deliberate recombination and engineering of polypeptide domains yielding artificial, synthesized fusion proteins that do not occur in nature and that possess at least one desirable functional activity or property for each required domain, i.e., the TPB domain provides a target protein binding function, the TMR domain provides a membrane-association function, and the combination of the TPB and TMR domains results in a fusion protein providing increased secretion of a co-expressed target protein. The CMP domain, when present, provides a significant enhancement in the level of secreted target protein compared to that obtained when the target protein is co-expressed with a CASE fusion protein comprising the TPB and TMR domains but lacking the CMP domain.
(62) According to the invention, co-expression in a host cell of a CASE fusion protein described herein with a target protein of interest enhances the level of target protein secreted from the host cell as compared to the level that is secreted when the target protein is expressed in the absence of the fusion protein, and the enhancement in the level of secretion of the target protein occurs wherein the CASE fusion protein remains associated with the host cell such that no significant amount of the fusion protein is secreted into the host cell extracellular culture media where it may otherwise be considered a new contaminant within the culture media containing the secreted target protein. By “no significant amount” in this context is meant that the level of CASE fusion protein in the culture media is not detectable or is at a level that is tolerable so as to not require steps specifically aimed at removal of the fusion protein from the culture media in the further purification or processing of the target protein. The United States Food and Drug Administration (FDA) has found that most biological products (biologics) contain ELISA-based host cell (non-product) protein levels between 1 and 100 ppm. See, The Handbook of Process Chromatography, Second Edition, Hagel et al., eds. (Academic Press, London, 2008), Chapter 5, page 131. Such a range of non-drug proteins of host cell origin serves as guidance for the production and regulatory approval of biologics. Accordingly, although a fusion protein of the invention is most preferably not secreted into a host cell culture medium, and therefore not detectable by ELISA, an insignificant and tolerable level of a fusion protein of the invention that is secreted into a host cell culture medium may be, but is not limited to, in order of increasing preference, less than 100 ppm, less than 80 ppm, less than 70 ppm, less than 60 ppm, less than 50 ppm, less than 40 ppm, less than 30 ppm, less than 20 ppm, less than 10 ppm, less than 5 ppm, less than 3 ppm, less than 2 ppm, less than 1 ppm, less than 0.3 ppm, less than 0.15 ppm, less than 0.10 ppm, less than 0.05 ppm, less than 0.02 ppm, less than 0.01 ppm, and less than 0.005 ppm.
(63) The domains of a CASE fusion protein described herein are chosen so that the fusion protein provides the desired activity of enhancing the level of a target protein of interest that is secreted from a host cell when the fusion protein is co-expressed with the target protein and to provide such enhancement in the level of secreted target protein without also being co-secreted with the target protein. While not intending to be bound by any particular scientific theory to explain the expression enhancement mechanism, it appears that the target protein binding (TPB) domain of a CASE fusion protein described herein binds a target protein that is expressed in the endoplasmic reticulum (ER) of a host cell and subsequently releases the target protein within the Golgi apparatus or at the formation of a secretory vesicle that envelopes the target protein for secretion from the cell, while the TMR domain of the fusion protein anchors the fusion protein to the cellular membrane of the secretory pathway without permanently retaining the fusion protein in the ER or without interfering with the formation of a secretory vesicle required for secretion of the target protein from the cell. The CASE fusion protein co-expressed with the target protein in a host cell appears to have a chaperone-like effect that improves or for reasons not known assists the intracellular processing of the target protein for secretion from the host cell.
(64) In addition to enhancing yields of target proteins secreted from cells into the media of production cultures, a CASE fusion protein of the invention also provides a technical solution when there is a failure to secrete desired or adequate quantities of an endogenous (i.e., component of the cell's proteome) or heterologous (i.e., recombinant) target protein of interest in cells of a eukaryotic organism, such as a plant, a non-human animal, or even a human subject. The present invention provides compositions and methods for treating non-human or human individuals for a disease or disorder in which there is a failure to secrete sufficient levels of a functional protein in vivo, where inadequate secretion of a protein or a functional version of a secreted protein leads to a pathological state. Examples of diseases in which such deficiency in adequate levels of secretion of a protein species has been demonstrated or implicated include, but are not limited to, cystic fibrosis (CF), Alzheimer's disease; Parkinson's disease; Huntington's disease; and prion-associated disease (transmissible spongiform encephalopathy).
(65) In order to more clearly describe the invention, the following comments and definitions of terms apply.
(66) Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear; however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In this application, the use of the term “or” means “and/or,” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting as is also the case for the terms “comprising,” “comprises,” and “comprised.”
(67) Generally, nomenclatures used in connection with and techniques of protein and nucleic acid chemistry (including methods of recombinant nucleic acid and polymerase chain reaction (PCR)), cell and tissue culture, molecular biology, genetics, microbiology, biochemistry, proteomics, pharmacology, and pharmaceutical science described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods in the art and as described in various general and more specific references available in the art. Assays and purification techniques are performed according to protocols available in the art, including in manuals of laboratory techniques and manufacturer's specifications, as commonly accomplished in the art or as described herein.
(68) Unless indicated otherwise, when the terms “about” and “approximately” are used in combination with an amount, number, or value, then that combination describes the recited amount, number, or value alone as well as the amount, number, or value plus or minus 10% of that amount, number, or value. By way of example, the phrases “about 40%” and “approximately 40%” disclose both “40%” and “from 36% to 44%, inclusive”.
(69) The terms “protein of interest”, “target protein of interest”, or “target protein” are synonymous and refer to any protein, polypeptide, or peptide for which there is a need or desire to enhance the level of secretion from a host cell that expresses the protein, polypeptide, or peptide.
(70) The term “isolated” as in an “isolated molecule” (e.g., “isolated protein” or “isolated nucleic acid”) is a molecule that by virtue of its origin or source of derivation: is not associated with naturally associated components that accompany it in its native state; is substantially free of other kinds of molecules from the same species; is expressed by a cell from a different species; or does not occur in nature. Thus, a protein (including, a polypeptide or a peptide) or nucleic acid molecule that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be “isolated” from its naturally associated components. Typically, a protein or nucleic acid molecule may also be rendered substantially free of naturally associated components by isolation, using respectively protein or nucleic acid purification techniques well known in the art.
(71) The term “vector”, as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded nucleic acid (typically, DNA) loop into which additional nucleic acid segments may be inserted. Another type of vector is a viral (i.e., virus-based) vector wherein additional nucleic acid segments may be inserted into an engineered viral genome for transport into a cell and, in some cases, then into a chromosome of the cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into a chromosome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, lentivirus-derived vectors, and adenovirus-derived vectors), which serve equivalent or comparable functions.
(72) The term “operably linked” refers to a juxtaposition of described components wherein the components are in a relationship permitting them to function in their intended manner. A control sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. “Operably linked” sequences may include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. The term “expression control sequence” refers to polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (such as, a Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term “control sequences” is intended to include components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Unless stated otherwise, a description or statement herein of inserting a nucleic acid molecule encoding a fusion protein of the invention into an expression vector means that the inserted nucleic acid has also been operably linked within the vector to a functional promoter and other transcriptional and translational control elements required for expression of the encoded fusion protein when the expression vector containing the inserted nucleic acid molecule is introduced into compatible host cells or compatible cells of an organism.
(73) The term “target protein binding domain” and its abbreviation “TPB domain” refer to any polypeptide that has a binding affinity for a target protein and bestows that binding affinity on a CASE fusion protein in which it is present. Preferably, a TPB domain will also show a high degree of specificity, namely, that its binding will be specific for one target protein, and the domain will not exhibit affinity for different, structurally unrelated proteins that may be present in the proteome of a host cell that is co-expressing the target protein and the CASE fusion protein. A TPB domain may be a naturally occurring domain that binds to a target protein. A TPB domain may also be a synthetic, non-naturally occurring polypeptide domain found to have the desired affinity for a target protein. Preferably (as noted above), a TPB domain of a CASE fusion protein described herein binds a target protein that is co-expressed with the fusion protein in the endoplasmic reticulum (ER) of a host cell and subsequently releases the target protein within the Golgi apparatus or at the formation of a secretory vesicle that envelopes the target protein for secretion from the cell. Polypeptides that can serve as TPB domains of CASE fusion protein of the invention may be discovered by screening for target protein binding affinity for a particular target protein. Known methods for such screening include, but are not limited to, phage display library screening, yeast two hybrid screening, far-western screening, high-throughput ELISA, and the like.
(74) The term “transmembrane retention domain,” its abbreviation “TMR domain”, and “transmembrane retention signal” as used herein refer to a polypeptide domain included in a CASE fusion protein of the invention that causes the fusion protein to remain associated with the host cell in which the fusion protein is co-expressed with a target protein of interest. The TMR domain comprises at least a portion of a transmembrane (TM) region of a transmembrane protein that normally traverses the membrane of a cell. The region of a transmembrane protein employed as a TMR domain in the fusion proteins of the present invention will comprise a sufficient fragment of the membrane-spanning region of a transmembrane protein so that, when incorporated into a CASE fusion protein of the invention, the fusion protein remains associated with the cell and is not secreted from the cell. The TMR domain used in the fusion proteins described herein may include all or an operative fragment of the transmembrane region of a transmembrane protein that is normally known to be embedded in the membrane. The portion of a transmembrane protein useful as a TMR domain is not limited to only the membrane-spanning region of the transmembrane protein but may also comprise additional flanking amino acids of the transmembrane protein that are located upstream (N-terminal) and/or downstream (C-terminal) to the membrane-spanning region. As discussed below, a particularly preferred TMR domain for use in fusion proteins according to the invention is derived from a type I transmembrane protein. Preferably, a TMR domain of a CASE fusion protein of the invention anchors the fusion protein to the cellular membrane of the secretory pathway without permanently retaining the fusion protein in the ER or without interfering with the formation of a secretory vesicle required for secreting the target protein from the cell. Accordingly, a transmembrane region of a protein that is known to reside in the endoplasmic reticulum (ER) or a transmembrane region that is otherwise known to localize a protein exclusively to the ER is not preferred for use as a TMR domain of a CASE fusion protein of the invention unless the ER-retaining function has been deleted or otherwise inactivated. For example, as shown herein, a transmembrane region of the KDEL 1 receptor (KDELR) protein, which is present in the ER membrane, is a preferred transmembrane region for use as a TMR domain of a CASE fusion protein of the invention. While not intending to be bound by any particular scientific theory of a mechanism, it is assumed that a transmembrane region that anchors a protein to the ER also blocks a fusion protein comprising such a transmembrane region from progressing to the Golgi apparatus of the secretory pathway and therefore would inhibit and not enhance secretion of a target protein bound by the fusion protein. The success shown in the examples below of using a transmembrane region from the KDELR protein, which is found in the ER, as a TMR domain in a CASE fusion protein of the invention may be due to the fact that the KDELR protein is not permanently anchored in the ER but must move back and forth between the ER and Golgi apparatus.
(75) The term “chaperone machinery polypeptide”, “chaperone machinery peptide”, and its abbreviation “CMP” refer to a polypeptide whose presence in a cell-associated secretion-enhancing (CASE) fusion protein described herein enhances the level of secretion of a co-expressed target protein above that observed when the target protein is co-expressed with the same or substantially the same CASE fusion protein lacking the CMP. As explained and exemplified in more detail below, a CMP domain useful in the invention may comprise one or more of the following: a known polypeptide domain of a known component of the ubiquitous Hsp70 chaperone system (or corresponding chaperone system), such as, but not limited to, a J domain of a J protein; an isolated polypeptide of a known domain of a known component protein of a chaperone system, such as, but not limited to, a defined peptide of a J domain of J protein; or a synthetic, non-naturally-occurring peptide analog of a naturally-occurring peptide of a known component protein of a chaperone system.
(76) While not wishing to be bound by any particular scientific theory as to the possible mechanism of expression enhancement provided by inclusion of a CMP domain, a CMP domain of a CASE fusion protein of the invention is presumed to engage or recruit some aspect of a host cell Hsp70 chaperone system (or equivalent system in other host cells) that provides a further enhancement in the level of secretion of a co-expressed target protein bound by the CASE fusion protein (as compared to the level observed when the target protein is co-expressed with the same or substantially the same CASE fusion protein lacking the CMP domain) perhaps by increasing the numbers of target proteins that are properly folded within the ER and that enter the secretory pathway.
(77) According to the nomenclature used herein, the source of a polypeptide employed as a TPB, TMR, or CMP domain in any fusion protein described herein may be referred to by an abbreviation of the name of the source protein or polypeptide set in parentheses to the right of the particular domain. For example, “TPB(gE)” indicates that the target protein binding (TPB) domain comprises all or a polypeptide fragment of the herpes simplex virus type-1 envelope (viral membrane) glycoprotein E (“gE”). The shorthand designation “TPB(gE)” does not, however, disclose whether TPB domain comprises all or a portion of the gE protein. The particular binding function and amino acid sequence of the particular polypeptide of gE used in the TPB domain of the fusion protein will be obtained from other information given in the disclosure. For example, as explained herein, the gE protein is known to bind the immunoglobulin Fc region and is employed in several examples of the disclosure for that property. Accordingly, a TPB domain may employ a portion of gE that binds a target protein of interest that comprises an Fc region. The particular amino acid sequence of the gE protein employed in such a TPB domain of a fusion protein is given in the description of particular embodiments in the text including, for example, in tables setting forth the amino acid sequences of the domains of particular fusion proteins. Similarly, the use of parenthetical abbreviations to the right of the terms “TMR” and “CMP” indicate the source protein or polypeptide used in selecting those domains. The actual amino acid sequence of the TMR or CMP domain must be obtained from descriptions in the text, including for example, the tables of the amino acid sequences of the domains of the particular fusion proteins included in the Examples section herein. The term “operative fragment” when used in conjunction with a transmembrane region means a polypeptide corresponding to some but not all amino acids of a membrane-spanning region of a transmembrane protein, which polypeptide is effective, when incorporated as the TMR domain of a CASE fusion protein of the invention, to cause the fusion protein to be retained with the cell.
(78) As used herein, “significantly enhanced” signifies an increase, e.g., in the yield or level of a target protein of interest secreted from a host cell, of at least 1.5-fold over a comparative standard amount (e.g., the amount of target protein secreted from cells in the absence of co-expression with a fusion protein of the invention). For a secreted target protein of interest that is also a therapeutically and commercially important protein, an enhancement of 1.5-fold or more would be recognized by persons in the pharmaceutical industry as providing a significant reduction in production costs and also a significant increase in the availability of the therapeutically and commercially important protein.
(79) When used to describe a negative threshold, e.g., as in “without significant secretion into the culture medium”, the term “significant” refers to an amount of a protein at the level of detection of the assay used to detect the presence of such protein. For example, a statement that expression of a fusion protein resulted in “no significant secretion” of the fusion protein from a host cell means that according to the technique used to assay for the presence of secreted fusion protein, no protein or only a negligible amount of the protein was detected in such assay. A “negligible” amount in this context would be an amount that is sufficiently low so as to be tolerable in preparations of the target protein, and “tolerable” may refer to causing no adverse effects that need to be neutralized or to requiring no further steps to eliminate the negligible amount of the substance from preparations. In a context of pharmaceutical preparations, specific limits for negligible or tolerable amounts of an impurity or contaminant may be set by a reviewing authority such as the FDA. Another way of expressing the result of no significant amount of CASE fusion protein being secreted to the culture media of a host cell for the purposes of the present invention will be that the extracellular culture media of the host cell expressing the CASE fusion protein is “essentially free” of the CASE fusion protein, wherein it will be understood that any amount of CASE fusion protein reaching the culture medium will be undetectable by standard assays (for example, ELISA) or will be an amount that is insufficient to affect the target protein biological activity in a preparation of the target protein made from the culture media.
(80) The terms “heterologous” and “exogenous” are synonymous and are used broadly as adjectives to describe any molecule (e.g., protein, polypeptide, nucleic acid) that is not native to a host cell containing or expressing the molecule. Accordingly, “heterologous” and “exogenous” encompass the term “recombinant” as defined below.
(81) As used herein, the term “recombinant” when used as an adjective describes non-naturally altered or manipulated nucleic acids, host cells transfected with exogenous (non-endogenous) nucleic acids, or polypeptides expressed non-naturally, through manipulation of isolated nucleic acid (typically DNA) and transfection of host cells or through manipulation of endogenous nucleic acid to alternative expression by introduction of non-endogenous nucleic acid. “Recombinant” is a term that specifically encompasses DNA molecules that have been constructed in vitro using genetic engineering techniques, and use of the term “recombinant” as an adjective to describe a molecule, construct, vector, cell, protein, polypeptide, peptide, or polynucleotide specifically excludes naturally occurring (“endogenous”) such molecules, constructs, vectors, cells, proteins, polypeptides, peptides, and polynucleotides in their respective, un-isolated, native locations (for example, intracellular, tissue, or organ locations).
(82) The term “recombinant host cell” (or simply, in context, “host cell”), as used herein, is intended to refer to a cell into which exogenous nucleic acid has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein. Host cells useful in various aspects of the invention may be prokaryotic and eukaryotic cells. Preferred prokaryotic host cells include various bacterial cells, including Escherichia coli. While some manipulations, constructions, expressions, or replications of nucleic acids or encoded polypeptides related to the invention may be conducted using prokaryotic or eukaryotic host cells, the preferred host cells for producing enhanced levels of a secreted target protein of interest according to the invention, are eukaryotic host cells. Preferred eukaryotic host cells include, without limitation, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell. Preferably, a mammalian host cell is a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, or an MDCK cell. Preferred fungal host cells include Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. A particularly preferred Saccharomyces host cell is a Saccharomyces cerevisiae cell. A particularly preferred insect host cell is an Sf9 cell.
(83) “Transgenic organism”, as known in the art and as used herein, refers to an organism having cells that contain a transgene, wherein the transgene introduced into the organism (or an ancestor of the organism) expresses a polypeptide not naturally expressed in the organism or not naturally expressed at the normal or proper level to provide the intended function of the polypeptide to the organism. A “transgene” is a nucleic acid construct, which is stably and operably integrated into the genome of a cell from which a transgenic organism develops, directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic organism. In transgenic plants and non-human animals, a nucleic acid encoding a particular protein (e.g., a fusion protein of the invention) is permanently incorporated into the genome as a functional gene (transgene) such that the plant or non-human animal not only expresses the fusion protein, but also passes a copy of the expressible transgene on to progeny.
(84) The terms “disease” and “disorder” are used interchangeably to indicate a pathological state identified according to accepted medical standards and practices in the art.
(85) As used herein, the term “effective amount” refers to the amount of a therapy that is sufficient to reduce or ameliorate the severity and/or duration of a disease or one or more symptoms thereof; to prevent the advancement of a detrimental or pathological state; to cause regression of a pathological state; to prevent recurrence, development, onset, or progression of one or more symptoms associated with a pathological state; to detect a disorder; or to enhance or improve the prophylactic or therapeutic effect(s) of a therapy (e.g., the administration of another prophylactic or therapeutic agent).
(86) A “biological sample,” as used herein, includes, but is not limited to, any quantity of a substance from a living organism or formerly living organism. Such organisms include, but are not limited to, humans, non-human primates, mice, rats, monkeys, dogs, rabbits, ruminants, and other animals. Such substances of a biological sample may include, but are not limited to, blood, serum, plasma, lymph, urine, saliva, sputum, mucus, synovial fluid, milk, amniotic fluid, spinal fluid, semen, cells, organs (for example, heart, spleen, lung, kidney, breast, brain, eye, tongue, stomach, pancreas, intestines, gall bladder, reproductive organs, appendix), tissues (for example, bone, cartilage, muscle, skin), bone marrow, and lymph nodes.
(87) A composition or method described herein as “comprising” (or which “comprises”) one or more named elements or steps is open-ended, meaning that the named elements or steps are essential, but other elements or steps may be added within the scope of the composition or method. To avoid prolixity, it is also understood that any composition or method described as “comprising” (or which “comprises”) one or more named elements or steps also describes the corresponding, more limited, composition or method “consisting essentially of” (or which “consists essentially of”) the same named elements or steps, meaning that the composition or method includes the named essential elements or steps and may also include additional elements or steps that do not materially affect the basic and novel characteristic(s) of the composition or method. It is also understood that any composition or method described herein as “comprising” (or which “comprises”) or “consisting essentially of” (or which “consists of”) one or more named elements or steps also describes the corresponding, more limited, and close-ended composition or method “consisting of” (or which “consists of”) the named elements or steps to the exclusion of any other unnamed element or step.
(88) In any composition or method disclosed herein, known or disclosed equivalents of any named essential element or step may be substituted for that element or step.
(89) Unless specifically indicated, a composition or method is not limited by any particular order of the listed elements or steps, unless a particular method step requires the prior performance of another step.
(90) It is also understood that an element or step “selected from the group consisting of” or “any of” (or equivalent phrase) refers to one or more of the elements or steps in the list that follows, including combinations of any two or more of the listed elements or steps.
(91) Unless otherwise indicated, reference to a range of values is understood to include both boundary values of the recited range, as well as all values in between. Thus, in a disclosure of a pH range, e.g., pH 6.8 to pH 7.2 (or the equivalent notation, pH 7.0±0.2), the disclosure will be understood to include any pH value from and including pH 6.8 and above, up to pH 7.2, inclusive.
(92) Cell-Associated Secretion-Enhancing (CASE) Fusion Proteins
(93) According to the invention, the level of a target protein of interest secreted from a host cell is significantly higher (i.e., at least 1.5-fold higher) when the target protein is co-expressed in the host cell with a cell-associated secretion-enhancing (CASE) fusion protein described herein as compared to the level of target protein secreted from the host cell when the target protein is expressed in the absence of the fusion protein.
(94) A cell-associated secretion-enhancing (CASE) fusion protein of the invention comprises two domains: (a) a target protein binding (TPB) domain, which specifically binds a target protein of interest co-expressed in a host cell, and (b) a transmembrane retention (TMR) domain, which is required for the fusion protein to be retained with the host cell while the co-expressed target protein is secreted from the host cell.
(95) The TPB and TMR domains may be contiguous or linked together by an amino acid or peptide linker (containing two or more peptide bonded amino acids) to form a linear fusion protein. Additional domains for detection or to aid purification of the fusion protein are also contemplated. A non-limiting example of such an addition domain is a Flag epitope tag or a V5 epitope tag or a hexahistidine affinity tag. Selection of the domains for construction of a CASE fusion protein according to the invention are discussed in detail below.
(96) In a preferred embodiment, a CASE fusion protein of the invention comprises three domains: (a) a target protein binding (TPB) domain, which specifically binds a target protein of interest co-expressed in a host cell, (b) a transmembrane retention (TMR) domain, which is required for the fusion protein to be retained with the host cell while the co-expressed target protein is secreted from the host cell, and (c) a chaperone machinery peptide (CMP) domain, which enhances expression and secretion of a co-expressed target protein of interest.
Target Protein Binding (TPB) Domains Useful in the Invention
(97) A cell-associated secretion-enhancing (CASE) fusion protein of the invention comprises a target protein binding (TPB) domain that binds a target protein of interest for which an elevated level of secretion from a host cell is desired. The more specific the binding affinity of a TPB domain is for a target protein, the less likely other proteins may potentially interfere with the enhancement in the level of expression and secretion of the target protein of interest when practicing the present invention.
(98) A CASE fusion protein according to the invention and a target protein of interest (for which the TPB domain has an affinity) will be co-expressed in the same host cell. To obtain the maximum benefit of the present invention the target protein will be a protein that is secreted to the extracellular media when expressed by the host cell, and the target protein binding domain will be selected primarily for its ability to bind with the target protein. A TPB domain of a fusion protein of the invention may be any protein, polypeptide, or binding domain that is capable of binding to a particular target protein of interest and permits the target protein to be secreted from the cell at significantly higher levels than in the absence of the fusion protein.
(99) The TPB domain must not only bind to a target protein but must also release the target protein into the cellular secretion pathway under conditions encountered inside the expressing host cell. A CASE fusion protein that incorporates a TPB domain that binds with too great an affinity or that cannot be induced to release the target protein at an appropriate stage of secretion will fail to enhance secretion of the target. This will often be marked by an accumulation of the fusion protein/target protein complex in a particular compartment of the producing host cell, such as the endoplasmic reticulum (ER). Among the intracellular conditions that influence the release of the target protein from a fusion protein/target protein complex is the local pH of specific organelles and vesicles of the cell. The pH of various eukaryotic organelles involved with expression and secretion of proteins has been measured. During the process of expression and secretion, a protein in a eukaryotic cell experiences a relatively rapid acidification as it passes through the ER to the Golgi complex (Golgi apparatus, Golgi) and into a secretory vesicle. In particular, a protein to be secreted will pass through the ER, which is typically maintained at around neutral pH 7.2 (±0.2), on to the Golgi complex, where the protein experiences a successive lowering of pH from pH 6.7 (±0.2) in the cis Golgi, to pH 6.3 (±0.2) in the medial Golgi, and down to pH 6.0 (±0.2) in the trans Golgi network, and thereafter the protein will be sequestered in a secretory vesicle in which the pH is 5.5 (±0.4) in preparation for secretion from the cell. See, for example, the review by Demaurex, News Physiol. Sci., 17: 1-5 (February 2002). Other intracellular conditions may also play a role in target protein dissociation from the fusion proteins of the invention and subsequent secretion from the host cell. As regards the influence of pH, however, particular embodiments of a fusion protein of the invention will advantageously bind the target protein in the ER at a pH of 7.2 (±0.2), but release the target protein at a pH that is below pH 7.2 (±0.2), as found in the Golgi apparatus and secretory vesicles. Accordingly, a preferred TPB domain of a fusion protein of the invention binds or remains bound to a target protein at pH 7.2 (±0.2) or the conditions of the host cell ER, and then releases or does not bind the target protein at a pH below 7 or under conditions as found in the subsequent secretory pathway. In another embodiment, a TPB domain of a fusion protein of the invention is a polypeptide that binds a target protein at pH 7 or the conditions of the host cell ER and releases or does not bind a target protein at pH 6.7 or the conditions as found in the cis Golgi of a host cell. In another embodiment, a TPB domain of a fusion protein of the invention is a polypeptide that binds a target protein at pH 7 or the conditions as found in the ER and releases or does not bind a target protein at pH 6.3 or the conditions as found in the medial Golgi of a host cell. In another embodiment, a TPB domain of a fusion protein of the invention is a polypeptide that binds a target protein at pH 7 or the conditions found in the ER and releases or does not bind a target protein at pH 6.0 or the conditions (pH or otherwise) as found in the trans Golgi of a host cell. In still another embodiment, a TPB domain of a fusion protein of the invention is a polypeptide that binds a target protein at pH 7 or the conditions as found in the ER and releases or does not bind a target protein at pH of 5.5 or the conditions (pH or otherwise) as found in secretory vesicles of a host cell. The foregoing having been stated, working examples presented infra demonstrate that target protein binding domains derived from polypeptides known to have dissociation thresholds at lower pH (e.g., ˜pH 4.5) have been shown to work, and work well, in the secretion-enhancing fusion proteins of the present invention—such results indicating that factors in addition to pH influence the optimized enhancement results achieved according to the teachings herein.
(100) Keeping in mind the requirement for a CASE fusion protein of the invention to bind and release a target protein passing from the ER to secretory vesicles, examples of polypeptides that may be used as a TPB domain in a fusion protein of the invention include, but are not limited to, an antibody or antigen binding fragment thereof that specifically binds a target protein, an immunoglobulin-specific binding protein that binds a target protein that is an immunoglobulin or fragment thereof, an Fc-binding protein (when a target protein comprises an antibody Fc region), a ligand binding domain of a receptor protein that binds a target protein that is a ligand of the receptor (e.g., a binding portion of an IL13 receptor, where the target protein is IL13), a protein ligand when the target protein is a receptor or ligand binding fragment of a receptor (for example a cytokine, where the target protein is a cytokine receptor, or cytokine-binding fragment thereof), a PDZ domain when the target protein comprises a PDZ-binding domain, and the like. Binding proteins or polypeptide fragments binding to a target protein may be discovered by any known method, such as by screening a phage display library, yeast 2 hybrid system screening, far-western screening, high-throughput ELISA screening, and other methods.
(101) In an embodiment of the invention, a TPB domain of a CASE fusion protein of the invention may advantageously be any of a variety of non-immunoglobulin proteins and polypeptides, or portions thereof, which are known to specifically bind Fc domains under intracellular conditions but to dissociate from the Fc domain at some point along the secretory pathway. For example, a TPB domain that binds to an Fc region at pH 7 and dissociates from the Fc-containing target protein at a pH below 7, for instance at pH 6.7, pH 6.5, pH 6.3, pH 5.7, or pH 5.5 is expected to release the target protein at pH conditions that can be found in cellular secretory vesicles. The typical pH range encountered in the secretion system of mammalian cells is from about pH 7 to pH 5.5, and therefore the most preferred TPB domains utilized in the present invention will have dissociation conditions from the target in this range. TPB domains that dissociate from the target protein at pH lower than 5.5 may have limited utility in the methods of the present invention unless a host cell having a secretory pathway exhibiting more acidic condition is used, or the host cell culture is treated (e.g., by altering culture conditions) in a manner to effect the dissociation of the target protein from any co-expressed fusion protein according to the invention.
(102) A variety of standard ligand binding assays are available in the field for use in determining whether a particular protein or polypeptide is able to bind a particular ligand at one or more pH values. Such assays may include binding assays in which a target protein is labeled (for example, using a radiolabel, fluorescent label, or other signaling system) so that target protein can be detected whether bound or unbound by a protein comprising a TPB domain. Other binding assays include, without limitation, an immunoblot or an enzyme-linked immunosorbent assay (ELISA) that employs a detection antibody directed to the target protein for use in determining whether or not the target protein is bound to a protein comprising a TPB domain. Binding can also be measured in real time using surface plasmon resonance (SPR) binding assays.
(103) In some embodiments, a TPB domain will be selected on the basis of affinity for the target protein, e.g., in terms of a relatively rapid on rate constant (k.sub.on) or a relatively slow off rate constant (k.sub.off), as measured, for example, by surface plasmon resonance. A dissociation constant (K.sub.D) can be calculated according to the formula K.sub.D=k.sub.off/k.sub.on. In particular embodiments of the invention, a CASE fusion protein will have a dissociation constant (K.sub.D) to the target protein of 10.sup.−6 M or less.
(104) Examples of polypeptides that may be used as or in a TPB domain of a CASE fusion protein of the invention include, but are not limited to, an antigen binding site isolated from natural and genetically engineered antibodies and antigen-binding fragments thereof, wherein the antigen binding site of an antibody or antigen-binding fragment binds a target protein for which an enhanced level of secretion from a host cell is desired. In this context, antibodies can easily be raised that bind a target protein using standard methods available in the art, and antigen-binding fragments can be produced from such antibodies by well-known techniques, such as papain or pepsin digestion or using recombinant DNA methods, PCR methods, or other standard methods of manipulating and recombining DNA. A variety of genetically engineered antibody formats are known in the art that may be used for a TPB domain of a CASE fusion protein of the invention. Such formats include, but are not limited to, Fab fragments, F(ab′).sub.2 fragments, single chain Fv (scFv) antibodies, and single domain antibodies (dAb). See, for example, a review of the variety of functional genetically engineered antibody binding formats available in the art in Marvin et al., Acta Pharmacol. Sin., 26(6): 649-658 (2005); Kufer et al, Trends Biotechnol., 22(5): 238-244 (2004); Kontermann, Acta Pharmacol. Sin., 26(1): 1-9 (2005), and Chan et al., Nat. Rev, 10: 301-316 (2010). Particularly useful in the invention are antibody molecules or fragments in which an antigen binding site directed to a target protein is provided in a single polypeptide because such polypeptides can be easily linked to another domain or transmembrane retention domain to form a fusion protein of the invention using standard in vitro methods for recombining nucleic acids. For example, a single chain Fv antibody (scFv) comprises both VH and VL domains of an antigen binding site linked in a single polypeptide. Another source of a single chain antigen binding site is a single domain antibody (dAb) in which the entire antigen binding site is present in a single heavy chain variable domain. See, for example, Ward et al., Nature, 341: 544-546 (1989); Muyldermans et al., Protein Eng., 7: 1129-1135 (1994); Vu et al., Mol. Immunol., 34: 1121-1131 (1997); Muyldermans et al., Trends Biochem. Sci., 26: 230-235 (2001); Nguyen et al., Immunogenetics, 54: 39-47 (2002).
(105) By way of non-limiting example, in the case in which a target protein is a receptor or functional ligand-binding portion thereof, the protein ligand, or a receptor-binding portion thereof, may be used as a TPB domain in a CASE fusion protein of the invention. Functional portions of receptors include, but are not limited to, the extracellular domain of a membrane-associated receptor that includes a functional ligand-binding site. Typically, such extracellular portions comprising a functional ligand binding site are referred to as “truncated receptors” because the transmembrane and cytoplasmic domains of the receptor molecule have been removed. Using standard nucleic acid recombinant methods, a truncated receptor may be fused to an Fc region (such as a hinge-CH2-CH3 region) to form a truncated receptor-Fc fusion protein that dimerizes to form a homodimeric “trap” molecule that can bind two ligand molecules (by analogy to a naturally-occurring IgG molecule). An example of a truncated receptor fragment (“TF”) employed in the Examples below is an extracellular fragment of the IL-13Rα2 receptor, and a trap molecule derived from the truncated fragment of the IL-13Rα2 receptor is designated “IL13Rα2TF-Fc”. According to the invention, the level of a truncated receptor-Fc trap molecule secreted from a host cell may be elevated by co-expression with a cell-associated secretion-enhancing (CASE) fusion protein of the invention comprising the corresponding protein ligand of the receptor, or receptor-binding portion of the ligand, as its TPB domain, wherein the protein ligand is a single polypeptide chain, such as certain cytokine polypeptides (for example, IL13, IL8, and the like). Depending on the particular receptor protein species, other protein ligands that may be used in a CASE fusion protein as a TPB domain to bind a target receptor protein or ligand-binding portion thereof include, without limitation, a polypeptide co-receptor, a polypeptide co-repressor, and a polypeptide co-factor.
(106) For use in enhancing secretion of a target immunoglobulin protein or a synthetic construct comprising an Fc region (including trap molecules discussed above), a CASE fusion protein of the invention may comprise a polypeptide or portion thereof that possess an Fc binding domain. Proteins that can serve as a source of an Fc-binding domain for use in a TPB domain of a CASE fusion protein of the invention include, but are not limited to, a glycoprotein E (gE) or Fc-binding portion thereof from herpes simplex virus type 1 (HSV-1), a staphylococcal Protein A, a streptococcal Protein G, an FcBP protein, and the like. A gE/gI complex also has affinity for Fc regions. A number of synthetic peptides also have been identified that bind Fc domains. See, for example, DeLano et al., Science, 287:1279-1283 (2000); Yang et al., J. Peptide Res., 66(Suppl. 1): 120-137 (2006). As shown in the Examples below, such Fc-binding proteins and peptides may be particularly useful as TPB domains in CASE fusion proteins of the invention to provide enhanced levels of target proteins comprising an Fc region that are secreted from a host cell.
(107) In another non-limiting example, when a target protein of interest is a protein ligand (for example, a cytokine) that is bound by a known receptor molecule, a TPB domain of a fusion protein of the invention may comprise the cognate receptor, or ligand-binding portion thereof, that binds the target ligand protein.
(108) In an embodiment wherein the target protein, such as the cystic fibrosis transmembrane conductance regulator (CFTR) protein, possesses a PDZ-binding domain, then the TPB domain of a CASE fusion protein of the invention preferably comprises a PDZ domain from any of a variety of proteins that possess a PDZ domain. In a preferred embodiment, when a target protein possesses a PDZ-binding domain, a TPB domain of a CASE fusion protein of the invention comprises a PDZ domain from any of the members of the NHERF family of PDZ adapter proteins including, but not limited to, NHERF1 (also known as NHERF, EBP50, or SLC9A3R1), NHERF2 (also known as E3KARP or SLC9A3R2), and PDZK1 (also known as CAP70 or NHERF3).
(109) Transmembrane Retention (TMR) Domains Useful in the Invention
(110) Transmembrane proteins are membrane-bound proteins that comprise one or more transmembrane regions that are embedded in and traverse at least once a cellular membrane. Such a transmembrane region or a functional fragment thereof may be used as a transmembrane retention (TMR) domain of a cell-associated secretion-enhancing (CASE) fusion protein of the invention. According to the invention, a TMR domain prevents the fusion protein from being secreted from a host cell without interfering with the enhancement of the level of secretion of the target protein from the host cell.
(111) A TMR domain useful in a fusion protein of the invention may be isolated from a transmembrane protein that is associated with any of a variety of membranes of a cell including, but not limited to, a cell membrane, an endoplasmic reticulum membrane, a Golgi complex membrane, a lysosomal membrane, a nuclear membrane, and a mitochondrial membrane.
(112) There are four general classes or types of transmembrane proteins (Types I-IV). See, Nelson and Cox, Principles of Biochemistry (2008), FIG. 8-22. A schematic diagram of the general relevant features of the four types of transmembrane proteins is shown in FIG. 8. In FIG. 8, the transmembrane regions of each type of transmembrane protein are indicated schematically by loops within the lipid bilayer and are not meant to indicate any particular primary, secondary, tertiary, or quaternary structure of any particular protein species.
(113) A Type I transmembrane protein has its N-terminal region targeted to the endoplasmic reticulum (ER) lumen and its C-terminal region directed to the cytoplasm. A type II transmembrane protein has its N-terminal region targeted to the cytoplasmic domain and its C-terminal region directed to the ER lumen. A Type III transmembrane protein is a “multi-pass” transmembrane protein that has more than one segment of the translated protein that spans the cellular membrane. A Type IV transmembrane protein is also a multi-pass transmembrane protein, where multiple membrane-spanning regions orient to form an aqueous channel through the cellular membrane.
(114) A TMR domain of a cell-associated secretion-enhancing (CASE) fusion protein of the invention comprises all or part of a transmembrane region of a transmembrane protein that normally traverses the membrane of a cell with which the transmembrane protein is normally associated. A TMR domain of a CASE fusion protein of the invention may comprise not only a membrane-spanning region of a transmembrane protein but also additional amino acids of the transmembrane protein that are located in flanking regions, either upstream (N-terminal) and/or downstream (C-terminal) to the membrane-spanning or membrane-embedded region of the transmembrane protein. For example, in particular embodiments, the entire transmembrane region of a transmembrane protein will be used. In additional embodiments, the entire transmembrane region and all or part of any upstream or downstream region of the membrane-embedded portion of a transmembrane protein may be used as the TMR domain of a fusion protein according to the invention. Additional amino acids located upstream (N-proximal) from the membrane-embedded portion of a transmembrane protein that may be part of a TMR domain of a fusion protein of the invention may have a range of sizes including, but not limited to, 1 to 70 amino acids, 1 to 75 amino acids, or 1 to 80 amino acids. In some embodiments, a region of 1 to 75 amino acids of the upstream region may be used along with all or part of the membrane-embedded region as the TMR domain of a CASE fusion protein of the invention.
(115) In some embodiments, a TMR domains of a CASE fusion protein of the invention may comprise a membrane-embedded portion of a transmembrane protein as well as all or a portion of the C-terminal (downstream) portion of the membrane-embedded region of the transmembrane protein. Additional amino acids located downstream (C-proximal) from the membrane-embedded portion of a transmembrane protein that may be part of a TMR domain of a fusion protein of the invention may have a range of sizes including, but not limited to, 1 to 10 amino acids, 1 to 15 amino acids, 1 to 20 amino acids, 1 to 30 amino acids, 1 to 40 amino acids, 1 to 50 amino acids, 1 to 60 amino acids, 1 to 70 amino acids, 1 to 80 amino acids, 1 to 90 amino acids, 1 to 100 amino acids, 1 to 110 amino acids, 1 to 120 amino acids, 1 to 130 amino acids, 1 to 140 amino acids, 1 to 150 amino acids, 1 to 160 amino acids, 1 to 170 amino acids, and 1 to 200 amino acids.
(116) A TMR domain of a fusion protein described herein may also comprise the entire cytoplasmic region attached to a transmembrane region of a transmembrane protein or a truncation of the cytoplasmic region by one or more amino acids, for example, to eliminate an undesired signaling function of the cytoplasmic tail. For example, the presence of tandem lysine residues (dilysine) in the C-terminal portion of a cytoplasmic region of a transmembrane protein can serve as a signal to retain the transmembrane protein in the ER. Accordingly, if the membrane-embedded (transmembrane) region and all or part of the adjacent cytoplasmic C-terminal region of an ER-associated transmembrane protein is to be used as a TMR domain of a fusion protein of the invention, any known functional dilysine signal for ER retention should be eliminated or disrupted so that a fusion protein comprising the transmembrane region and any adjacent cytoplasmic region is not prevented by a dilysine ER retention motif from progressing out of the ER to the Golgi apparatus and/or secretory vesicles.
(117) Table 1, below, provides a list of several examples of transmembrane proteins along with the amino acid sequences of a portion of the protein that contains the transmembrane (TM) region (underlined). A TMR domain that may be used in a cell-associated secretion-enhancing (CASE) fusion proteins of the invention, will use a part of the transmembrane region sequence sufficient to cause the fusion protein to be retained with the cell (preferably, within the cellular membrane of the secretory pathway) when expressed in a host cell. Other portions of the transmembrane protein, including segments of the flanking regions upstream or downstream of the TM region may be used to construct a TMR domain, so long as their inclusion enhances, or at least does not significantly diminish the transmembrane retention functionality of the TMR domain. Within each of the fragmentary amino acid sequences for selected transmembrane proteins presented in Table 1, all of the sequences given in the table may potentially be used as a TMR domain, although not all transmembrane regions are as efficient as others in functioning as a TMR domain in CASE fusion proteins of the invention. Alternatively, internal segments including at least a portion of the underlined membrane-spanning region may be used to make up a TMR domain for a CASE fusion protein of the invention, so long as the selected segments provide the function of causing the expressed fusion protein to be retained in the host cell while the co-expressed target protein is secreted from the host cell.
(118) TABLE-US-00006 TABLE 1 Amino Acid Sequences of Representative Transmembrane Retention (TMR) Domains Amino Acid Sequence of isolated Name and Type of Transmembrane Retention Domain Transmembrane Protein SEQ ID NO. 123456789012345678901234567890 VSV-G (NP_955548; SEQ ID NO: 62 DDESLFFGDTGLSKNPIELVEGWFSSWKSS Vesicular stomatitis Indiana IASFFFIIGLIIGLFLVLRVGIHLCIKLKH virus glycoprotein) TKKRQIYTDIEMNRLGK Type I Human herpesvirus 1 SEQ ID NO: 63 PTHPHVGAPPHAPPTHGALRLGAVMGAALL Envelope glycoprotein E LSALGLSVWACMTCWRRRAWRAVKSRASGK (NP_044670.1) GPTYIRVADSELYADWSSDSEGERDQVPWL Type I APPERPDSPSTNGSGFEILSPTAPSVYPRS DGHQSRRQLTTFGSGRPDRRYSQASDSSVF W Human herpesvirus 1 SEQ ID NO: 64 PHGVNHEPPSNATRATRDSRSALTVTQIIQ Envelope glycoprotein I IAIPASIIALVFLGSCICFIHRCQRRYRRS (NP_044669.1) RRPIYMPQIPTGISCAVNEAAMARLGAELK Type I SHPSTPPKSRRRSSRTPMPSLTAIAEESEP AGAAGLPTPPVDPTTSTPTPPLLV human p23 SEQ ID NO: 65 TRVLYFSIFSMFCLIGLATWQVFYLRRFFK (NP_006818.3; AKKLIE Transmembrane emp24 domain-containing protein 10) Type I human p24 SEQ ID NO: 66 SRVVLWSFFEALVLVAMTLGQIYYLKRFFE (NP_006806.1; VRRW Transmembrane emp24 domain-containing protein 2) Type I human CD4 SEQ ID NO: 67 QPMALIVLGGVAGLLLFIGLGIFFCVRCRH (NP_000607.1; T-cell RRRQAERMSQIKRLLSEKKTCQCPHRFQKT surface glycoprotein CD4) CSPI Type I human Integrin αV SEQ ID NO: 68 PVPVWVIILAVLAGLLLLAVLVFVMYRMGF (NP_001138471.1; Integrin FKRVRPPQEEQEREQLQPHENGEGNSET alpha-V) Type I human UGT1 SEQ ID NO: 69 LDVIGFLLAVVLTVAFITFKCCAYGYRKCL NP_000454.1; UDP- GKKGRVKKAHKSKTH glucuronosyltransferase 1-1) Type I human Calnexin SEQ ID NO: 70 PFRMTPFSAIGLELWSMTSDIFFDNFIICA (NP_001019820.1; DRRIVDDWANDGWGLKKAADGAAEPGVVGQ Calnexin) MIEAAEERPWLWVVYILTVALPVFLVILFC Type I CSGKKQTSGMEYKKTDAPQPDVKEEEEEKE EEKDKGDEEEEGEEKLEEKQKSDAEEDGGT VSQEEEDRKPKAEEDEILNRSPRNRKPRRE human KDEL receptor 1 SEQ ID NO: 71 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG (NP_006792.1; ER lumen ISGKSQVLFAVVFTARYLDLFTNYISLYNT protein retaining receptor 1) CMKVVYIACSFTTVWLIYSKFKATYDGNHD Type III TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A Gp73 SEQ ID NO: 72 MMGLGNGRRSMKSPPLVLAALVACIIVLGF (NP_057632.2; Golgi NYWIA membrane protein 1) Type II human LAMP2 SEQ ID NO: 73 TILIPIIVGAGLSGLIIVIVIAYVIGRRKS (NP_001116078.1; YAGYQTL Lysosome-associated membrane glycoprotein 2) Type I human LIMP2 SEQ ID NO: 74 MGRCCFYTAGTLSLLLLVTSVTLLVARVF (NP_001191184.1; Lysosome membrane protein 2) fragment of TM domain Type III human LIMP2 SEQ ID NO: 75 TLIITNIPYIIMALGVFFGLVFTWLACKGQ fragment of TM domain GSMDEGTADERAPLIRT Type III human CD Man-6-P SEQ ID NO: 76 SHLSVGSILLVTFASLVAVYWGGFLYQRL receptor VVGAKGMEQFPHLAFWQDLGNLVADGCDFV (NP_002346.1; Cation- CRSKPRNVPAAYRGVGDDQLGEESEERDDH dependent mannose-6- LLPM phosphate receptor) Type I human CI Man-6-P receptor SEQ ID NO: 77 SQAVGAVLSLLLVALTCCLLALLLYKKERR (NP_000867.2; Cation- ETVISKLTTCCRRSSNVSYKYSKVNKEEET independent mannose-6- DENETEWLMEEIQLPPPRQGKEGQENGHIT phosphate receptor) TKSVKALSSLHGDDQDSEDEVLTIPEVKVH Type I SGRGAGAESSHPVRNAQSNALQEREDDRVG LVRGEKARKGKSSSAQQKTVSSTKLVSFHD DSDEDLLHI VSV-G (Vesicular SEQ ID NO: 78 SSWKSSIASFFFIIGLIIGLFLVLRVGIHL stomatitis Indiana virus CIKLKHTKKRQIYTDIEMMRLGK glycoprotein) truncated TMR domain Type I human Calnexin Truncated SEQ ID NO: 79 PFRMTPFSAIGLELWSMTSDIFFDNFIICA TMR DRRIVDDWANDGWGLKKAADGAAEPGVVGQ (NP_001019820.1; MIEAAEERPWLWVVYILTVALPVFLVILFC Calnexin) CSG Type I human KDEL receptor1 SEQ ID NO: 80 DLIAIVAGLVQTVLYCDFFYLYITKVLKGK truncated TMR domain KLSLPA (NP_006792.1; ER lumen protein retaining receptor 1) Type III Human ERGIC-53 SEQ ID NO: 81 LSTVHFIIFVVVQTVLFIGYIMYRSQQEAA (NP_005561; ER-Golgi AKKFF intermediate compartment 53 kDa protein) Type I gp84 Borna disease virus SEQ ID NO: 82 LGGVLYLISLCVSLPASFARRRRLGRWQE glycoprotein (NP_042023.1) Type I
(119) Selecting a TMR Domain
(120) Data provided in the Examples below indicate that several factors should be considered in selecting a transmembrane region for use as TMR domain in a CASE fusion protein of the invention. Among these factors are a recognition of what is the particular transmembrane protein type (Type I, II, III, or IV) being considered for use as the source of the TMR domain, a recognition of the natural subcellular location of the transmembrane protein, and a recognition that the target protein binding (TPB) domain and the TMR domain and, when present, the chaperone machinery polypeptide (CMP) domain, in a fusion protein according to the invention may affect each other's function in the overall process described herein for enhancing expression and secretion of a target protein of interest.
(121) As noted above and diagrammed in
(122) Knowing that a transmembrane region is derived from a particular type of transmembrane protein suggests a preferred orientation and location for the TMR domain relative to the CMP and TPB domains in a CASE fusion protein of the invention. This is particularly important with respect to Type I and Type II transmembrane proteins, which have fixed orientations and locations for their N- and C-termini with respect to the cytoplasm and ER lumen on either side of the transmembrane region. For example, when a transmembrane region from a Type I transmembrane protein is used as the TMR domain of a CASE fusion protein of the invention, the Type I-derived TMR is preferably located as the most C-terminal domain relative to the CMP and TPB domains. Thus, the most common configurations of a CASE fusion protein of the present invention that have a Type I-derived TMR domain will comprise an N-terminal to C-terminal linear structure illustrated as follows:
(123) (1) (TPB domain)-L-(TMR domain),
(124) (2) (CMP domain)-L-(TPB domain)-L-(TMR domain), or
(125) (3) (TPB domain)-L-(CMP domain)-L-(TMR domain),
(126) where each L in the formulae represents a direct peptide bond linking two domains or a linker of one or more amino acid residues.
(127) A preferred transmembrane region for use in a TMR domain of a CASE fusion protein of the invention is derived from the Type I vesicular stomatitis virus glycoprotein (VSV-G) as shown in Table 1 and in several of the examples below. In contrast, see Examples 10 and 22, in which the localization of a fusion protein utilizing the VSVG TMR domain is altered by introducing a dilysine motif near the end of the cytoplasmic tail that localizes the fusion protein in the ER, abolishing target protein secretion.
(128) In addition, a CASE fusion protein comprising a Type I-derived TMR domain preferably comprises an N-terminal signal sequence, which is characteristic of Type I transmembrane proteins to direct the N-terminus of the fusion protein through the ER membrane and into the ER lumen.
(129) When a transmembrane region of a Type II transmembrane protein is employed as a TMR domain, a CASE fusion protein of the invention preferably should comprise an arrangement of domains wherein the Type II-derived TMR domain is the most N-terminal domain relative to the CMP domain and the TPB domain. For example, a CASE fusion protein may comprise an arrangement of domains wherein, in an N-terminal to C-terminal direction, a Type II-derived TMR domain is linked to a CMP domain, which in turn is linked to a TPB domain. See, for example, the description of a Flag-tagged TMR(gp73)-CMP-TPB(gE) fusion protein in Table 49 of Example 21, below. In another example, the relative positions of the CMP domain and the TPB domain may be switched so that the fusion protein comprises an arrangement of domains wherein, in an N-terminal to C-terminal direction, a Type II-derived TMR domain is fused to a TPB domain, which in turn is fused to a CMP domain. In both arrangements, each domain may be linked to an adjacent domain directly (direct peptide bond) or via a linker of one or more amino acid residues. Thus, the most common configurations of a CASE fusion protein of the present invention that have a Type II-derived TMR domain will comprise an N-terminal to C-terminal linear structure illustrated as follows:
(130) (1) (TMR domain)-L-(TPB domain),
(131) (2) (TMR domain)-L-(CMP domain)-L-(TPB domain), or
(132) (3) (TMR domain)-L-(TPB domain)-L-(CMP domain),
(133) where each L in the formulae represents a direct peptide bond linking two domains or a linker of one or more amino acid residues.
(134) When a transmembrane region from a Type III transmembrane protein is used as the TMR domain of a CASE fusion protein of the invention, the location of the TMR domain in the linear structure of the fusion protein will vary according to how many membrane-spanning regions of the transmembrane region are selected and what is the orientation of the membrane-spanning region(s) selected, N-terminal to C-terminal, relative to the cytoplasmic and ER sides of the cellular membrane. Use of more than one TMR domain is also contemplated, especially when Type III-derived TMR domains are used, with the CMP domain and TPB domain preferably forming a loop oriented in the ER lumen between two membrane-anchoring TMR domains. See,
(135) Accordingly, possible linear configurations for a fusion protein of the invention utilizing TMR domains derived from Type III transmembrane proteins may be illustrated as follows and may include the use of plural TMR domains:
(136) (1) (TMR domain)-L-(TPB domain)
(137) (2) (TMR domain)-L-(CMP domain)-L-(TPB domain),
(138) (3) (TMR domain)-L-(TPB domain)-L-(CMP domain),
(139) (4) (TMR domain 1)-L-(TPB domain)-L-(TMR domain 2),
(140) (5) (TMR domain 1)-L-(CMP domain)-L-(TPB domain)-L-(TMR domain 2),
(141) (6) (TMR domain 1)-L-(TPB domain)-L-(CMP domain)-L-(TMR domain 2),
(142) (7) (TPB domain)-L-(TMR domain),
(143) (8) (CMP domain)-L-(TPB domain)-L-(TMR domain), or
(144) (9) (TPB domain)-L-(CMP domain)-L-(TMR domain),
(145) where each L in the formulae represents a direct peptide bond linking two domains or a linker of one or more amino acid residues and wherein “TMR domain 1” may be the same as or different from “TMR domain 2”.
(146) In preferred embodiments a TMR domain derived from all or a portion of a Type III protein transmembrane region is located as the most C-terminal domain relative to the CMP and TPB domains, similar to the preferred arrangement for using a Type I-derived TMR domain. Unlike Type I transmembrane proteins, Type III transmembrane proteins do not require an N-terminal signal sequence to direct the N-terminus of the transmembrane protein into the ER membrane and through to the ER lumen. In a CASE fusion protein comprising a Type III-derived TMR domain, however, an N-terminal signal sequence may still be required to achieve the desired position of the CMP and TPB domains in the ER lumen.
(147) In the same manner as TMR domains may be selected from the transmembrane region of a Type III protein, a suitable TMR domain may be selected from all or a portion of a Type IV protein. It will be recognized, however, that for the purposes of the present invention, the channel-forming function of a Type IV transmembrane region will typically be an unwanted property; consequently, the TMR domain selected will have that channel-forming function disrupted and only a transmembrane retention function will be retained.
(148) Least preferred as a source of a transmembrane region for a TMR domain in a CASE fusion protein of the invention is any protein that naturally and permanently resides in the membrane of the endoplasmic reticulum (ER). The transmembrane regions of such ER-associated proteins, such as calnexin, appear to be particularly well-anchored to the ER membrane and prevent the protein from passing into the Golgi apparatus. Fusion proteins comprising a TMR domain comprising the transmembrane region of ER-associated proteins, such as calnexin, are greatly diminished in the ability to promote secretion of target proteins of interest relative to fusion proteins in which the TMR domain comprises the transmembrane region of a protein that does not naturally reside in the ER.
(149) Moreover, the presence of tandem lysine residues (dilysine) in the C-terminal portion of a cytoplasmic region of a transmembrane protein can serve as a signal to retain the transmembrane protein in the ER. Jackson et al., EMBO J., 9(10): 3153-3162 (1990). This tandem lysine ER-retention motif typically occurs as the most C-terminal set of tandem lysine residues, such as at −4 and −3 positions from the C-terminus of a protein. Accordingly, if the transmembrane region of such an ER-associated transmembrane protein is to be used as a TMR domain of a fusion protein of the invention, the functional dilysine signal for ER retention should be eliminated or disrupted so that a fusion protein comprising the transmembrane region and any additional cytoplasmic region does not prevent the fusion protein from progressing out of the ER to the Golgi apparatus.
(150) A preferred transmembrane region for use in a TMR domain of a CASE fusion protein of the invention is derived from the Type III KDEL receptor 1 (KDELR) protein as shown in Table 1 and in the examples below, such as Examples 19 and 21. Unlike proteins known to reside exclusively in the ER, the KDELR protein is known to move between the ER and Golgi and therefore, it is presumed, the transmembrane region does not function to permanently anchor the protein in the ER.
(151) Standard Assays for Polypeptides Useful as Transmembrane Retention (TMR) Domains
(152) In addition to the particular features of the invention elucidated in the examples below, it is evident that proteins comprising an Fc region, such as the IL13Rα2TF-Fc and TNFR1TF-Fc fusion proteins, are also useful as representative target proteins of interest in assays to determine whether or not a particular polypeptide is useful as a transmembrane retention (TMR) domain in a cell-associated secretion-enhancing (CASE) fusion protein according to the invention. In such a TMR assay, a recombinant nucleic acid molecule is produced by standard methods (for example, nucleic acid synthesis, recombinant DNA techniques, and/or polymerase change reaction (PCR) methods) that encodes the amino acid sequence of a fusion protein comprising a target protein binding (TPB) domain comprising a polypeptide that binds the Fc region fused in frame with a candidate TMR domain. The candidate TMR domain comprises a portion of a membrane protein that normally resides in or traverses a cellular or intracellular membrane in accordance with the features of a TMR domain described herein.
(153) Non-limiting, illustrative, examples of pairs of fusion proteins differing in TMR domains include the TPB(gE)-TMR(VSVG) fusion protein in Table 5 and the TPB(gE)-TMR(KDELR) fusion protein in Table 8, the TPB(gE)-TMR(VSGV) fusion protein in Table 10 and the TPB(gE)-TMR(KDELR) fusion protein in Table 8, the TPB(Prot A)-TMR(VSVG) fusion protein in Table 11 and the TPB(Prot A)-TMR(KDELR) fusion protein in Table 14, the TPB(Prot G)-TMR(VSVG) fusion protein in Table 12 and the TPB(Prot G)-TMR(KDELR) fusion protein in Table 15, and the TPB(GB919)-TMR(VSVG) fusion protein in Table 13 and the TPB(GB919)-TMR(KDELR) fusion protein in Table 16. Thus, by way of non-limiting example, in order to test or assess any candidate polypeptide as a TMR domain, a nucleic acid encoding the candidate TMR domain is linked in frame to a nucleic acid encoding the common portion of any of the above pairs of fusion proteins. The resulting recombinant nucleic acid encoding the test fusion protein is then inserted into an expression vector, such as the pcDNA′ expression vector used in the examples. A separate recombinant vector is made to express the target protein, such as the IL13Rα2TF-Fc or TNFR1TF-Fc target protein. Cells of a mammalian cell line, such as HEK 293 cells used in the examples below, are co-transfected with the two expression vectors. Control cells are transfected only with the expression vector encoding the target protein. The transfected cells are then isolated and grown in culture under conditions that permit expression of the proteins encoded on the expression vectors. Control cells are transfected only with the recombinant expression vector encoding the target protein. Samples of the culture media are assayed for the level of secreted target protein, for example using enzyme linked immunosorbent assay (ELISA) as described herein. An enhancement in the level of secreted target protein as compared to the level of target protein in the media of control cells indicates that the fusion protein, and therefore the candidate polypeptide was useful as TMR domain in accordance with the invention. Preferably, the level of enhancement in the level of target protein secreted into the media of cultures of cells co-expressing the fusion protein and the target protein is at least 1.5-fold higher than that of the control cells expressing the target protein alone. Enhancing the level of secreted target protein that is also a therapeutically and commercially important protein by 1.5-fold or more can provide a significant reduction in production costs and also a significant increase in the availability of the therapeutically and commercially important protein.
(154) Chaperone Machinery Polypeptide (CMP) Domains Useful in the Invention
(155) The ability of a cell-associated secretion-enhancing (CASE) fusion protein of the invention comprising a target protein binding (TPB) domain and a transmembrane retention (TMR) domain to enhance the level of secretion of a co-expressed target protein may be still further enhanced by incorporating into the fusion a chaperone machinery peptide (CMP) domain. Whereas the interactions of the TMR and TPB domains with cell components are relatively well defined, i.e., the secretory membrane system and the intended co-expressed target protein, respectively, the precise interaction of a CMP domain with the cell is not. However, as explained and demonstrated herein, in view of the fact that a significant enhancement of the level of target protein secreted from a host cell ion is observed using portions of known components of a cell's chaperone system, it is presumed that a CMP, whether a portion of a known chaperone protein or a synthetic derivative thereof, in some way recruits some aspect of chaperone system to increase the yield of target protein secreted from a host cell. Especially preferred for use as a CMP domain of a CASE fusion protein according to the invention are isolated J domains of J proteins, polypeptides from within the a helix II region of J domains, and analogs of such polypeptides from within the a helix H region of J domains defined by structural formula I as described below.
(156) Chaperone and Co-Chaperone Proteins as CMP Domains
(157) To deal with the continual risk of not attaining or maintaining proper functional protein conformations, cells possess a system of proteins that serve as molecular chaperones to assist in the folding and refolding of nascent and mature proteins into their proper conformations. The heat shock 70 kilodalton (kDa) proteins (also referred to “Hsp70s”) constitute one of the most ubiquitous classes of chaperone proteins in the cells of a wide variety of eukaryotic and prokaryotic cells. The “Hsp70 machinery” comprises chaperone proteins, co-chaperone proteins, such as J proteins, and nucleotide exchange factors (NEFs). A protein of the Hsp70 machinery of a cell may be used as a CMP domain of a fusion protein of the invention. Perhaps reflecting the fact that such chaperone proteins are ubiquitous in both eukaryotic and prokaryotic cells, eukaryotic chaperone proteins, such as BipATPase, as well as prokaryotic chaperone proteins, such as DnaK, may be used as a CMP domain in fusion proteins of the invention for promoting secretion of a target protein of interest from a eukaryotic host cell. A CMP domain of a fusion protein of the invention may also be a fragment of a functional chaperone or co-chaperone protein. A preferred co-chaperone protein for use as a CMP domain of a fusion protein of the invention is a co-chaperone protein such as a J protein. A CMP domain of a fusion protein of the invention may also comprise a J domain of a J protein, a polypeptide from a J domain, or a J domain analog that comprises amino acid sequences that may not be known to be present in any J domain.
(158) J Domains as CMP Domains
(159) Members of the family of J proteins, including so-called Hsp40-like proteins, are classically defined by the presence of a J domain, which is a region typically between 45-75 amino acids in length with structural and sequence features similar to the prototypical 73-amino acid DnaJ protein of Escherichia coli. The J domains of a variety of co-chaperone J proteins have been determined. See, for example, Kampinga et al., Nat. Rev., 11: 579-592 (2010); Hennessy et al., Protein Science, 14:1697-1709 (2005). A J domain useful as a CMP domain of a cell-associated secretion-enhancing (CASE) fusion protein of the invention has the key defining features of a J domain of members of the J protein family, namely, a polypeptide domain from a J protein characterized by four α-helices (I, II, III, IV) and typically having the highly conserved tripeptide sequence of histidine, proline, and aspartic acid (referred to as the “HPD motif”) located at the amino terminal end of a “loop” region between helices II and III. Only a few J domains have been identified that lack the HPD motif. The site of interaction (binding) of a J domain with an Hsp70-ATP chaperone protein complex is believed to be a region extending from within helix II and including the HPD motif. Representative J domains include, but are not limited to, a J domain of the bacterial DnaJ protein, a J domain of an ERdj protein (for example, a J domain of ERdj3 or ERdj5), a J domain of a large T antigen of SV40, and a J domain of a mammalian cysteine string protein (CSP-α). The amino acid sequences for these and other, non-limiting representative J domains that may be used as CMP domains in fusion proteins of the invention are provided in Table 2 below.
(160) It is noted that computer programs used to identify J domains are typically in agreement with respect to identifying the above-mentioned essential regions and motifs that define a J domain within a J protein. However, there can be some variability between programs with respect to which amino acids of a J protein are identified as the amino and carboxy residues of the J domain with the J domain. Such variability is typically with respect to the inclusion or exclusion of from one to several amino acid residues at the amino and carboxy termini of the output sequence of the entire J domain. In the construction and use of various CASE fusion proteins according to the invention, such as in the Examples below, no evidence has been obtained that would implicate such minor variations in the boundary residues of a J domain within a J protein as causing any significant difference in the results.
(161) TABLE-US-00007 TABLE 2 Amino acid Sequences of Representative Isolated J Domains SEQ ID J Domain Amino Acid Sequence J Protein Source of J Domain NO: 123456789012345678901234567890 human Hsp40 16 KDYYQTLGLARGASDEEIKRAYRRQALRYH (NP_006136; Heat Shock Protein PDKNKEPGAEEKFKEIAEAYDVLSDPRK 40) human ErdJ1 17 LNFYQFLGVQQDASSADIRKAYRKLSLTLH (NM_022365; DnaJC1, HTJ1, PDKNKDENAETQFRQLVAIYEVLKDDER MTJ1, DnaJ homolog subfamily C member 1 protein, DNAJL1) human ErdJ2 18 YNPYEVLNLDPGATVAEIKKQYRLLSLKYH (NM_001017975; HFM1, PDKGGDEVMFMRIAKAYAALTDEES SEC63 domain containing 1 protein, MER3, hHFM1) human ErdJ3 19 RDFYKILGVPRSASIKDIKKAYRKLALQLH (NM_016306; DNAJB11, DnaJ PDRNPDDPQAQEKFQDLGAAYEVLSDSEK (Hsp40) homolog, subfamily B, member 11, ERj3p, HEDJ, ERj3, ABBP2, ER-associated DNAJ protein 3) human ErdJ4 20 KSYYDILGVPKSASERQIKKAFHKLAMKYH (NM_012328; DNAJB9, PDKNKSPDAEAKFREIAEAYETLSDANR microvascular differentiation gene 1 protein, MDG1, endothelial Mdg1) human ErdJ5 21 QDFYSLLGVSKTASSREIRQAFKKLALKLH (NM_018981; DNAJC10, ER- PDKNPNNPNAHGDFLKINRAYEVLKDEDL resident protein ERdj5, JPD1, J- domain-containing protein disulfide isomerase-like protein, DnaJ (Hsp40) homolog, subfamily C, member 10, hMTHr protein) human ErdJ6 22 RDYYKILGVKRNAKKQEIIKAYRKLALQWH (NM_006260; DNAJC3, PDNFQNEEEKKKAEKKFIDIAAAKEVLSDP DnaJ (Hsp40) EM homolog, subfamily C, member 3 protein, protein-kinase, interferon- inducible double stranded RNA dependent inhibitor protein, P58IPK protein, PRKRI, 58 kDa cellular inhibitor protein, p58 inhibitor of protein kinase) human CSP 23 ESLYHVLGLDKNATSDDIKKSYRKLALKYH (NP_079495; cysteine string PDKNPDNPEAADKFKEINNAHAILTDATK protein alpha, CSPalpha protein, DNAJC5 protein, cysteine string protein, DnaJ (Hsp40) homolog, subfamily C, member 5 protein, CSP protein) SV40 large T antigen 24 LQLMDLLGLERSAWGNIPLMRKAYLKKCKE (YP_003708382; large tumor FHPDKGGDEEKMKKMNTLYKKMEDGVK antigen T-ag [Simian virus 40]) DnaJ 25 QDYYEILGVSKTAEEREIKKAYKRLAMKYH PDRNQGDKEAEAKFKEIKEAYEVLTDSQK human dnaJ homolog subfamily C, 26 NPFEVLQIDPEVTDEEIKKRFRQLSILVHP member 8 DKNQDDADRAQKAFEAVDKAYKLLLDQEQK KRALDVIQ human dnaJ homolog subfamily C, 27 EALYEILGLHKGASNEEIKKTYRKLALKHH member 5B PDKNPDDPAATEKFKEINNAHATLTDISK human dnaJ homolog subfamily C, 28 LNPFHVLGVEATASDVELKKAYRQLAVMVH member 14 PDKNHHPPAEEAFKVLRAAWDIVSNAEK human dnaJ homolog subfamily C, 29 RDCYEVLGVSRSAGKAEIARAYRQLARRYH member 25 precursor PDRYRPQPGDEGPGRTPQSAEEAFLLVATA YETLKDEET human dnaJ homolog subfamily B, 30 ASYYEILDVPRSASADDIKKAYRRKALQWH member 2, isoform a PDKNPDNKEFAEKKFKEVAEAYEVLSDKHK human dnaJ homolog subfamily B, 31 ASYYEILDVPRSASADDIKKAYRRKALQWH member 2, isoform b PDKNPDNKEFAEKKFKEVAEAYEVLSDKHK Chain A, 32 TTYYDVLGVKPNATQEELKKAYRKLALKYH nmr structure of Bc008182 PDKNPNEGSKFKQISQAYEVLSDAKK protein, a human Dnaj-like domain Chain A, 33 ASYYEILDVPRSASADDIKKAYRRKALQWH solution structure of J Domain of PDKNPDNKEFAEKKFKEVAEAYEVLSDKHK Hsj1a Chain A, 34 KDSWDMLGVKPGASRDEVNKAYRKLAVLLH solution structure of a Dnaj-like PDKCVAPGSEDAFKAVVNARTALLKNIK domain from human ras-associated protein Rap1 Chain A, 35 VDYYEVLDVPRQASSEAIKKAYRKLALKWH solution structure of Dnaj domain PDKNPENKEEAERRFKQVAEAYEVLSDAKK of human protein Hcg3, a hypothetical protein Tmp_locus_21 Chain A, 36 GDYYQILGVPRNASQKEIKKAYYQLAKKYH solution structure of J domain PDTNKDDPKAKEKFSQLAEAYEVLSDEVK from Dnaj homolog, human Tid1 protein Chain A, 37 GSYYDILGVPKSASERQIKKAFHKLAMKYH solution structure of J domain PDKNKSPDAEAKFREIAEAYETLSDANR from human Dnaj subfamily B, member 9 Chain A, 38 GDYYEILGVSRGASDEDLKKAYRRLALKFH solution structure of J domain PDKNHAPGATEAFKAIGTAYAVLSNPEK from human Dnaj subfamily B, member 12 Chain A, 39 KDYYQTLGLARGASDEEIKRAYRRQALRYH human Hsp40 (HDJ-1), nmr PDKNKEPGAEEKFKEIAEAYDVLSDPRK Chain A, solution structure of 40 TALYDLLGVPSTATQAQIKAAYYRQCFLYH Dnaj domain from human PDRNSGSAEAAERFTRISQAYVVLGSATL Williams-Beuren syndrome chromosome region 18 protein Chain A, solution structure of J 41 ANYYEVLGVQASASPEDIKKAYRKLALRWH domain of Dnaj homolog PDKNPDNKEEAEKKFKLVSEAYEVLSDSKK subfamily B, member 8 Chain A, solution structure of J 42 EDYYTLLGCDELSSVEQILAEFKVRALECH domain of Dnaj homolog PDKHPENPKAVETFQKLQKAKEILTNEES subfamily C, member 12 Chain A, Dnaj domain of human 43 SILKEVTSWEQAWKLPESERKKIIRRLYL Kiaa0730 protein KWHPDKNPENHDIANEVFKHLQNEINR human dnaJ homolog, subfamily 44 VDYYEVLGVQRHASPEDIKKAYRKLALKWH B, member 6, isoform a PDKNPENKEEAERKFKQVAEAYEVLSDAKK human dnaJ homolog, subfamily 45 VDYYEVLGVQRHASPEDIKKAYRKLALKWH B, member 6, isoform b PDKNPENKEEAERKFKQVAEAYEVLSDAKK human dnaJ homolog, subfamily 46 KSYYDILGVPKSASERQIKKAFHKLAMKYH B, member 9 precursor PDKNKSPDAEAKFREIAEAYETLSDANR human DnaJ (Hsp40) homolog, 47 LNPFEVLQIDPEVTDEEIKKRFRQLSILVH subfamily C, member 8, PDKNQDDADRAQKAFEAVDKAYKLLLDQEQ isoform CRA_c human DnaJ (Hsp40) homolog, 48 DDAYEVLNLPQGQGPHDESKIRKAYFRLAQ subfamily C, member 13, KYHPDKNPEGRDMFEKVNKAYEFLCTKSA isoform CRA_b human DnaJ (Hsp40) homolog, 49 REAALILGVSPTANKGKIRDAHRRIMLLNH subfamily C, member 19, PDKGK isoform CRA_e human DnaJ (Hsp40) homolog, 50 ESLYHVLGLDKNATSDDIKKSYRKLALKYH subfamily C, member 5, PDKNPDNPEAADKFKEINNAHAILTDATK isoform CRA_b human DnaJ (Hsp40) homolog, 51 STYYELLGVHPGASTEEVKRAFFSKSKELH subfamily C, member 4, PDRDPGNPSLHSRFVELSEAYRVLSREQS isoform CRA_f human zinc finger, CSL-type 52 KDWYSILGADPSANISDLKQKYQKLILMYH containing 3, isoform CRA_c PDKQSTDVPAGTVEECVQKFIEIDQAWKIL GNEET human DnaJ (Hsp40) homolog, 53 MDLYALLGIEEKAADKEVKKAYRQKALSCH subfamily C, member 17, PDKNPDNPRAAELFHQLSQALEVLTDAAA isoform CRA_a human DnaJ (Hsp40) homolog, 54 KSYYDILGVPKSASERQIKKAFHKLAMKYH subfamily B, member 9, PDKNKSPDAEAKFREIAEGASVPAASSF isoform CRA_a human DnaJ (Hsp40) homolog, 55 STYYELLGVHPGASTEEVKRAFFSKSKELH subfamily C, member 4, PDRDPGNPSLHSRFVELSEAYRVLSREQS isoform CRA_g human DnaJ (Hsp40) homolog, 56 STYYELLGVHPGASTEEVKRAFFSKSKELH subfamily C, member 4, PDRDPGNPSLHSRFVELSEAYRVLSREQS isoform CRA_a human DnaJ (Hsp40) homolog, 57 EDYYSLLNVRREASSEELKAAYRRLCMLYH subfamily C, member 11, PDKHRDPELKSQAERLFNLVKQAYEVLSDP isoform CRA_c QT human zinc finger, CSL-type 58 KDWYSILGADPSANISDLKQKYQKLILMYH containing 3, isoform CRA_b PDKQSTDVPAGTVEECVQKFIEIDQAWKIL G-NEET human J-type co-chaperone 59 RDYFSLMDCNRSFRVDTAKLQHRYQQLQRL HSC20, isoform CRA_c VHPDFFSQRSQTEKDFSEKHSTLVNDAYKT LLAPLS human hCG1994888, isoform 60 RDCYEVLGVSRSAGKAEIARAYRQLARRYH CRA_d PDRYRPQPGDEGPGRTPQSAEEAFLLVATA YETLKDEET human DnaJ (Hsp40) homolog, 61 TTYYDVLGVKPNATQEELKKAYRKLALKYH subfamily A, member 1, PDKNPNEGEKVKMLYISSQ isoform CRA_a
(162) J Domain Active Fragments and J Domain Analogs as CMP Domains
(163) The terms “J domain active fragment” or “active fragment of a J domain” refer to a fragment of a J domain of a co-chaperone J protein that retains the ability to increase the level of secreted target protein when present as a CMP domain in a cell-associated secretion-enhancing (CASE) fusion protein described herein. J domain active fragments useful in the invention will commonly retain the region of a J domain at the C-terminal extremity of a helix II. Larger portions of a J domain may be active as well, but excision of all or part of the C-terminal nine amino acids of a helix II invariably leads to loss of protein secretion enhancement activity.
(164) Only a relatively small portion of a J domain is required for use as a CMP domain of a CASE fusion to provide an enhancement in the level of target protein secreted from a host cell. Such enhancement in the level of target protein secreted from a cell may be provided by a polypeptide fragment isolated from within a J domain and that consists of as little as 9 or 10 amino acids. Individual J domain polypeptide fragments useful in the invention are not all identical in amino acid sequence, but may share some sequence homology and structural features in addition to providing an enhanced activity required for use as a CMP domain of a CASE fusion protein of the invention. J domain active fragments and J domain analog polypeptides useful in the invention include those previously described for enhancing expression of a target protein expressed in transfected host cells in International Publication No. WO 2014/089375. In particular, a J domain analog that may be used as a CMP domain in a CASE fusion protein of the invention may be a polypeptide that comprises the amino acid sequence of formula I:
(165) TABLE-US-00008 (I) (SEQ ID NO: 1) X1-X2-X3-X4-X5-X6-X7-X8-X9, X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M); X2 and X3 are each independently any amino acid with the proviso that one or both are K or R; X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present; X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F); X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present.
(166) Examples of J domain analog polypeptides that may be used as CMP domain in CASE fusion protein of the invention include, but are not limited to:
(167) TABLE-US-00009 Amino Acid Sequence Sequence Identifier 123456789012345 SEQ ID NO: 6 IKKAYRKLA SEQ ID NO: 2 IKKAYKLALQ SEQ ID NO: 3 IKKAYRLALQ SEQ ID NO: 4 IKKAYRKALQ SEQ ID NO: 5 IKKAYRKLLQ SEQ ID NO: 203 IKKYRKLA SEQ ID NO: 204 IKKAYKLA SEQ ID NO: 205 IKKAYRLA SEQ ID NO: 206 IKKAYRKA SEQ ID NO: 207 LKKAYRKLA SEQ ID NO: 208 VKKAYRKLA SEQ ID NO: 209 MKKAYRKLA SEQ ID NO: 210 AKKAYRKLA SEQ ID NO: 211 IAKAYRKLA SEQ ID NO: 212 IKAAYRKLA SEQ ID NO: 213 IKKRYRKLA SEQ ID NO: 214 IKKSYRKLA SEQ ID NO: 215 IKKQYRKLA SEQ ID NO: 216 IKKEYRKLA SEQ ID NO: 217 IKKFYRKLA SEQ ID NO: 218 IKKCYRKLA SEQ ID NO: 219 IKKAFRKLA SEQ ID NO: 220 IKKAWRKLA SEQ ID NO: 221 IKKAYRKQA SEQ ID NO: 222 IKKAYRKMA SEQ ID NO: 223 IKKAYRKIA SEQ ID NO: 224 IKKAYRKAA SEQ ID NO: 225 IKKAYRKVA SEQ ID NO: 226 IKKAYRKRA SEQ ID NO: 227 IKKAYRKLM SEQ ID NO: 228 IKKAYRKLI SEQ ID NO: 229 IKKAYRKLV SEQ ID NO: 230 IKKAYRKLC SEQ ID NO: 231 IKKAYRKLS SEQ ID NO: 232 IKKAYRKLY SEQ ID NO: 7 IRKAYRKLSLTL SEQ ID NO: 8 IKKQYRLLSLKY SEQ ID NO: 9 IKKAFHKLAMKY SEQ ID NO: 10 IRQAFKKLALKL SEQ ID NO: 11 IIKAYRKLALQW SEQ ID NO: 12 IARAYRQLARRY SEQ ID NO: 13 IKRAYRRQALRY SEQ ID NO: 14 IKKSYRKLALKY SEQ ID NO: 15 IKKAYKRLAMKY
(168) A preferred polypeptide of the foregoing formula I for use as a CMP domain in a CASE fusion of protein of the invention is an isolated peptide having or comprising the amino acid sequence I-K-K-A-Y-R-K-L-A (SEQ ID NO:6), which also corresponds to a region within the J domain of the Erdj3 protein.
(169) In addition to a J domain active fragment or a J domain analog polypeptide of formula I described herein, another polypeptide that may be used as a CMP domain in a cell-associated secretion-enhancing (CASE) fusion protein of the invention is a decapeptide selected from the group consisting of:
(170) TABLE-US-00010 (SEQ ID NO: 2) IKKAYKLALQ, (SEQ ID NO: 3) IKKAYRLALQ, (SEQ ID NO: 4) IKKAYRKALQ, and (SEQ ID NO: 5) IKKAYRKLLQ.
(171) Another polypeptide that may be used as a CMP domain in a CASE fusion protein of the invention is an isolated polypeptide from a J domain of a J protein comprising an amino acid sequence selected from the group consisting of:
(172) TABLE-US-00011 (SEQ ID NO: 6) IKKAYRKLA, (SEQ ID NO: 7) IRKAYRKLSLTL, (SEQ ID NO: 8) IKKQYRLLSLKY, (SEQ ID NO: 9) IKKAFHKLAMKY, (SEQ ID NO: 10) IRQAFKKLALKL, (SEQ ID NO: 11) IIKAYRKLALQW, (SEQ ID NO: 12) IARAYRQLARRY, (SEQ ID NO: 13) IKRAYRRQALRY, (SEQ ID NO: 14) IKKSYRKLALKY, and (SEQ ID NO: 15) IKKAYKRLAMKY.
(173) Particularly preferred for use as a CMP domain in a CASE fusion protein of the invention is an isolated polypeptide having or comprising the amino acid sequence IKKAFHKLAMKY (SEQ ID NO:9), which is the sequence of an isolated polypeptide of the Erdj4 protein.
(174) The smaller size of J domain polypeptide fragments and of J domain analog polypeptides compared to complete (full-length) J domains reduces the size of the fusion protein that is constructed and co-expressed with a target protein in a host cell. Thus, the size of recombinant nucleic acid molecules encoding such fusion proteins can be correspondingly smaller than nucleic acid molecules that encode fusion proteins comprising a complete J domain as a CMP domain.
(175) BAG Domains as CMP Domains
(176) Members of the BAG family of proteins found in eukaryotes are a type of co-factor of the chaperone system referred to as a nucleotide exchange factor (NEF). NEF possess diverse N-terminal domains and a conserved C-terminal Hsp70-binding domain (the BAG domain) that can interact with the ATPase domain of Hsp70. See, for example, Kampinga et al., Nat. Rev. Biol., 11:579-592 (2010). BAG proteins have a topology, binding domains, and binding specificities that are consistent with a protein designed to participate in recruiting the Hsp70 chaperone machinery. Although a BAG protein might participate as a NEF in the Hsp70 machinery, many studies suggest that BAG proteins may predominantly be involved in regulatory mechanisms to control a variety of activities, including promoting cell growth, quiescence, or apoptosis; regulating transcription complex formation; and modulating signal transduction. See, for example, the review by Takayama et al., Nat. Cell Biol., 3: E237-E241 (2001). Recently, it has been reported that when recombinant proteins of interest are linked to a BAG domain, the resulting fusion proteins are expressed at levels that are greater than those of the protein alone. See, International Publication No. WO 2012/087835 A2.
(177) A cell-associated secretion-enhancing (CASE) fusion protein of the invention clearly has a structure and function unlike any of the previously described BAG fusion proteins. A BAG domain may serve as a CMP domain in a CASE fusion protein described herein provided the co-expression of the fusion protein with a target protein of interest in a host cell significantly enhances the level of target protein secreted from the host cell as compared to the level in the absence of the fusion protein and provided the fusion protein remains associated with the host cell.
(178) In addition to those mentioned above, suitable CMP domains may be derived from other molecular chaperones of cellular chaperone machinery known to those skilled in the art. Additional CMP domains may be found, for example, in molecular chaperones such as Bip (Binding immunoglobulin protein), molecular co-chaperones such as a nucleotide exchange factor, or a protein molecule involved in protein folding/cellular quality control systems. Table 3, below, lists several proteins involved in cellular chaperone machinery that may be used as sources of polypeptides for use in a CMP domain of a CASE fusion protein of the invention.
(179) TABLE-US-00012 TABLE 3 Proteins of Cellular Chaperone Machinery Providing CMP Domains Source of CMP sequence ER resident member Function/Activity Hsp70 family Bip/Grp78/HSPA5 Protein folding Hsp40 family Erdj1/Mtj1/DnaJC1 Protein folding Erdj2/hSec63/DnaJC2 Protein folding Erdj3/HEDJ/Erj3/ABBP-2/DnaJB11 Protein folding Erdj4/Mdg1/DnaJB9 Protein folding Erdj5/JPDI/DnaJC10 Protein folding Erdj6/P58IPK/PRKRI/DnaJC3 Protein folding Erdj7/Erj7/DnaJC25 Protein folding Hsp90 family Grp94/Hsp90b1/Tra1 Protein folding Hsp60 family N/A Protein folding Small heat shock N/A Protein folding proteins Lectin Calnexin Protein folding/ recognition of protein misfolding Calreticulin Protein folding/ recognition of protein misfolding OS9 Protein degradation/ recognition of protein misfolding XTPB-3/XTP3 Protein degradation/ recognition of protein misfolding Lectin/EDEM family EDEM1 Protein degradation/ recognition of protein misfolding EDEM2 Protein degradation/ recognition of protein misfolding EDEM3 Protein degradation/ recognition of protein misfolding Cyclophilin Cyclophilin B Peptidyl-prolyl isomerase FKBP FKBP2 Peptidyl-prolyl isomerase FKBP7 Peptidyl-prolyl isomerase FKBP9 Peptidyl-prolyl isomerase FKBP10 Peptidyl-prolyl isomerase FKBP11 Peptidyl-prolyl isomerase FKBP13 Peptidyl-prolyl isomerase FKBP14 Peptidyl-prolyl isomerase FKBP23 Peptidyl-prolyl isomerase FKBP52 Peptidyl-prolyl isomerase FKBP60 Peptidyl-prolyl isomerase FKBP65 Peptidyl-prolyl isomerase Other Peptidyl-prolyl Peptidyl-prolyl cis-trans isomerase Peptidyl-prolyl isomerases D/Cyp40 isomerase CNPY3/Protein canopy homolog 3 Protein folding Ero1 Ero1 alpha Sulfydryl oxidase Ero1 beta Sulfydryl oxidase Oxidereductase PDI Protein disulfide- isomerase PDIR Protein disulfide- isomerase Erp5/P5/Protein disulfide-isomerase A6 Protein disulfide- isomerase ERp18/Thioredoxin domain- Protein disulfide- containing protein 12 isomerase ERp19/Thioredoxin domain- Protein disulfide- containing protein 12 isomerase ERp27 Protein disulfide- isomerase ERp29 Protein disulfide- isomerase ERp46/Thioredoxin domain- Protein disulfide- containing protein 5 isomerase ERp72/Protein disulfide-isomerase Protein disulfide- A4 isomerase ERp57/Grp58/Protein disulfide- Protein disulfide- isomerase A3 isomerase SEP15 Protein disulfide- isomerase PDI-Erv QSOX1 Thiol oxidase QSOX2 Thiol oxidase Hsp110/HSP105 N/A Nucleotide Exchange Factor BAG family N/A Nucleotide Exchange Factor Nucleotide Exchange GRP170/HYOU1/ORP150 Protein folding Factor for Bip Nucleotide Exchange BAP/SIL1 Protein folding Factor for Bip Sel1 Protein degradation/ recognition of protein misfolding Glycosyl transferase UGGT/UDP-glucose:glycoprotein recognition of protein glucosyltransferase 1 misfolding/ Glycosylation
(180) The efficacy of an isolated CMP domain to enhance the level of secretion of a target protein may be determined experimentally by comparing the level of target protein secreted from a host cell that co-expresses the target protein and a fusion protein comprising a TPB domain that binds the target protein, a TMR domain, and the CMP domain with the level of target protein that is secreted from a host cell that co-expresses the target protein and the same or essentially the same fusion protein, but lacking the CMP domain. Such experimental methods are illustrated in the working examples below.
(181) Linkers
(182) Within a cell-associated secretion-enhancing (CASE) fusion protein of the invention, any domain may be linked to an adjacent domain by methods known in the art. By way of non-limiting example, a chaperone machinery peptide (CMP) domain may be linked directly to a target protein binding (TPB) domain or linked indirectly via a linker of one or more amino acid residues. Or, in another non-limiting example, a TPB domain may be linked directly to a transmembrane retention (TMR) domain or linked indirectly via a linker of one or more amino acid residues. Other domains, such as an epitope tag, may also be linked directly to an adjacent domain or linked indirectly via a linker in a CASE fusion protein of the invention. A CASE fusion protein of the invention may use one or more linkers to link one or more adjacent domains, and the linkers may be the same or different in amino acid composition and in length of amino acid residues.
(183) At the amino acid level, a linker may be one or more amino acids, including 1 to 10 amino acids, 1 to 20 amino acids, and even 1 to 50 amino acids. Typically, for CASE fusion proteins comprising TPB, TMR, and CMP domains, with respect to linking a CMP domain to a TPB domain or to a TMR domain, it is not necessary to use a linker that is more than 20 amino acids because linking a CMP domain via a short linker of 20 or fewer amino acids to a TPB domain does not significantly diminish the necessary biochemical and functional properties of the TPB domain (data not shown).
(184) Selecting one or more polypeptide linkers to produce a CASE fusion protein according to the invention is within the knowledge and skill of practitioners in the art. See, for example, Arai et al., Protein Eng., 14(8): 529-532 (2001); Crasto et al., Protein Eng., 13(5): 309-314 (2000); George et al., Protein Eng., 15(11): 871-879 (2003); Robinson et al., Proc. Natl. Acad. Sci. USA, 95: 5929-5934 (1998). General considerations for using a particular linker to link one domain with another domain in a CASE fusion protein may include those in making other fusion proteins in which one functional domain is linked to another functional domain, for example, as may be considered in linking immunoglobulin variable and/or constant domains in a wide variety of formats for producing engineered functional binding proteins. Clearly, a linker preferably does not interfere with the respective functions of the domains in a CASE fusion protein according to the invention. A linker, if present in a fusion protein of the invention, is selected to optimize the yield of the target protein secreted from a cell, and it may be omitted if direct attachment of a one domain to another domain of the fusion protein achieves a desired enhanced level of secretion of a co-expressed target protein. Linkers present in a CASE fusion protein of the invention may comprise one or more amino acids encoded by a nucleotide sequence present on a segment of nucleic acid in or around a cloning site of an expression vector into which is inserted in frame a nucleic acid segment encoding one or more protein domains (e.g., TPB, TMR, and/or CMP domain) or an entire fusion protein as described herein.
(185) Linkers, especially those that are four amino acids and longer, preferably possess a flexibility that permits the component domains of the fusion protein to fold into its proper, functional conformation. A variety of relatively flexible linkers are known in the field for linking functional domains. A linker may also be used to link one or more additional domains, such as an epitope tag, to a domain of a CASE fusion protein of the invention. Examples of linkers of two or more amino acids that may be used in preparing a fusion protein according to the invention include, but are not limited to, LE, SR, LEG, GSR, GTGSEFDIAAALE (SEQ ID NO:175); GTGSGEF (SEQ ID NO:176); DIAAA (SEQ ID NO:83); DIAAALE (SEQ ID NO:84); GTGSEF (SEQ ID NO:85); AS; TVA; ASTK (SEQ ID NO:86); GGGSGGSGGSGG (SEQ ID NO:87); DIGGGSGGSGGSGGAAA (SEQ ID NO:88); DIGGGGSGGGGSGGGGSAAA (SEQ ID NO:178); AKTTPKLEEGEFSEAR (SEQ ID NO:89); AKTTPKLEEGEFSEARV (SEQ ID NO:90); AKTTPKLGG (SEQ ID NO:91); SAKTTPKLGG (SEQ ID NO:92); SAKTTP (SEQ ID NO:93); RADAAP (SEQ ID NO:94); RADAAPTVS (SEQ ID NO:95); RADAAAAGGPGS (SEQ ID NO:96); RADAAAA(G.sub.4S).sub.4 (SEQ ID NO:97); SAKTTPKLEEGEFSEARV (SEQ ID NO:98); ADAAP (SEQ ID NO:99); ADAAPTVSIFPP (SEQ ID NO:100); TVAAP (SEQ ID NO:101); TVAAPSVFIFPP (SEQ ID NO:102); QPKAAP (SEQ ID NO:103); QPKAAPSVTLFPP (SEQ ID NO:104); AKTTPP (SEQ ID NO:105); AKTTPPSVTPLAP (SEQ ID NO:106); AKTTAP (SEQ ID NO:107); AKTTAPSVYPLAP (SEQ ID NO:108); ASTKGP (SEQ ID NO:109); ASTKGPSVFPLAP (SEQ ID NO:110); GGGGS (SEQ ID NO:181); GGGGSGGGGS (SEQ ID NO:180); GGGGSGGGGSGGGGS (SEQ ID NO:111); GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:179); GENKVEYAPALMALS (SEQ ID NO:112); GPAKELTPLKEAKVS (SEQ ID NO:113); GHEAAAVMQVQYPAS (SEQ ID NO:114); GGGGGGGP (SEQ ID NO:115); GGGGGGGGP (SEQ ID NO:116); PAPNLLGGP (SEQ ID NO:117); PNLLGGP (SEQ ID NO:118); GGGGGGP (SEQ ID NO:119); PAPELLGGP (SEQ ID NO:120); PTISPAPNLLGGP (SEQ ID NO:121); TVAADDDDKSVFIVPP (SEQ ID NO:122); TVDDDDKAAP (SEQ ID NO:123); LVPRGSAAP (SEQ ID NO:124); ASTKGPSV (SEQ ID NO:125); ASTKGPSVFP (SEQ ID NO:126); TVAAPSV (SEQ ID NO:127); TVAAPSVFI (SEQ ID NO:128); and the like. Particular mention is made of the series of linkers based on polymers of GGGGS (SEQ ID NO:181), having the shorthand formula “(G.sub.4S).sub.x”, wherein x is an integer, preferably 1, 2, 3, or 4.
(186) As will be apparent from studying diagrams and the amino acid sequences of fusion protein constructs described in detail below, only linker sequences of 8 amino acid residues or more are depicted schematically in the diagrams of fusion proteins appearing in the drawings. Examples of polypeptide linkers of 8 or more amino acids are depicted in
(187) Fusion Protein Constructs
(188) A cell-associated secretion-enhancing (CASE) fusion protein of the invention comprises at least two main domains: a target protein binding (TPB) domain and a transmembrane retention (TMR) domain. A CASE fusion protein of the invention may further comprise a chaperone machinery peptide (CMP) domain. Although not wishing to be bound by any particular scientific theory of how a fusion protein of the invention operates, a rational approach for constructing a fusion protein of the invention is to consider the orientation of the Type (I-IV) of transmembrane protein from which the TMR domain is derived and then arrange the TPB domain and, if present, the CMP domain, relative to that TMR domain so that the TPB domain and, if present, the CMP domain, will be present in the lumen of the endoplasmic reticulum (ER) where the target protein of interest is also located, as explained below. The CASE fusion protein is believed to act as a sort of synthetic chaperone protein, assisting in the transmission of the target protein to which it binds along the secretory pathway.
(189) In addition to a TPB domain, a TMR domain, and, if present, a CMP domain, a CASE fusion protein according to the invention may also comprise an appropriate signal sequence to direct the TPB domain and, if present, a CMP domain of the fusion protein on expression into the lumen of the endoplasmic reticulum (ER). In particular embodiments, the signal sequence will be fused at the N-terminus of the fusion protein, in particular where the TMR domain is derived from a Type I transmembrane protein and is located at the C-terminal end of the fusion protein. The signal sequence may conveniently correspond to the signal sequence of the protein from which the N-terminal domain of the fusion protein is derived. For example, where the most N-terminal domain is a J domain of a J protein (or a fragment or analog thereof), it is preferred to use a signal sequence from the same J protein that supplied the J domain. Alternatively, the signal sequence of a soluble secreted protein may be used, as in the constructs disclosed below that utilize the signal sequence from human insulin. However, any suitable signal sequence that operates to translocate the TPB and/or CMP domains of the CASE fusion protein to the ER may be utilized.
(190) The orientations of the transmembrane regions of the four types (Types I-IV) of transmembrane proteins with respect to cytoplasm and ER lumen are diagrammed in
(191) In contrast to the Type I transmembrane protein, in a Type II transmembrane protein, the TM region is in the N-terminal region of the protein so that the N-terminus of the protein is in the cytoplasm and the C-terminal region of the protein is in the ER lumen. See,
(192) For the construction of a CASE fusion protein with a TMR domain derived from a multi-pass transmembrane protein (having more than one traversal of the cellular membrane), such as a Type III transmembrane protein, the location of a TPB domain and, when present, a CMP domain in a CASE fusion protein of the invention, will depend on the known configuration of the multi-pass transmembrane protein. See,
(193) Nucleic Acids Encoding CASE Fusion Proteins
(194) Standard techniques may be used for constructing recombinant nucleic acid molecules, transfecting cells (for example, without limitation, electroporation, liposome-mediated transfection, transformation methods) with vector molecules, and culturing host cells to express a cell-associated secretion-enhancing (CASE) fusion protein of the invention alone or to co-express the fusion protein with a target protein of interest. Enzymatic reactions and purification techniques may be performed as commonly accomplished in the art, as described in a manufacturer's specifications, or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) and Ausubel et al. (eds.), Current Protocols in Molecular Biology (John Wiley & Sons, New York, 2012), which are incorporated herein by reference.
(195) Using standard methods available in the art as mentioned above, a nucleic acid molecule (typically DNA) is constructed that encodes a CASE fusion protein that promotes secretion of a co-expressed target protein of interest from a host cell at a significantly enhanced level as compared to the level of target protein secreted in the absence of the CASE fusion protein. A nucleic acid molecule encoding a desired CASE fusion protein can be inserted into any of a variety cloning vectors available in the art for the purpose of replicating the recombinant structural gene for the CASE fusion protein. For expressing a CASE fusion protein, a nucleic acid molecule encoding the CASE fusion protein can be inserted into any of a variety of expression vectors available in the art, wherein the inserted nucleic acid is operably linked to transcriptional and translational signals required for expression in a compatible host cell. An expression vector with the inserted nucleic acid encoding the CASE fusion protein is then introduced into a compatible host cell that permits expression of the fusion protein from the expression vector. In one embodiment, the vector may also contain a copy of a functional structural gene encoding the target protein of interest if the host cell does not already possess a functional gene for the target protein of interest, for example, in the chromosome of the host cell or in another expression vector present in the host cell.
(196) While a description herein for assembling a nucleic acid construct encoding a CASE fusion protein of the invention may suggest a particular stepwise order to the linking of various nucleic acid molecules followed by insertion of the fully assembled nucleic acid construct into an expression vector, it will be understood and appreciated that the exact order of linking segments of nucleic acid molecules to produce a nucleic acid construct encoding a desired CASE fusion protein is at the discretion of the practitioner in this art. Moreover, although it is possible to first link all segments together to form a nucleic acid molecule encoding a CASE fusion protein prior to insertion into an expression vector, in some cases, a nucleic acid segment encoding one or more domains may already properly reside within an expression vector so that it is practical to insert one or more nucleic acid segments adjacent to the segment(s) already residing in the expression vector and thereby assemble within the expression vector an operably linked structural gene for a desired fusion protein of the invention.
(197) Expression vectors encoding a CASE fusion protein of the invention may be transfected into any of a variety of host cells that are compatible for expressing the fusion protein from the particular expression vector. Although some steps in the process of constructing a recombinant structural gene encoding a CASE fusion protein of the invention may be conducted in either prokaryotic or eukaryotic cells, the preferred host cell for expressing and using CASE fusion protein to enhance the level of secretion of a co-expressed target protein of interest is a eukaryotic host cell, more preferably a cell of an isolated animal cell line, and even more preferably a cell of an isolated mammalian cell line. Examples of eukaryotic host cells that are useful in the invention include, but are not limited to, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell. Mammalian host cells useful for co-expressing a fusion protein of the invention and a target protein of interest include, but are not limited to, a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, and an MDCK cell. Fungal host cells useful for expressing a fusion protein of the invention include, but are not limited to, Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. A particularly useful Saccharomyces host cell is a Saccharomyces cerevisiae cell.
(198) By following the methods and examples described herein, significantly enhanced levels of a target protein of interest secreted from a recombinant host cell may be achieved. For the purposes of the invention, a significantly enhanced level of a target protein secreted from a host cell is achieved where at least a 1.5-fold increase in the level of secreted target protein is obtained, when compared with the level of the same target protein secreted from a host cell not utilizing a co-expressed CASE fusion protein according to the invention. As noted above, for a secreted target protein of interest that is also a therapeutically and commercially important protein, an enhancement of 1.5-fold or more would be recognized by persons in the pharmaceutical industry as providing a significant reduction in production costs and also a significant increase in the availability of the therapeutically and commercially important protein. As demonstrated in the examples that follow, increases in the level of target protein secreted from a host cell of greater than 1.5-fold, 2-fold, 2.5-fold, 3-fold, 4-fold, 4.5-fold, 6-fold, 7-fold, 8-fold, 10-fold, and 15-fold have been achieved. In preferred embodiments, an enhanced level of target protein secreted from a host cell of at least 2-fold the level of target protein secreted from a host cell in the absence of a CASE fusion protein is achieved. More preferably, use of a CASE fusion protein of the invention results in an increase in the level of a co-expressed target protein secreted from a host cell of 2.5-fold or higher. Most preferably, the enhanced level of target protein secreted from a host cell is achieved without a significant amount of the CASE fusion protein being co-secreted with the target protein into the extracellular media.
EXAMPLES
Example 1
Compositions and Methods for Enhancing Levels of Secretion of Target Proteins Using a Co-Expressed Cell-Associated Secretion-Enhancing (CASE) Fusion Protein Retained in the Host Cell
(199) Expression vector plasmids were constructed for expressing fusion proteins for enhancing the level of secretion of specific proteins (target proteins). As described below, fusion proteins were usually linked to a standard epitope tag for easy identification or isolation using a corresponding anti-tag antibody and standard immunoblot (such as dot blot, Western blot) assays.
(200) A DNA linker molecule having a nucleotide sequence containing various restriction enzyme sites for cloning heterologous DNA molecules was produced by annealing two single-stranded DNA molecules having the sequences shown below (5′ to 3′):
(201) TABLE-US-00013 (SEQ ID NO: 129) AGCTTGGTACCGGATCCGAATTCGATATCGCGGCCGCTCTCGAGTCTAGA GGGCC and (SEQ ID NO: 130) CTCTAGACTCGAGAGCGGCCGCGATATCGAATTCGGATCCGGTACCA.
(202) The annealed linker molecule was then inserted into plasmid pcDNA3 (catalogue no. V790-20, Invitrogen) digested with HindIII and ApaI downstream of a CMV promoter to yield the expression vector plasmid pcDNA′ for use in mammalian host cells. The pcDNA′ expression vector was used in the studies described in the examples below that show an enhancement in the level of a target protein of interest secreted from transfected cells co-expressing the target protein and a fusion protein according to the invention.
(203) DNA molecules encoding the V5 epitope tag (GKPIPNPLLGLDST; SEQ ID NO:131) or the Flag epitope tag (DYKDDDDK; SEQ ID NO:132) were synthesized and inserted into plasmid pcDNA′ digested with XhoI and XbaI, to yield plasmids V5-pcDNA′ and Flag-pcDNA′, respectively.
(204) A DNA molecule having the coding sequence for the Flag epitope tag, i.e., GATTACAAGGATGACGATGACAAG (SEQ ID NO:133), was inserted into plasmid pcDNA′ digested with XhoI and XbaI to yield plasmid Flag-pcDNA′.
(205) To express Factor VII protein (FVII), a DNA molecule encoding FVII protein was inserted into plasmid V5-pcDNA′ digested with HindIII and KpnI.
(206) A DNA molecule encoding an Fc region polypeptide of a human IgG1 molecule was synthesized and inserted into V5-pcDNA′ digested with XbaI and ApaI.
(207) Unless indicated otherwise, each DNA molecule encoding a target protein binding (TPB) domain for a corresponding target protein of interest in the examples below was inserted into plasmid Flag-pcDNA′ digested with NotI and XhoI to yield the corresponding (TPB domain)-pcDNA′ vector.
(208) Unless indicated otherwise, a DNA molecule encoding a C-terminal transmembrane retention (TMR) domain was cloned into a (TPB domain)-Flag-pcDNA′ vector digested with XbaI and ApaI to yield the corresponding (TPB domain)-Flag-(TMR domain)-pcDNA′ plasmid vector.
(209) Unless indicated otherwise, a DNA molecule encoding an N-terminal transmembrane retention (TMR) domain was cloned into plasmid Flag-pcDNA′ digested with HindIII and KpnI to yield the corresponding (TMR domain)-(TPB domain)-Flag-pcDNA′ vector.
(210) Unless indicated otherwise, a DNA molecule encoding a chaperone machinery peptide (CMP) was inserted into Flag-pcDNA′ vectors digested with EcoRI and EcoRV to yield the corresponding (CMP)-Flag-pcDNA′ vector.
(211) Expression and Detection of Target Proteins in HEK293 Cells and Culture Media
(212) A host cell was transfected with a separate expression vector for each protein (target protein, fusion protein, green fluorescent protein) that was intended to be expressed in the host cell. Expression vector plasmids encoding various protein constructs were transfected into human embryonic kidney (HEK293) cells with X-tremeGENE™ HP transfection reagent (catalogue no. 06365752001, Roche Applied Science, Penzberg, Germany) or with FUGENE® HD transfection reagent (catalogue no. E2311, Promega, Madison, Wis., USA), which yielded comparable transfection efficiencies.
(213) Unless otherwise indicated, every transfection included a plasmid expressing a green fluorescent protein (GFP) as an internal control for monitoring transfection efficiency.
(214) Cultures of transfected cells were incubated for two days, and cells were lysed in lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM EDTA, 2% SDS) containing 2 mM phenylmethylsulfonyl fluoride (PMSF) protease inhibitor. After brief sonication, cells were analyzed for expressed proteins using dot blot or Western immunoblot (Western blot) assays. For Western blot analysis, culture samples (for example, cells, cell-free culture medium, or cells and medium) were boiled in SDS-sample buffer (reducing and denaturing conditions) and run on polyacrylamide electrophoresis gel, followed by transfer of separated protein bands to polyvinylidene difluoride membrane (PVDF membrane). The expression of GFP as an internal transfection control was detected using an anti-GFP antibody.
(215) Expressed proteins in dot and Western blots were detected using a chemiluminescent signal. Briefly, blots were reacted with a primary antibody that binds the particular epitope tag (e.g., V5 or Flag) carried by the proteins. After rinsing away unreacted primary antibody, a secondary, enzyme-linked antibody (e.g., horseradish peroxidase-linked anti-IgG antibody) was allowed to react with primary antibody molecules bound to the blots. After rinsing, manufacturer's chemiluminescent reagent was added. Chemiluminescent signals in blots were captured on X-ray film. Where indicated, the images of the chemiluminescent signals were scanned with a densitometer and analyzed using the NIH ImageJ image processing program.
(216) Plasmid for humanized anti-IL-8 antibody, p6G425V11N35A.choSD (catalog No. 209552) was purchased from the American Type Culture Collection (Manassas, Va.).
(217) Fc Fusion Proteins
(218) One strategy that has been employed to generate more stable forms of therapeutically relevant proteins, and especially receptor proteins, is to prepare a fusion protein version of a protein of interest in which all or a functional portion of the protein of interest is linked to an immunoglobulin “Fc region” comprising the “CH2-CH3” or “hinge-CH2-CH3” regions of an immunoglobulin heavy chain using, for example, recombinant DNA methods, including polymerase chain reaction (PCR). Upon expression, the Fc regions of each of two fusion proteins can associate to form a homodimer in a manner similar to what occurs when two immunoglobulin heavy chains dimerize via their respective Fc regions, while preserving the functional portion of the protein of interest fused to each Fc region so that the homodimer comprises two functional portions of the protein of interest. Such an Fc target protein format has been used to design families of potentially useful drugs that provide a desired therapeutically relevant activity and, owing to the presence of the dimerized Fc regions, also exhibits an increased in vivo serum half-life, which in turn should reduce dosing frequencies. Several such Fc target proteins have been constructed to illustrate the operation of the present invention in the following examples. Fc target proteins include those in which a truncated form (TF) of a cell surface receptor protein comprises the extracellular ligand-binding portion of the cell surface receptor protein that is fused to an Fc region to yield a soluble version of the receptor referred to as a “trap” molecule. Such Fc trap molecules include the IL13Rα2TF-Fc fusion protein and the TNFR1TF-Fc fusion protein used in the studies described in the Examples below. Such Fc trap molecules may comprise a standard epitope tag, such as a Flag or V5 epitope tag, which permits the Fc trap molecule to be detected using a corresponding standard anti-tag antibody (for example, anti-Flag or anti-V5 epitope tag antibody). Such epitope tags may be located at the N-terminus or C-terminus of the Fc fusion protein or even within the Fc fusion protein, for example, between the amino acid sequence of the truncated receptor (IL13Rα2TF or TNFR1TF) and the amino acid sequence for the Fc region, as shown in the examples described below.
Example 2
Enhanced Level of Secreted IL13Rα2-Fc Target Protein
(219) In this experiment, an IL13Rα2-Fc target protein (trap molecule) was used as a representative example of an Fc target protein. The IL13 receptor, IL13Rα2, is a membrane protein that binds to interleukin-13 (IL13) and mediates allergic inflammation. The IL13Rα2 receptor protein is known to be an unstable protein in a mammalian cell due to the difficulties of protein folding (Genetic Engineering & Biotechnology News, 28(5) (2008)). Part of the expressed IL13Rα2 protein is digested on the cell surface and shed into the extracellular space. The truncated form that is shed from the cell surface is approximately the N-terminal 320 amino acids of mature IL13Rα2. This truncated form of IL13Rα2 still possesses the ability to bind IL13, but cannot transmit a signal to the cell owing to the absence of transmembrane and cytoplasmic regions of the full-length IL13Rα2 protein. Therefore, the truncated form of IL13Rα2 has been used as a type of decoy receptor to treat asthma by binding IL13 molecules without transducing a signal to the cell to set off an inflammatory response (Zhang, et al., J. Biol. Chem., 272(14): 9474-80 (1997)). A genetically engineered, truncated form of IL13Rα2 has been expressed in bacteria, however the protein aggregates into inclusion bodies. It is known that one limitation to the expression of the truncated IL13Rα2 protein by transfected cells has been ascribed to inefficient folding into its proper functional conformation. When proteins cannot fold into their proper conformation they are ushered to the proteasome for degradation and scavenging of amino acids. Accordingly, production of truncated IL13Rα2 molecules in transfected cells has been recognized as a technical problem by industry and there is a persistent desire to overcome the natural limitations of expression and secretion for this protein (Lee et al., Cell Technol. for Cell Products, 29-39 (2007)).
(220) The truncated form of IL13Rα2 used herein is referred to as “IL13Rα2TF”. In this experiment, the IL13Rα2TF was fused to an Fc region (hinge-CH2-CH3) to form an IL13Rα2TF-Fc trap molecule, which was employed as a target protein of interest. Upon expression, the IL13Rα2TF-Fc trap molecule forms a homodimer by pairing of CH3 domains of two monomers. This experiment examined the effect of co-expression of the IL13Rα2TF-Fc target protein and a cell-associated secretion-enhancing (CASE) fusion protein on the level of secretion of the IL13Rα2TF-Fc target protein from a transfected HEK293 host cell.
(221)
(222) TABLE-US-00014 TABLE 4 Amino Acid Sequence of a V5-Tagged IL13Rα2TF-Fc Target Protein Monomer Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 V5-tagged SEQ ID NO: 137 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI IL13Rα2TF-Fc KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD target protein HFKECTVEYELKYRNIGSETWKTIITKNLH YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ SSWAETTYWISPQGIPETKVQDMDCVYYNW QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH ALQCVDYIKADGQNIGCRFPYLEASDYKDF YICVNGSSENKPIRSSYFTFQLQNIVKPLP PVYLTFTRESSCEIKLKWSIPLGPIPARCF DYEIEIREDDTTLVTATVENETYTLKTTNE TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC WEGEDLSKKGTGSEFDIAAALEGKPIPNPL LGLDSTSRPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK IL13Rα2 signal Residues 1-26 MAFVCLAIGCLYTFLISTTFGCTSSS sequence of SEQ ID NO: 137 IL13Rα2TF residues 27-339 DTEIKVNPPQDFEIVDPGYLGYLYLQWQPP of SEQ ID LSLDHFKECTVEYELKYRNIGSETWKTIIT NO: 137 KNLHYKDGFDLNKGIEAKIHTLLPWQCTNG SEVQSSWAETTYWISPQGIPETKVQDMDCV YYNWQYLLCSWKPGIGVLLDTNYNLFYWYE GLDHALQCVDYIKADGQNIGCRFPYLEASD YKDFYICVNGSSENKPIRSSYFTFQLQNIV KPLPPVYLTFTRESSCEIKLKWSIPLGPIP ARCFDYEIEIREDDTTLVTATVENETYTLK TTNETRQLCFVVRSKVNIYCSDDGIWSEWS DKQCWEGEDLSKK Linker residues 340-352 GTGSEFDIAAALE of SEQ ID NO: 137 V5 epitope residues 353-366 GKPIPNPLLGLDST domain of SEQ ID NO: 137 Linker residues 367-368 SR of SEQ ID NO: 137 Fc domain residues 369-599 PKSCDKTHTCPPCPAPELLGGPSVFLFPPK of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN NO: 137 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK
(223)
(224) TABLE-US-00015 TABLE 5 Amino Acid Sequence of a Flag-Tagged TPB(gE)-TMR(VSVG) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 182 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(gE)- FDIAAAGTPKTSWRRVSVGEDVSLLPAPGP TMR(VSVG) fusion TGRGPTQKLLWAVEPLDGCGPLHPSWVSLM protein PPKQVPETVVDAACMRAPVPLAMAYAPPAP SATGGLRTDFVWQERAAVVNRSLVIHGVRE TDSGLYTLSVGDIKDPARQVASVVLVVQPA PVPTPPPTPADYDEDDNDEGEDESLAGTPA SGTPRLPPPPAPPRSWPSAPEVSHVRGVTV RMETPEAILFSPGETFSTNVSIHAIAHDDQ TYSMDVVWLRFDVPTSCAEMRIYESCLYHP QLPECLSPADAPCAASTWTSRLAVRSYAGC SRTNPPPRCSAEAHMEPVPGLAWQAASVNL EFRDASPQHSGLYLCVVYVNDHIHAWGHIT ISTAAQYRNAVVEQPLPQRGADLAELEGDY KDDDDKGSRSSWKSSIASFFFIIGLIIGLF LVLRVGIHLCIKLKHTKKRQIYTDIEMNRL GK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 182 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 182 TPB(gE) Domain residues 37-415 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 182 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 416-418 LEG of SEQ ID NO: 182 Flag epitope residues 419-426 DYKDDDDK domain of SEQ ID NO: 182 Linker residues 427-429 GSR of SEQ ID NO: 182 TMR(VSVG) Domain residues 430-482 SSWKSSIASFFFIIGLIIGLFLVLRVGIHL of SEQ ID CIKLKHTKKRQIYTDIEMNRLGK NO: 182
(225) HEK293 cells were transfected with expression vector plasmids to compare levels of IL13Rα2TF-Fc target protein secreted into culture media when the IL13Rα2TF-Fc target protein was expressed alone or co-expressed with the TPB(gE)-TMR(VSVG) fusion protein. Transfected cells were cultured for two days, and samples of cell cultures were harvested and analyzed by Western blot (immunoblot) assay using a horseradish peroxidase-conjugated goat anti-human IgG (heavy and light chains) polyclonal F(ab′).sub.2 antibody (Code No. 109-036-088, Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.) to detect the IL13Rα2TF-Fc target protein in Western blots. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as negative controls. The results of culturing the transfectant host cells and detecting IL13Rα2TF-Fc target protein expression by Western blot are shown in
Example 3
Comparison of Enhanced Levels of Secreted IL13Rα2TF-Fc Target Protein Using Fusion Proteins with Different Transmembrane Retention (TMR) Domains
(226) This experiment compared the level of IL13Rα2-Fc target protein secreted from a host cell when co-expressed with either of two fusion proteins that differ in their transmembrane retention (TMR) domains or when co-expressed with either of the component TMR domains of the fusion proteins.
(227) The V5-tagged IL13Rα2TF-Fc target protein used in this experiment was the same as described in Example 2 and Table 4 above.
(228)
(229) Two different Flag-tagged TMR polypeptides were used in this study as “TMR only” polypeptides. One of the Flag-tagged TMR polypeptides comprised a transmembrane region of the VSVG protein. The amino acid sequence for this Flag-tagged TMR(VSVG) polypeptide is shown in Table 6 below.
(230) TABLE-US-00016 TABLE 6 Amino Acid Sequence for Flag-Tagged TMR(VSVG) Polypeptide Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 183 MALWMRLLPLLALLALWGPDPAAAGTGSGE TMR(VSVG) fusion FDIAAALEGDYKDDDDKGSRSSWKSSIASF protein FFIIGLIIGLFLVLRVGIHLCIKLKHTKKR QIYTDIEMNRLGK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 183 Linker residues 25-39 GTGSGEFDIAAALEG of SEQ ID NO: 183 Flag epitope residues 40-47 DYKDDDDK domain of SEQ ID NO: 183 Linker residues 48-50 GSR of SEQ ID NO: 183 TMR(VSVG) Domain residues 51-103 SSWKSSIASFFFIIGLIIGLFLVLRVGIHL of SEQ ID CIKLKHTKKRQIYTDIEMNRLGK NO: 183
(231) The other Flag-tagged TMR polypeptide used in this experiment comprised a transmembrane region of the KDEL receptor 1 protein. The amino acid sequence for this Flag-tagged TMR(KDELR) polypeptide is shown in Table 7 below.
(232) TABLE-US-00017 TABLE 7 Amino Acid Sequence of a Flag-Tagged TMR(KDELR) Polypeptide Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 184 MALWMRLLPLLALLALWGPDPAAAGTGSGE TMR(KDELR) FDIAAALEGDYKDDDDKGSRNLFRFLGDLS fusion protein HLLAIILLLLKIWKSRSCAGISGKSQVLFA VVFTARYLDLFTNYISLYNTCMKVVYIACS FTTVWLIYSKFKATYDGNHDTFRVEFLVVP TAILAFLVNHDFTPLEILWTFSIYLESVAI LPQLFMVSKTGEAETITSHYLFALGVYRTL YLFNWIWRYHFEGFFDLIAIVAGLVQTVLY CDFFYLYITKVLKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 184 Linker residues 25-39 GTGSGEFDIAAALEG of SEQ ID NO: 184 Flag epitope residues 40-47 DYKDDDDK domain of SEQ ID NO: 184 Linker residues 48-50 GSR of SEQ ID NO: 184 TMR(KDELR) residues 51-261 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 184 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(233)
(234) One of the fusion proteins was the Flag-tagged TPB(gE)-TMR(VSVG) fusion protein described in Example 2 and Table 5. The other fusion protein differed from the Flag-tagged TPB-TMR(VSVG) fusion protein in that the TMR domain was a transmembrane region from the human KDEL receptor 1 protein (KDELR). The amino acid sequence for the Flag-tagged TPB-TMR(KDELR) fusion protein used in this experiment is shown in Table 8 below.
(235) TABLE-US-00018 TABLE 8 Amino Acid Sequence of a Flag-Tagged TPB(gE)-TMR(KDELR) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 185 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB-TMR(KDELR) FDIAAAGTPKTSWRRVSVGEDVSLLPAPGP fusion protein TGRGPTQKLLWAVEPLDGCGPLHPSWVSLM PPKQVPETVVDAACMRAPVPLAMAYAPPAP SATGGLRTDFVWQERAAVVNRSLVIHGVRE TDSGLYTLSVGDIKDPARQVASVVLVVQPA PVPTPPPTPADYDEDDNDEGEDESLAGTPA SGTPRLPPPPAPPRSWPSAPEVSHVRGVTV RMETPEAILFSPGETFSTNVSIHAIAHDDQ TYSMDVVWLRFDVPTSCAEMRIYESCLYHP QLPECLSPADAPCAASTWTSRLAVRSYAGC SRTNPPPRCSAEAHMEPVPGLAWQAASVNL EFRDASPQHSGLYLCVVYVNDHIHAWGHIT ISTAAQYRNAVVEQPLPQRGADLAELEGDY KDDDDKGSRNLFRFLGDLSHLLAIILLLLK IWKSRSCAGISGKSQVLFAVVFTARYLDLF TNYISLYNTCMKVVYIACSFTTVWLIYSKF KATYDGNHDTFRVEFLVVPTAILAFLVNHD FTPLEILWTFSIYLESVAILPQLFMVSKTG EAETITSHYLFALGVYRTLYLFNWIWRYHF EGFFDLIAIVAGLVQTVLYCDFFYLYITKV LKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 185 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 185 TPB(gE) Domain residues 37-415 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 185 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 416-418 LEG of SEQ ID NO: 185 Flag epitope residues 419-426 DYKDDDDK domain of SEQ ID NO: 185 Linker residues 427-429 GSR of SEQ ID NO: 185 TMR(KDELR) residues 430-640 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 185 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(236) HEK293 cells were transfected with expression vector plasmids to compare levels of IL13Rα2TF-Fc target protein secreted into culture media when the IL13Rα2TF-Fc target protein was expressed alone, when co-expressed with a Flag-tagged TPB-TMR(VSVG) fusion protein described in Example 2, when co-expressed with the Flag-tagged TMR(VSVG) polypeptide, when co-expressed with the Flag-tagged TPB(gE)-TMR(KDELR) fusion protein, or when co-expressed with the Flag-tagged TMR(KDELR) polypeptide. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. IL13Rα2TF-Fc target protein in culture samples was determined by ELISA.
(237) The relative levels of IL13Rα2TF-Fc target protein secreted into the media of the various transfectant cell cultures are shown in the bar graphs in
Example 4
Enhanced Level of Secreted TNFR1TF-Fc Target Protein
(238) This experiment examined the enhancement in the level of a TNFα receptor 1 trap molecule when co-expressed with the TPB(gE)-TMR(VSVG) fusion protein.
(239) The TPB(gE)-TMR(VSVG) fusion protein used in this experiment was the same as described in Example 2 and Table 5 above.
(240) The target protein comprised a truncated form (TF) of the TNFα receptor 1 protein fused to an Fc region (hinge-CH2-CH3). The amino acid sequence of the “TNFR1TF-Fc” target protein monomer is shown in the Table 9, below. On expression, the monitor will homodimerize through the Fc region, resulting in a bivalent target protein.
(241) TABLE-US-00019 TABLE 9 Amino Acid Sequence of a V5-Tagged TNFR1TF-Fc Target Protein Monomer Protein Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 TNFR1TF Fc SEQ ID NO: 186 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL fusion protein VPHLGDREKRDSVCPQGKYIHPQNNSICCT KCHKGTYLYNDCPGPGQDTDCRECESGSFT ASENHLRHCLSCSKCRKEMGQVEISSCTVD RDTVCGCRKNQYRHYWSENLFQCFNCSLCL NGTVHLSCQEKQNTVCTCHAGFFLRENECV SCSNCKKSLECTKLCLPQIENVKGTEDSGT TGTGSEFDIAAALEGKPIPNPLLGLDSTSR PKSCDKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK TNFR1TF residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL of SEQ ID VPHLGDREKRDSVCPQGKYIHPQNNSICCT NO: 186 KCHKGTYLYNDCPGPGQDTDCRECESGSFT ASENHLRHCLSCSKCRKEMGQVEISSCTVD RDTVCGCRKNQYRHYWSENLFQCFNCSLCL NGTVHLSCQEKQNTVCTCHAGFFLRENECV SCSNCKKSLECTKLCLPQIENVKGTEDSGT T Linker residues 212-224 GTGSEFDIAAALE of SEQ ID NO: 186 V5 epitope residues 225-238 GKPIPNPLLGLDST domain of SEQ ID NO: 186 Linker residues 239-240 SR of SEQ ID NO: 186 Fc domain residues 241-471 PKSCDKTHTCPPCPAPELLGGPSVFLFPPK of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN NO: 186 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK
(242) HEK293 cells were transfected with expression vector plasmids for co-expression of the TNFR1TF-Fc target protein and the TPB(gE)-TMR(VSVG) fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. TNFR1TF-Fc target protein in culture samples was determined by ELISA.
(243) The relative levels of TNFR1TF-Fc target protein secreted into culture medium are shown in
(244) Additional Experiments: Comparison of Enhanced Levels of Secreted TNFR1TF-Fc Target Protein Using Fusion Proteins with Different Target Protein Binding (TPB) and Transmembrane Retention (TMR) Domains.
(245) This example examined the effectiveness of various fusion proteins comprising alternative target protein binding (TPB) and transmembrane retention (TMR) domains for enhancing the level of secretion of a V5 epitope-tagged TNFR1TF-Fc target protein into the media of cultures of transfected host cells.
(246)
(247) The V5-tagged TNFR1TF-Fc target protein used in this study was the same as that described in Table 9 above.
(248) The Flag-tagged TPB(gE)-TMR(VSVG) fusion protein (SEQ ID NO:190) used in this study is shown in Table 10 below.
(249) TABLE-US-00020 TABLE 10 Amino Acid Sequence for a Flag-tagged TPB(gE)- TMR(VSVG) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 190 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(gE)- FDIAAAGTPKTSWRRVSVGEDVSLLPAPGP TMR(VSVG) fusion TGRGPTQKLLWAVEPLDGCGPLHPSWVSLM protein PPKQVPETVVDAACMRAPVPLAMAYAPPAP SATGGLRTDFVWQERAAVVNRSLVIHGVRE TDSGLYTLSVGDIKDPARQVASVVLVVQPA PVPTPPPTPADYDEDDNDEGEDESLAGTPA SGTPRLPPPPAPPRSWPSAPEVSHVRGVTV RMETPEAILFSPGETFSTNVSIHAIAHDDQ TYSMDVVWLRFDVPTSCAEMRIYESCLYHP QLPECLSPADAPCAASTWTSRLAVRSYAGC SRTNPPPRCSAEAHMEPVPGLAWQAASVNL EFRDASPQHSGLYLCVVYVNDHIHAWGHIT ISTAAQYRNAVVEQPLPQRGADLAELEGDY KDDDDKGSRDDESLFFGDTGLSKNPIELVE GWFSSWKSSIASFFFIIGLIIGLFLVLRVG IHLCIKLKHTKKRQIYTDIEMNRLGK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 190 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 190 TPB(gE) Domain residues 37-415 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 190 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 416-418 LEG of SEQ ID NO: 190 Flag epitope residues 419-426 DYKDDDDK domain of SEQ ID NO: 190 Linker residues 427-429 GSR of SEQ ID NO: 190 TMR Domain residues 430-506 DDESLFFGDTGLSKNPIELVEGWFSSWKSS (VSVG) of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 190 TKKRQIYTDIEMNRLGK
(250) The amino acid sequence for a Flag-tagged TPB(Prot A)-TMR(VSVG) fusion is shown in Table 11 below.
(251) TABLE-US-00021 TABLE 11 Amino Acid Sequence of a Flag-Tagged TPB(Prot A)- TMR(VSVG) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 195 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(Prot A)- FDIAAAADNKFNKEQQNAFYEILNMPNLNE TMR(VSVG) fusion EQRNGFIQSLKDDPSQSANVLGEAKKLNDS protein QAPKLEGDYKDDDDKGSRDDESLFFGDTGL SKNPIELVEGWFSSWKSSIASFFFIIGLII GLFLVLRVGIHLCIKLKHTKKRQIYTDIEM NRLGK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 195 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 195 TPB(Prot A) residues 37-94 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF Domain of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK (from Protein A) NO: 195 Linker residues 95-97 LEG of SEQ ID NO: 195 Flag epitope residues 98-105 DYKDDDDK domain of SEQ ID NO: 195 Linker residues 106-108 GSR of SEQ ID NO: 195 TMR(VSVG)Domain residues 109-185 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 195 TKKRQIYTDIEMNRLGK
(252) The amino acid sequence for a Flag-tagged TPB(Prot G)-TMR(VSVG) fusion is shown in Table 12 below.
(253) TABLE-US-00022 TABLE 12 Amino Acid Sequence of a Flag-Tagged TPB(Prot G)- TMR(VSVG) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 196 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(Prot G)- FDIAAATYKLVINGKTLKGETTTEAVDAAT TMR(VSVG) fusion AEKVFKQYANDNGVDGEWTYDDATKTFTVT protein EKPEVIDASELTPAVTLEGDYKDDDDKGSR DDESLFFGDTGLSKNPIELVEGWFSSWKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKH TKKRQIYTDIEMNRLGK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 196 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 196 TPB(Prot G) residues 37-106 TYKLVINGKTLKGETTTEAVDAATAEKVFK Domain of SEQ ID QYANDNGVDGEWTYDDATKTFTVTEKPEVI (from Protein G) NO: 196 DASELTPAVT Linker residues 107-109 LEG of SEQ ID NO: 196 Flag epitope residues 110-117 DYKDDDDK domain of SEQ ID NO: 196 Linker residues 118-120 GSR of SEQ ID NO: 196 TMR(VSVG)Domain residues 121-197 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 196 TKKRQIYTDIEMNRLGK
(254) Another fusion protein comprised a TPB domain comprising an Fe-binding region of the GB919 protein. The GB919 is a histidine-substituted Fe-binding mutant Protein G that was engineered to make the dissociation from bound IgG more pH sensitive in order to reduce the harsh acidic conditions (e.g., pH 3) that are normally required to elute Fc-containing proteins bound to Protein G. The mutant GB919 exhibited an Fc-binding that was more pH sensitive than that of wildtype Protein G and also an increased affinity for IgG by a factor of 11 as compared with wildtype Protein G (Watanabe et al., J. Biol. Chem., 284 (10):12373-12383 (2009)). In particular, the IgG bound to the GB919 mutant protein could be eluted at conditions more typical of using Protein A, such as pH 4.2, instead of much harsher pH, such as pH 3-3.1, required for elution from wildtype Protein G (Watanabe et al., 2009, supra).
(255) The amino acid sequence for a Flag-tagged TPB(GB919)-TMR(VSVG) fusion is shown in Table 13 below.
(256) TABLE-US-00023 TABLE 13 Amino Acid Sequence of a Flag-Tagged TPB(GB919)- TMR(VSVG) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 197 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(GB919)- FDIAAADTYKLILNGKTLKGETTTEAVDAA TMR(VSVG) fusion TELEGDYKDDDDKGSRDDESLFFGDTGLSK protein TAEKVFKHYANEHGVHGHWTYDPETKTFTV NPIELVEGWFSSWKSSIASFFFIIGLIIGL FLVLRVGIHLCIKLKHTKKRQIYTDIEMNR LGK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 197 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 197 TPB(GB919) residues 37-92 DTYKLILNGKTLKGETTTEAVDAATAEKVF Domain of SEQ ID KHYANEHGVHGHWTYDPETKTFTVTE NO: 197 Linker residues 93-95 LEG of SEQ ID NO: 197 Flag epitope residues 96-103 DYKDDDDK domain of SEQ ID NO: 197 Linker residues 104-106 GSR of SEQ ID NO: 197 TMR(VSVG)Domain residues 107-183 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 197 TKKRQIYTDIEMNRLGK
(257) The Flag-tagged TPB(gE)-TMR(KDELR) fusion protein (SEQ ID NO:185) used in this experiment is the same as that described in Table 8 of Example 3 above.
(258) The amino acid sequence of a Flag-tagged TPB(Prot A)-TMR(KDELR) fusion protein used in this experiment is shown in Table 14 below.
(259) TABLE-US-00024 TABLE 14 Amino Acid Sequence of a Flag-Tagged TPB(Prot A)- TMR(I(DELR) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 198 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(Prot A)- FDIAAAADNKFNKEQQNAFYEILNMPNLNE TMR(KDELR) EQRNGFIQSLKDDPSQSANVLGEAKKLNDS fusion protein QAPKLEGDYKDDDDKGSRNLFRFLGDLSHL LAIILLLLKIWKSRSCAGISGKSQVLFAVV FTARYLDLFTNYISLYNTCMKVVYIACSFT TVWLIYSKFKATYDGNHDTFRVEFLVVPTA ILAFLVNHDFTPLEILWTFSIYLESVAILP QLFMVSKTGEAETITSHYLFALGVYRTLYL FNWIWRYHFEGFFDLIAIVAGLVQTVLYCD FFYLYITKVLKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 198 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 198 TPB(Prot A) residues 37-94 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF Domain of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK (from Protein A) NO: 198 Linker residues 95-97 LEG of SEQ ID NO: 198 Flag epitope residues 98-105 DYKDDDDK domain of SEQ ID NO: 198 Linker residues 106-108 GSR of SEQ ID NO: 198 TMR(KDELR) residues 109-319 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 198 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(260) The amino acid sequence of a Flag-tagged TPB(Prot G)-TMR(KDELR) fusion protein comprising an Fc-binding region of Protein G as a target protein binding domain and a Flag epitope tag is shown in the Table 15 below.
(261) TABLE-US-00025 TABLE 15 Amino Acid Sequence of a Flag-Tagged TPB(Prot G)- TMR(KDELR) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 199 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(Prot G)- FDIAAAATYKLVINGKTLKGETTTEAVDAA TMR(KDELR) TAEKVFKQYANDNGVDGEWTYDDATKTFTV fusion protein TEKPEVIDASELTPAVTLEGDYKDDDDKGS RNLFRFLGDLSHLLAIILLLLKIWKSRSCA GISGKSQVLFAVVFTARYLDLFTNYISLYN TCMKVVYIACSFTTVWLIYSKFKATYDGNH DTFRVEFLVVPTAILAFLVNHDFTPLEILW TFSIYLESVAILPQLFMVSKTGEAETITSH YLFALGVYRTLYLFNWIWRYHFEGFFDLIA IVAGLVQTVLYCDFFYLYITKVLKGKKLSL PA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 199 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 199 TPB(Prot G) residues 37-107 TYKLVINGKTLKGETTTEAVDAATAEKVFK Domain of SEQ ID QYANDNGVDGEWTYDDATKTFTVTEKPEVI (from Protein G) NO: 199 DASELTPAVT Linker residues 108-110 LEG of SEQ ID NO: 199 Flag epitope residues 111-118 DYKDDDDK domain of SEQ ID NO: 199 Linker residues 119-121 GSR of SEQ ID NO: 199 TMR(KDELR) residues 122-332 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 199 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(262) The amino acid sequence for a TPB(GB919)-TMR(KDELR) fusion is shown in Table 16 below.
(263) TABLE-US-00026 TABLE 16 Amino Acid Sequence of a Flag-Tagged TPB(GB919) - TMR(KDELR) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 200 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(GB919)- FDIAAADTYKLILNGKTLKGETTTEAVDAA TMR(KDELR) TAEKVFKHYANEHGVHGHWTYDPETKTFTV fusion protein TELEGDYKDDDDKGSRNLFRFLGDLSHLLA IILLLLKIWKSRSCAGISGKSQVLFAVVFT ARYLDLFTNYISLYNTCMKVVYIACSFTTV WLIYSKFKATYDGNHDTFRVEFLVVPTAIL AFLVNHDFTPLEILWTFSIYLESVAILPQL FMVSKTGEAETITSHYLFALGVYRTLYLFN WIWRYHFEGFFDLIAIVAGLVQTVLYCDFF YLYITKVLKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 200 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 200 TPB(GB919) residues 37-92 DTYKLILNGKTLKGETTTEAVDAATAEKVF Domain of SEQ ID KHYANEHGVHGHWTYDPETKTFTVTE NO: 200 Linker residues 93-95 LEG of SEQ ID NO: 200 Flag epitope residues 96-103 DYKDDDDK domain of SEQ ID NO: 200 Linker residues 104-106 GSR of SEQ ID NO: 200 TMR(KDELR) residues 107-317 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 200 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(264) HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture media of cells expressing the TNFR1TF-Fc target protein alone or co-expressing the target protein and each of the fusion proteins, i.e., TPB(gE)-TMR(VSVG), TPB(Prot A)-TMR(VSVG), TPB(Prot G)-TMR(VSVG), TPB(GB919)-TMR(VSVG), TPB(gE)-TMR(KDELR), TPB(Prot A)-TMR(KDELR), TPB(Prot G)-TMR(KDELR), or TPB(GB919)-TMR(KDELR). Transfected cells were cultured for two days, and samples of the culture media were harvested and analyzed by ELISA. The ELISA used a recombinant purified Protein A immobilized in the wells of 96-well microtiter plates as a binding protein for the TNFR1TF-Fc target protein and a peroxidase-conjugated goat anti-human IgG F(ab′).sub.2 antibody fragment (Jackson ImmunoResearch Laboratories, Product No. 109-036-098) as a detection reagent for TNFR1TF-Fc target protein bound to the immobilized Protein A. Wells coated with the recombinant purified Protein A were incubated with media of transfected cells that expressed the TNFR1TF-Fc target protein alone or that co-expressed the TNR1TF-Fc target protein and each of the fusion proteins.
(265) The results are shown in the bar graphs in
(266) Taken together, the results shown in
Example 5
Enhanced Level of Secreted Anti-TNFα Monoclonal Antibody
(267) Adalimumab (Humira®, AbbVie Inc.) is a fully human monoclonal antibody that binds and inhibits TNFα. The antibody is useful in the treatment of inflammatory and autoimmune disorders. This experiment examined the enhancement in the level of an anti-TNFα fully human monoclonal antibody (Mab) target protein when co-expressed with the TPB(gE)-TMR(VSVG) fusion protein.
(268) The TPB(gE)-TMR(VSVG) fusion protein used in this experiment was the same as described in Example 2 and Table 5 above.
(269) The amino acid sequences for the light and heavy chains of the anti-TNFα Mab target protein (adalimumab) employed in this experiment are shown in Table 17, below.
(270) TABLE-US-00027 TABLE 17 Amino Acid Sequences of Light and Heavy Chains of Anti-TNFα Mab Target Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Light chain SEQ ID NO: 144 MGWSCIILFLVATATGVHSDIQMTQSPSSL SASVGDRVTITCRSSQGIRNYLHWYQQKPG KAPKLLIYAASTLQSGVPSRFSGSGSGTDF TLTISSLQPEDVATYYCQRYNRAPYTFGQG TKVEIKRTVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVDNALQSGNSQE SVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC Heavy chain SEQ ID NO: 145 MGWSLIILFLVATATGVHSEVQLVESGGGL VQPGRSLRLSCAASGFTFDDYAMHWVRQAP GKGLEWVSAITWNSGHIDYADSVEGRFTIS RDNAKNSLYLQMNSLRAEDTAVYYCAKVSY LSTASSLDVWGQGTLVTVSSASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK
(271) HEK293 cells were transfected with expression vector plasmids for co-expression of the anti-TNFα Mab target protein and the TPB(gE)-TMR(VSVG) fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. Anti-TNFα Mab target protein in culture samples was determined by ELISA.
(272) The relative levels of anti-TNFα Mab target protein secreted into culture medium are shown in
Example 6
Enhanced Level of Secreted Anti-VEGF Monoclonal Antibody
(273) This experiment examined the enhancement in the level of an anti-VEGF-A humanized monoclonal antibody (bevacizumab) target protein when co-expressed with the TPB(gE)-TMR(VSVG) fusion protein.
(274) The TPB(gE)-TMR(VSVG) fusion protein used in this experiment was the same as described above in Example 2 and Table 5.
(275) The amino acid sequences for the light and heavy chains of the anti-VEGF Mab target protein (anti-VEGF Mab) employed in this experiment are shown in Table 18 below.
(276) TABLE-US-00028 TABLE 18 Amino Acid Sequences of Light and Heavy Chains of Anti-VEGF Mab Target Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Light chain SEQ ID NO: 142 MGWSCIILFLVATATGVHSDIQMTQSPSSL SASVGDRVTITCSASQDISNYLNWYQQKPG KAPKVLIYFTSSLHSGVPSRFSGSGSGTDF TLTISSLQPEDFATYYCQQYSTVPWTFGQG TKVEIKRTVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVDNALQSGNSQE SVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC Heavy chain SEQ ID NO: 143 MGWSLIILFLVATATGVHSEVQLVESGGGL VQPGGSLRLSCAASGYTFTNYGMNWVRQAP GKGLEWVGWINTYTGEPTYAADFKRRFTFS LDTSKSTAYLQMNSLRAEDTAVYYCAKYPH YYGSSHWYFDVWGQGTLVTVSSASTKGPSV FPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK
(277) HEK293 cells were transfected with expression vector plasmids for co-expression of the anti-VEGF Mab target protein and the TPB(gE)-TMR(VSVG) fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. Anti-VEGF Mab target protein in culture samples was determined by ELISA.
(278) The relative levels of anti-VEGF Mab target protein secreted into culture medium are shown in
Example 7
Enhanced Level of Secreted FVII-Fc Target Protein
(279) Factor VII (FVII) is the serine esterase of the extrinsic coagulation pathway and is widely used to treat a variety of bleeding complications. See, Hedner, Semin. Hematol., 43(suppl 1): S105S107 (2006). A complex of FVII and tissue factor (TF) in the presence of phospholipids and calcium activates Factor X to Factor Xa. However, the production of FVII is also inefficient owing to difficulties in expression and secretion of the protein. In this experiment, a FVII-Fc target protein was used as a representative example of an Fc drug comprising a protein of interest, i.e., FVII, fused to an immunoglobulin Fc region (hinge-CH2-CH3). The expressed FVII-Fc fusion polypeptide is expected to homodimerize via the Fc regions. This experiment examined the enhancement in the level of a FVII-Fc molecule secreted into culture medium when co-expressed with TPB(gE)-TMR(VSVG) fusion protein in transfectant host cells.
(280) The Flag-tagged TPB(gE)-TMR(VSVG) fusion protein used in this experiment is the same as described in Example 2 and Table 5 above.
(281) The amino acid sequence of the monomer chain of a V5-tagged FVII-Fc target protein is shown in the Table 19 below.
(282) TABLE-US-00029 TABLE 19 Amino Acid Sequence of a V5-Tagged FVII-Fc Target Protein Monomer Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 V5-tagged FVII- SEQ ID NO: 187 MVSQALRLLCLLLGLQGCLAAGGVAKASGG Fc target ETRDMPWKPGPHRVFVTQEEAHGVLHRRRR protein ANAFLEELRPGSLERECKEEQCSFEEAREI FKDAERTKLFWISYSDGDQCASSPCQNGGS CKDQLQSYICFCLPAFEGRNCETHKDDQLI CVNENGGCEQYCSDHTGTKRSCRCHEGYSL LADGVSCTPTVEYPCGKIPILEKRNASKPQ GRIVGGKVCPKGECPWQVLLLVNGAQLCGG TLINTIWVVSAAHCFDKIKNWRNLIAVLGE HDLSEHDGDEQSRRVAQVIIPSTYVPGTTN HDIALLRLHQPVVLTDHVVPLCLPERTFSE RTLAFVRFSLVSGWGQLLDRGATALELMVL NVPRLMTQDCLQQSRKVGDSPNITEYMFCA GYSDGSKDSCKGDSGGPHATHYRGTWYLTG IVSWGQGCATVGHFGVYTRVSQYIEWLQKL MRSEPRPGVLLRAPFPLEGKPIPNPLLGLD STSRPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK FVII residues 1-466 MVSQALRLLCLLLGLQGCLAAGGVAKASGG of SEQ ID ETRDMPWKPGPHRVFVTQEEAHGVLHRRRR NO: 187 ANAFLEELRPGSLERECKEEQCSFEEAREI FKDAERTKLFWISYSDGDQCASSPCQNGGS CKDQLQSYICFCLPAFEGRNCETHKDDQLI CVNENGGCEQYCSDHTGTKRSCRCHEGYSL LADGVSCTPTVEYPCGKIPILEKRNASKPQ GRIVGGKVCPKGECPWQVLLLVNGAQLCGG TLINTIWVVSAAHCFDKIKNWRNLIAVLGE HDLSEHDGDEQSRRVAQVIIPSTYVPGTTN HDIALLRLHQPVVLTDHVVPLCLPERTFSE RTLAFVRFSLVSGWGQLLDRGATALELMVL NVPRLMTQDCLQQSRKVGDSPNITEYMFCA GYSDGSKDSCKGDSGGPHATHYRGTWYLTG IVSWGQGCATVGHFGVYTRVSQYIEWLQKL MRSEPRPGVLLRAPFP Linker residues 467-468 LE of SEQ ID NO: 187 V5 epitope residues 469-482 GKPIPNPLLGLDST domain of SEQ ID NO: 187 Linker residues 483-484 SR of SEQ ID NO: 187 Fc domain residues 485-715 PKSCDKTHTCPPCPAPELLGGPSVFLFPPK of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN NO: 187 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK
(283) HEK293 cells were transfected with expression vector plasmids for co-expression of the FVII-Fc target protein and the TPB(gE)-TMR(VSVG) fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. FVII-Fc target protein in culture samples was determined by ELISA.
(284) The relative levels of FVII-Fc target protein secreted into culture medium are shown in
Example 8
Enhanced Level of Secreted FIX-Fc Target Protein
(285) This experiment examined the enhancement in the level of a FIX-Fc molecule secreted into culture medium when co-expressed with TPB(gE)-TMR(VSVG) fusion protein in transfectant host cells.
(286) The TPB(gE)-TMR(VSVG) fusion protein used in this experiment was the same as described in Example 2 and Table 5 above.
(287) The amino acid sequence of the monomer chain of a V5-tagged FIX-Fc target protein is shown in the Table 20 below.
(288) TABLE-US-00030 TABLE 20 Amino Acid Sequence of a V5-Tagged FIX-Fc Target Protein Monomer Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 V5-tagged FIX-Fc SEQ ID NO: 188 MQRVNMIMAESPGLITICLLGYLLSAECTV target protein FLDHENANKILNRPKRYNSGKLEEFVQGNL ERECMEEKCSFEEAREVFENTERTTEFWKQ YVDGDQCESNPCLNGGSCKDDINSYECWCP FGFEGKNCELDVTCNIKNGRCEQFCKNSAD NKVVCSCTEGYRLAENQKSCEPAVPFPCGR VSVSQTSKLTRAETVFPDVDYVNSTEAETI LDNITQSTQSFNDFTRVVGGEDAKPGQFPW QVVLNGKVDAFCGGSIVNEKWIVTAAHCVE TGVKITVVAGEHNIEETEHTEQKRNVIRII PHHNYNAAINKYNHDIALLELDEPLVLNSY VTPICIADKEYTNIFLKFGSGYVSGWGRVF HKGRSALVLQYLRVPLVDRATCLRSTKFTI YNNMFCAGFHEGGRDSCQGDSGGPHVTEVE GTSFLTGIISWGEECAMKGKYGIYTKVSRY VNWIKEKTKLTLEGKPIPNPLLGLDSTSRP KSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK FIX residues 1-461 MQRVNMIMAESPGLITICLLGYLLSAECTV of SEQ ID FLDHENANKILNRPKRYNSGKLEEFVQGNL NO: 188 ERECMEEKCSFEEAREVFENTERTTEFWKQ YVDGDQCESNPCLNGGSCKDDINSYECWCP FGFEGKNCELDVTCNIKNGRCEQFCKNSAD NKVVCSCTEGYRLAENQKSCEPAVPFPCGR VSVSQTSKLTRAETVFPDVDYVNSTEAETI LDNITQSTQSFNDFTRVVGGEDAKPGQFPW QVVLNGKVDAFCGGSIVNEKWIVTAAHCVE TGVKITVVAGEHNIEETEHTEQKRNVIRII PHHNYNAAINKYNHDIALLELDEPLVLNSY VTPICIADKEYTNIFLKFGSGYVSGWGRVF HKGRSALVLQYLRVPLVDRATCLRSTKFTI YNNMFCAGFHEGGRDSCQGDSGGPHVTEVE GTSFLTGIISWGEECAMKGKYGIYTKVSRY VNWIKEKTKLT Linker residues 462-463 LE of SEQ ID NO: 188 V5 epitope residues 464-477 GKPIPNPLLGLDST domain of SEQ ID NO: 188 Linker residues 478-479 SR of SEQ ID NO: 188 Fc domain residues 480-710 PKSCDKTHTCPPCPAPELLGGPSVFLFPPK of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN NO: 188 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK
(289) HEK293 cells were transfected with expression vector plasmids for co-expression of the FIX-Fc target protein and the TPB(gE)-TMR(VSVG) fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. FIX-Fc target protein in culture samples was determined by ELISA.
(290) The relative levels of FIX-Fc target protein secreted into culture medium are shown in
Example 9
Enhanced Level of Secreted FVIII-Fc Target Protein
(291) The biological importance of Factor VIII (FVIII) is demonstrated in hemophilia A, a congenital bleeding disorder occurring primarily in males that results from an X-chromosome-linked deficiency of FVIII. Standard treatment is replacement therapy that involves supply of functional exogenous FVIII to the patient, which enables natural clotting to stop the bleeding. A FVIII-Fc protein (providing a Factor VIII dimer) was developed to provide a prolonged half-life of FVIII activity in hemophilia A patients (Powell et al., Blood, 119(13): 3031-3037 (2012)). A B-domain deleted FVIII-Fc protein was approved by the United States Food and Drug Administration in 2013 (ELOCTATE®; Biogen Idec). This experiment examined the enhancement in the level of a FVIII-Fc molecule secreted into culture medium when co-expressed with a TPB(gE)-TMR(KDELR) fusion protein in transfectant host cells.
(292) The amino acid sequence for a Flag-tagged TPB(gE)-TMR(KDELR) fusion protein used in this experiment is the same as that shown in Table 8 of Example 3 above.
(293) The amino acid sequence of a V5-tagged FVIII-Fc target protein monomer used in this experiment is shown in Table 21, below.
(294) TABLE-US-00031 TABLE 21 Amino Acid Sequence of a V5-Tagged FVIII-Fc Target Protein Monomer Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 V5-tagged FVIII- SEQ ID NO: 189 MQIELSTCFFLCLLRFCFSATRRYYLGAVE Fc target LSWDYMQSDLGELPVDARFPPRVPKSFPFN protein TSVVYKKTLFVEFTDHLFNIAKPRPPWMGL LGPTIQAEVYDTVVITLKNMASHPVSLHAV GVSYWKASEGAEYDDQTSQREKEDDKVFPG GSHTYVWQVLKENGPMASDPLCLTYSYLSH VDLVKDLNSGLIGALLVCREGSLAKEKTQT LHKFILLFAVFDEGKSWHSETKNSLMQDRD AASARAWPKMHTVNGYVNRSLPGLIGCHRK SVYWHVIGMGTTPEVHSIFLEGHTFLVRNH RQASLEISPITFLTAQTLLMDLGQFLLFCH ISSHQHDGMEAYVKVDSCPEEPQLRMKNNE EAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLA PDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTL LIIFKNQASRPYNIYPHGITDVRPLYSRRL PKGVKHLKDFPILPGEIFKYKWTVTVEDGP TKSDPRCLTRYYSSFVNMERDLASGLIGPL LICYKESVDQRGNQIMSDKRNVILFSVFDE NRSWYLTENIQRFLPNPAGVQLEDPEFQAS NIMHSINGYVFDSLQLSVCLHEVAYWYILS IGAQTDFLSVFFSGYTFKHKMVYEDTLTLF PFSGETVFMSMENPGLWILGCHNSDFRNRG MTALLKVSSCDKNTGDYYEDSYEDISAYLL SKNNAIEPRSFSQNSRHPSTRQKQFNATTI PENDIEKTDPWFAHRTPMPKIQNVSSSDLL MLLRQSPTPHGLSLSDLQEAKYETFSDDPS PGAIDSNNSLSEMTHFRPQLHHSGDMVFTP ESGLQLRLNEKLGTTAATELKKLDFKVSST SNNLISTIPSDNLAAGTDNTSSLGPPSMPV HYDSQLDTTLFGKKSSPLTESGGPLSLSEE NNDSKLLESGLMNSQESSWGKNVSSTESGR LFKGKRAHGPALLTKDNALFKVSISLLKTN KTSNNSATNRKTHIDGPSLLIENSPSVWQN ILESDTEFKKVTPLIHDRMLMDKNATALRL NHMSNKTTSSKNMEMVQQKKEGPIPPDAQN PDMSFFKMLFLPESARWIQRTHGKNSLNSG QGPSPKQLVSLGPEKSVEGQNFLSEKNKVV VGKGEFTKDVGLKEMVFPSSRNLFLTNLDN LHENNTHNQEKKIQEEIEKKETLIQENVVL PQIHTVTGTKNFMKNLFLLSTRQNVEGSYD GAYAPVLQDFRSLNDSTNRTKKHTAHFSKK GEEENLEGLGNQTKQIVEKYACTTRISPNT SQQNFVTQRSKRALKQFRLPLEETELEKRI IVDDTSTQWSKNMKHLTPSTLTQIDYNEKE KGAITQSPLSDCLTRSHSIPQANRSPLPIA KVSSFPSIRPIYLTRVLFQDNSSHLPAASY RKKDSGVQESSHFLQGAKKNNLSLAILTLE MTGDQREVGSLGTSATNSVTYKKVENTVLP KPDLPKTSGKVELLPKVHIYQKDLFPTETS NGSPGHLDLVEGSLLQGTEGAIKWNEANRP GKVPFLRVATESSAKTPSKLLDPLAWDNHY GTQIPKEEWKSQEKSPEKTAFKKKDTILSL NACESNHAIAAINEGQNKPEIEVTWAKQGR TERLCSQNPPVLKRHQREITRTTLQSDQEE IDYDDTISVEMKKEDFDIYDEDENQSPRSF QKKTRHYFIAAVERLWDYGMSSSPHVLRNR AQSGSVPQFKKVVFQEFTDGSFTQPLYRGE LNEHLGLLGPYIRAEVEDNIMVTFRNQASR PYSFYSSLISYEEDQRQGAEPRKNFVKPNE TKTYFWKVQHHMAPTKDEFDCKAWAYFSDV DLEKDVHSGLIGPLLVCHTNTLNPAHGRQV TVQEFALFFTIFDETKSWYFTENMERNCRA PCNIQMEDPTFKENYRFHAINGYIMDTLPG LVMAQDQRIRWYLLSMGSNENIHSIHFSGH VFTVRKKEEYKMALYNLYPGVFETVEMLPS KAGIWRVECLIGEHLHAGMSTLFLVYSNKC QTPLGMASGHIRDFQITASGQYGQWAPKLA RLHYSGSINAWSTKEPFSWIKVDLLAPMII HGIKTQGARQKFSSLYISQFIIMYSLDGKK WQTYRGNSTGTLMVFFGNVDSSGIKHNIFN PPIIARYIRLHPTHYSIRSTLRMELMGCDL NSCSMPLGMESKAISDAQITASSYFTNMFA TWSPSKARLHLQGRSNAWRPQVNNPKEWLQ VDFQKTMKVTGVTTQGVKSLLTSMYVKEFL ISSSQDGHQWTLFFQNGKVKVFQGNQDSFT PVVNSLDPPLLTRYLRIHPQSWVHQIALRM EVLGCEAQDLYLEGKPIPNPLLGLDSTSRP KSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK FVIII signal Residues 1-19 MQIELSTCFFLCLLRFCFS sequence of SEQ ID NO: 189 FVIII residues 20-2351 ATRRYYLGAVELSWDYMQSDLGELPVDARF of SEQ ID PPRVPKSFPFNTSVVYKKTLFVEFTDHLFN NO: 189 IAKPRPPWMGLLGPTIQAEVYDTVVITLKN MASHPVSLHAVGVSYWKASEGAEYDDQTSQ REKEDDKVFPGGSHTYVWQVLKENGPMASD PLCLTYSYLSHVDLVKDLNSGLIGALLVCR EGSLAKEKTQTLHKFILLFAVFDEGKSWHS ETKNSLMQDRDAASARAWPKMHTVNGYVNR SLPGLIGCHRKSVYWHVIGMGTTPEVHSIF LEGHTFLVRNHRQASLEISPITFLTAQTLL MDLGQFLLFCHISSHQHDGMEAYVKVDSCP EEPQLRMKNNEEAEDYDDDLTDSEMDVVRF DDDNSPSFIQIRSVAKKHPKTWVHYIAAEE EDWDYAPLVLAPDDRSYKSQYLNNGPQRIG RKYKKVRFMAYTDETFKTREAIQHESGILG PLLYGEVGDTLLIIFKNQASRPYNIYPHGI TDVRPLYSRRLPKGVKHLKDFPILPGEIFK YKWTVTVEDGPTKSDPRCLTRYYSSFVNME RDLASGLIGPLLICYKESVDQRGNQIMSDK RNVILFSVFDENRSWYLTENIQRFLPNPAG VQLEDPEFQASNIMHSINGYVFDSLQLSVC LHEVAYWYILSIGAQTDFLSVFFSGYTFKH KMVYEDTLTLFPFSGETVFMSMENPGLWIL GCHNSDFRNRGMTALLKVSSCDKNTGDYYE DSYEDISAYLLSKNNAIEPRSFSQNSRHPS TRQKQFNATTIPENDIEKTDPWFAHRTPMP KIQNVSSSDLLMLLRQSPTPHGLSLSDLQE AKYETFSDDPSPGAIDSNNSLSEMTHFRPQ LHHSGDMVFTPESGLQLRLNEKLGTTAATE LKKLDFKVSSTSNNLISTIPSDNLAAGTDN TSSLGPPSMPVHYDSQLDTTLFGKKSSPLT ESGGPLSLSEENNDSKLLESGLMNSQESSW GKNVSSTESGRLFKGKRAHGPALLTKDNAL FKVSISLLKTNKTSNNSATNRKTHIDGPSL LIENSPSVWQNILESDTEFKKVTPLIHDRM LMDKNATALRLNHMSNKTTSSKNMEMVQQK KEGPIPPDAQNPDMSFFKMLFLPESARWIQ RTHGKNSLNSGQGPSPKQLVSLGPEKSVEG QNFLSEKNKVVVGKGEFTKDVGLKEMVFPS SRNLFLTNLDNLHENNTHNQEKKIQEEIEK KETLIQENVVLPQIHTVTGTKNFMKNLFLL STRQNVEGSYDGAYAPVLQDFRSLNDSTNR TKKHTAHFSKKGEEENLEGLGNQTKQIVEK YACTTRISPNTSQQNFVTQRSKRALKQFRL PLEETELEKRIIVDDTSTQWSKNMKHLTPS TLTQIDYNEKEKGAITQSPLSDCLTRSHSI PQANRSPLPIAKVSSFPSIRPIYLTRVLFQ DNSSHLPAASYRKKDSGVQESSHFLQGAKK NNLSLAILTLEMTGDQREVGSLGTSATNSV TYKKVENTVLPKPDLPKTSGKVELLPKVHI YQKDLFPTETSNGSPGHLDLVEGSLLQGTE GAIKWNEANRPGKVPFLRVATESSAKTPSK LLDPLAWDNHYGTQIPKEEWKSQEKSPEKT AFKKKDTILSLNACESNHAIAAINEGQNKP EIEVTWAKQGRTERLCSQNPPVLKRHQREI TRTTLQSDQEEIDYDDTISVEMKKEDFDIY DEDENQSPRSFQKKTRHYFIAAVERLWDYG MSSSPHVLRNRAQSGSVPQFKKVVFQEFTD GSFTQPLYRGELNEHLGLLGPYIRAEVEDN IMVTFRNQASRPYSFYSSLISYEEDQRQGA EPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHT NTLNPAHGRQVTVQEFALFFTIFDETKSWY FTENMERNCRAPCNIQMEDPTFKENYRFHA INGYIMDTLPGLVMAQDQRIRWYLLSMGSN ENIHSIHFSGHVFTVRKKEEYKMALYNLYP GVFETVEMLPSKAGIWRVECLIGEHLHAGM STLFLVYSNKCQTPLGMASGHIRDFQITAS GQYGQWAPKLARLHYSGSINAWSTKEPFSW IKVDLLAPMIIHGIKTQGARQKFSSLYISQ FIIMYSLDGKKWQTYRGNSTGTLMVFFGNV DSSGIKHNIFNPPIIARYIRLHPTHYSIRS TLRMELMGCDLNSCSMPLGMESKAISDAQI TASSYFTNMFATWSPSKARLHLQGRSNAWR PQVNNPKEWLQVDFQKTMKVTGVTTQGVKS LLTSMYVKEFLISSSQDGHQWTLFFQNGKV KVFQGNQDSFTPVVNSLDPPLLTRYLRIHP QSWVHQIALRMEVLGCEAQDLY Linker residues 2352-2353 LE of SEQ ID NO: 189 V5 epitope residues 2354-2367 GKPIPNPLLGLDST domain of SEQ ID NO: 189 Linker residues 2368-2369 SR of SEQ ID NO: 189 Fc domain residues 2370-2600 PKSCDKTHTCPPCPAPELLGGPSVFLFPPK of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN NO: 189 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK
(295) HEK293 cells were transfected with expression vector plasmids for co-expression of the FVIII-Fc target protein and the TPV(gE)-TMR(KDELR) fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. FVIII-Fc target protein in culture samples was determined by ELISA.
(296) The relative levels of FVIII-Fc target protein secreted into culture medium are shown in
Example 10
Effect of Retaining Fusion Protein in Endoplasmic Reticulum on Secretion of Target Protein
(297) This experiment compared the level of secretion of a target protein when co-expressed with a TPB(gE)-TMR(VSVG) fusion protein, comprising the Fc binding region of gE and the transmembrane region of the VSV-G protein, and when co-expressed with essentially the same fusion protein but wherein TMR domain was engineered to include a known endoplasmic reticulum (ER) retention sequence (dilysine motif) at its C-terminus.
(298) The target protein was the V5-tagged IL13Rα2TF-Fc target protein described above in Example 2 and Table 4.
(299)
(300)
(301) TABLE-US-00032 TABLE 22 Amino Acid Sequence for a Flag-Tagged TPB(gE)-TMR(VSVG) with KK Motif Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 191 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(gE)- FDIAAAGTPKTSWRRVSVGEDVSLLPAPGP TMR(VSVG) with TGRGPTQKLLWAVEPLDGCGPLHPSWVSLM KK motif fusion PPKQVPETVVDAACMRAPVPLAMAYAPPAP protein SATGGLRTDFVWQERAAVVNRSLVIHGVRE TDSGLYTLSVGDIKDPARQVASVVLVVQPA PVPTPPPTPADYDEDDNDEGEDESLAGTPA SGTPRLPPPPAPPRSWPSAPEVSHVRGVTV RMETPEAILFSPGETFSTNVSIHAIAHDDQ TYSMDVVWLRFDVPTSCAEMRIYESCLYHP QLPECLSPADAPCAASTWTSRLAVRSYAGC SRTNPPPRCSAEAHMEPVPGLAWQAASVNL EFRDASPQHSGLYLCVVYVNDHIHAWGHIT ISTAAQYRNAVVEQPLPQRGADLAELEGDY KDDDDKGSRDDESLFFGDTGLSKNPIELVE GWFSSWKSSIASFFFIIGLIIGLFLVLRVG IHLCIKLKHTKKRQIYTDIEMNRLGKKTC Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 191 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 191 TPB(gE) Domain residues 37-415 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 191 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 416-418 LEG of SEQ ID NO: 191 Flag epitope residues 419-426 DYKDDDDK domain of SEQ ID NO: 191 Linker residues 427-429 GSR of SEQ ID NO: 191 TMR(VSVG) Domain residues 430-509 DDESLFFGDTGLSKNPIELVEGWFSSWKSS with KK motif of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 191 TKKRQIYTDIEMNRLGKKTC
(302) HEK293 cells were transfected with expression vector plasmids to compare levels of IL13Rα2TF-Fc target protein secreted into culture media when the IL13Rα2TF-Fc target protein was expressed alone, when co-expressed with a Flag-tagged TPB(gE)-TMR (VSVG) fusion protein, or when co-expressed with the Flag-tagged TPB(gE)-TMR(VSVG) with KK motif fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. IL13Rα2TF-Fc target protein in samples of culture media was determined by ELISA.
(303) The relative levels of IL13Rα2TF-Fc target protein secreted into the media of the various transfectant cell cultures are shown in the bar graphs in
(304) Additional Experiments: Further Examples of the Effect of Retaining Fusion Protein in Endoplasmic Reticulum on Secretion of Target Protein.
(305) The following study was conducted to further examine the effect of ER retention of fusion proteins on the level of a target protein of interest secreted from host cells. In this study, the target protein was the TNFR1TF-Fc described above in Table 9 of Example 4. The fusion proteins used in this study comprised one of three different TPB domains that bind the Fc region of the target protein in combination with either the wildtype or mutant (dilysine motif) versions of the TMR(VSVG) domains employed in Example 10 above.
(306)
(307) The Flag-tagged TPB(gE)-TMR(VSVG) fusion protein used in this study comprising a TPB domain comprising an Fc binding portion of the gE protein and a TMR domain comprising a wildtype transmembrane region of VSVG was the same as that described above in Table 10 of Example 4.
(308) The Flag-tagged TPB(gE)-TMR(VSVG) “with KK” fusion protein used in this study comprising a TPB domain comprising an Fc binding portion of gE and a TMR domain comprising a transmembrane region of the VSVG protein engineered to contain tandem lysine residues inserted at positions −3 and −4 of the C-terminal cytoplasmic region of the fusion protein was the same as described above in Table 22, above.
(309) The amino acid sequence for a Flag-tagged TPB(Prot A)-TMR(VSVG) fusion comprising a TPB domain comprising an Fc-binding portion of Protein A and a TMR domain comprising a wildtype transmembrane region of VSVG was the same as shown in Table 11 of Example 4, above.
(310) The amino acid sequence for a Flag-tagged TPB(Prot A)-TMR(VSVG) with KK motif is shown in Table 23 below.
(311) TABLE-US-00033 TABLE 23 Amino Acid Sequence of a Flag-Tagged TPB(Prot A)- TMR(VSVG) with KK Motif Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 201 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(Prot A)- FDIAAAADNKFNKEQQNAFYEILNMPNLNE TMR(VSVG) fusion EQRNGFIQSLKDDPSQSANVLGEAKKLNDS protein QAPKLEGDYKDDDDKGSRDDESLFFGDTGL SKNPIELVEGWFSSWKSSIASFFFIIGLII GLFLVLRVGIHLCIKLKHTKKRQIYTDIEM NRLGKKTC Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 201 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 201 TPB(Prot A) residues 37-94 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF Domain of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK (from Protein A) NO: 201 Linker residues 95-97 LEG of SEQ ID NO: 201 Flag epitope residues 98-105 DYKDDDDK domain of SEQ ID NO: 201 Linker residues 106-108 GSR of SEQ ID NO: 201 TMR(VSVG) Domain residues 109-188 DDESLFFGDTGLSKNPIELVEGWFSSWKSS with KK motif of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 201 TKKRQIYTDIEMNRLGKKTC
(312) The amino acid sequence for a Flag-tagged TPB(Prot GB919)-TMR(VSVG) fusion protein comprising a TPB domain that comprises an Fc-binding portion of Protein GB919 and a TMR domain comprising a wildtype transmembrane region of VSVG was the same as shown in Table 13 of Example 4, above.
(313) The amino acid sequence for a Flag-tagged TPB(Prot GB919)-TMR(VSVG) with KK motif is shown in Table 24 below.
(314) TABLE-US-00034 TABLE 24 Amino Acid Sequence of a Flag-Tagged TPB(Prot GB919)- TMR(VSVG) with KK Motif Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 202 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(GB919)- FDIAAADTYKLILNGKTLKGETTTEAVDAA TMR(VSVG) fusion TAEKVFKHYANEHGVHGHWTYDPETKTFTV protein TELEGDYKDDDDKGSRDDESLFFGDTGLSK NPIELVEGWFSSWKSSIASFFFIIGLIIGL FLVLRVGIHLCIKLKHTKKRQIYTDIEMNR LGKKTC Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 202 Linker residues 25-36 GTGSGEFDIAAA of SEQ ID NO: 202 TPB(GB919) residues 37-92 DTYKLILNGKTLKGETTTEAVDAATAEKVF Domain of SEQ ID KHYANEHGVHGHWTYDPETKTFTVTE NO: 202 Linker residues 93-95 LEG of SEQ ID NO: 202 Flag epitope residues 96-103 DYKDDDDK domain of SEQ ID NO: 202 Linker residues 104-106 GSR of SEQ ID NO: 202 TMR(VSVG) Domain residues 107-186 DDESLFFGDTGLSKNPIELVEGWFSSWKSS with KK motif of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 202 TKKRQIYTDIEMNRLGKKTC
(315) HEK293 cells were transfected with expression vector plasmids to compare levels of TNFR1TF-Fc target protein secreted into culture media when the TNFR1TF-Fc target protein was expressed alone and when co-expressed with each of the fusion proteins: Flag-tagged TPB(gE)-TMR (VSVG), Flag-tagged TPB(gE)-TMR (VSVG) with KK motif, Flag-tagged TPB(Prot A)-TMR(VSVG), Flag-tagged TPB(Prot A)-TMR(VSVG) with KK motif, Flag-tagged TPB(GB919)-TMR(VSVG), and Flag-tagged TPB(GB919)-TMR(VSVG) with KK motif. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. TNFR1TF-Fc target protein in samples of culture media was determined by ELISA.
(316) The relative levels of TNFR1TF-Fc target protein secreted into the media of the various transfectant cell cultures are shown in the bar graphs in
Example 11
Further Enhancement of Level of Target Protein Secreted from Cells Co-Expressing a CASE Fusion Protein Comprising a CMP Domain
(317) This experiment examined the effect of adding a chaperone machinery peptide (“CMP”) as an additional domain in a cell-associated secretion-enhancing (CASE) a fusion protein previously shown to enhance the level of secretion of a co-expressed target protein.
(318) The target protein used in this study was the V5-tagged IL13Rα2TF-Fc target protein described above in Example 2 and Table 4.
(319) The cell-associated secretion-enhancing (CASE) Flag-tagged TPB(gE)-TMR(VSVG) fusion protein used in this experiment was the same as described above in Example 2 and Table 5.
(320)
(321) TABLE-US-00035 TABLE 25 Amino Acid Sequence of a Flag-Tagged CMP-TPB(Prot A) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged CMP- SEQ ID NO: 192 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(Prot A) FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS fusion protein AAAQQNAFYEILNMPNLNEEQRNGFIQSLK DDPSQSANVLGEAKKLNDSLEGDYKDDDDK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 192 Linker residues 25-31 GTGSGEF of SEQ ID NO: 192 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 192 Linker residues 44-63 DIGGGSGGSGGSGGAAA of SEQ ID NO: 192 TPB(Prot A) residues 64-109 QQNAFYEILNMPNLNEEQRNGFIQSLK Domain of SEQ ID DDPSQSANVLGEAKKLNDS NO: 192 Linker residues 110-112 LEG of SEQ ID NO: 192 Flag epitope residues 113-120 DYKDDDDK domain of SEQ ID NO: 192
(322)
(323) TABLE-US-00036 TABLE 26 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)- TMR(VSVG) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 134 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(VSVG) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRSSWKSSIASFFFIIGLIIGLFLVL RVGIHLCIKLKHTKKRQIYTDIEMNRLGK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 134 Linker residues 25-31 GTGSGEF of SEQ ID NO: 134 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4 NO: 134 protein) Linker residues 44-63 DIGGGSGGSGGSGGAAA of SEQ ID NO: 134 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 134 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 134 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 134 Linker residues 454-456 GSR of SEQ ID NO: 134 TMR(VSVG) Domain residues 457-509 SSWKSSIASFFFIIGLIIGLFLVLRVGIHL of SEQ ID CIKLKHTKKRQIYTDIEMNRLGK NO: 134
(324) HEK293 cells were transfected with expression vector plasmids for co-expression of the IL13Rα2TF-Fc target protein and the CMP-TPB(Prot A) fusion protein, the previously described TPB(gE)-TMR(VSVG) fusion protein, or the CMP-TPB(gE)-TMR(VSVG). Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as a negative control. IL13Rα2TF-Fc target protein in culture samples was determined by ELISA.
(325) The relative levels of IL13Rα2TF-Fc target protein secreted into culture media are shown in the bar graphs in
(326) Surprisingly, an unexpected and significant further enhancement in the level of target protein secreted into the culture medium was observed when the IL13Rα2TF-Fc target protein was co-expressed with the CMP-TPB(gE)-TMR(VSVG) fusion protein as shown in bar graph 5 of
(327) The results show that co-expression of a target protein and a fusion protein comprising a TPB domain, a TMR domain, and a CMP domain may result in a significantly greater enhancement in the level of target protein secreted from a host cells as compared to the level of target protein secreted from cells that co-express the target protein and a CASE fusion protein comprising a TPB domain and a TMR domain, but lacking a CMP domain.
Example 12
Enhanced Level of FVII-Fc Target Protein Secreted from Cells
(328) In this experiment, two fusion proteins were constructed and compared for the ability to enhance the level of FVII-Fc target protein secreted from a host cell co-expressing the target protein and each of the fusion proteins as compared to the level of target protein secreted from a host cell that expressed the target protein alone. Both fusion proteins possessed a J domain of the Erdj3 co-chaperone protein and an Fc-binding region, which was either the Fc-binding region of Protein G (CAA27638.1, GenBank, NCBI) or the Fc-binding domain the gE protein of herpes simplex virus-1 (Baucke et al., J. Virol., 32(3): 779-789 (1979), Para et al., J. Virol., 34(3): 512-520 (1980)). Protein G is the streptococcal Protein G that is well-known for its binding with high affinity to the Fc region of immunoglobulins, such as IgG antibodies. The gE protein is known to bind Fc regions (Chapman et al., J. Biol. Chem., 274:6911-19 (1999)).
(329) As in Example 7 above, in this experiment, the FVII-Fc target protein was used as a representative example of trap molecule (“Fc drug”) comprising a protein of interest, i.e., FVII, fused to an immunoglobulin Fc region (hinge-CH2-CH3).
(330)
(331) TABLE-US-00037 TABLE 27 Amino Acid Sequence of a Flag-Tagged CMP-TPB(Prot G) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged CMP- SEQ ID NO: 135 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL TPB(Prot G) GVPRSASIKDIKKAYRKLALQLHPDRNPDD fusion protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG GSGGSGGAAATYKLVINGKTLKGETTTEAV DAATAEKVFKQYANDNGVDGEWTYDDATKT FTVTEKPEVIDASELTPAVTLEGDYKDDDD KGSRGPYSIVSPKC Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 135 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 135 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 135 TPB(Prot G) residues 101-170 TYKLVINGKTLKGETTTEAVDAATAEKVFK Domain of SEQ ID QYANDNGVDGEWTYDDATKTFTVTEKPEVI NO: 135 DASELTPAVT Linker residues 171-173 LEG of SEQ ID NO: 135 Flag epitope residues 174-181 DYKDDDDK domain of SEQ ID NO: 135 C-terminal residues 182-194 GSRGPYSIVSPKC vector residues of SEQ ID NO: 135
(332)
(333) TABLE-US-00038 TABLE 28 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)- TMR(VSVG) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 136 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL CMP-TPB(gE)- GVPRSASIKDIKKAYRKLALQLHPDRNPDD TMR(VSVG) fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG protein GSGGSGGAAAGTPKTSWRRVSVGEDVSLLP APGPTGRGPTQKLLWAVEPLDGCGPLHPSW VSLMPPKQVPETVVDAACMRAPVPLAMAYA PPAPSATGGLRTDFVWQERAAVVNRSLVIH GVRETDSGLYTLSVGDIKDPARQVASVVLV VQPAPVPTPPPTPADYDEDDNDEGEDESLA GTPASGTPRLPPPPAPPRSWPSAPEVSHVR GVTVRMETPEAILFSPGETFSTNVSIHAIA HDDQTYSMDVVWLRFDVPTSCAEMRIYESC LYHPQLPECLSPADAPCAASTWTSRLAVRS YAGCSRTNPPPRCSAEAHMEPVPGLAWQAA SVNLEFRDASPQHSGLYLCVVYVNDHIHAW GHITISTAAQYRNAVVEQPLPQRGADLAEL EGDYKDDDDKGSRDDESLFFGDTGLSKNPI ELVEGWFSSWKSSIASFFFIIGLIIGLFLV LRVGIHLCIKLKHTKKRQIYTDIEMNRLGK Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 136 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 136 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 136 TPB(gE) Domain residues 101-479 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 136 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 480-482 LEG of SEQ ID NO: 136 Flag epitope residues 483-490 DYKDDDDK domain of SEQ ID NO: 136 Linker residues 491-493 GSR of SEQ ID NO: 136 TMR(VSVG) Domain residues 494-570 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 136 TKKRQIYTDIEMNRLGK
(334) In addition to determining whether either of the fusion proteins were effective in enhancing the level of FVII-Fc target protein secreted from a host cell, the experiment also examined whether or not the CMP-TPB(Prot G) fusion protein would be co-secreted with the target protein into the culture medium along with the co-expressed FVII-Fc target protein and whether the CMP-TPB(gE)-TMR(VSVG) fusion protein would be retained in the host cell while the co-expressed FVII-Fc target protein was secreted into the culture medium.
(335) HEK293 cells were transfected with expression vector plasmids to compare levels of FVII-Fc target protein secreted into culture media when the FVII-Fc target protein was expressed alone, co-expressed with the CMP-TPB(Prot G) fusion protein, or co-expressed with the CMP-TPB(gE)-TMR(VSVG) fusion protein. Transfected cells were cultured for two days, and samples of cell cultures were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect V5-tagged FVII-Fc target protein. The level of expression of the FVII-Fc target protein was determined in both culture media and lysates of transfected host cells expressing the FVII-Fc target protein alone, co-expressing the FVII-Fc target protein and the CMP-TPB(Prot G) fusion protein, and co-expressing the FVII-Fc target protein and the CMP-TPB(gE)-TMR(VSVG) fusion protein. Mock cultures containing cells transfected with “empty vector”, i.e., an expression vector lacking a structural gene for expressing any protein, were included as negative controls. The results of culturing transfected host cells and detecting protein expression by Western blot are shown in
(336) In addition, the results in
(337) In contrast to the localization of the CMP-TPB(Prot G) fusion protein in both cells and culture media (lanes 7 and 11, respectively) and the possible association of the FVII-Fc target protein with the CMP-TPB(Prot G) protein, the CMP-TPB(gE)-TMR(VSVG) fusion protein was only detected within transfected cells (lane 8), and no significant amount of the CMP-TPB(gE)-TMR(VSVG) fusion protein was detected in the culture media of transfected cells that co-expressed the FVII-Fc target protein and the CMP-TPB(gE)-TMR(VSVG) fusion protein of the invention (lane 12). Accordingly, since the CMP-TPB(gE)-TMR(VSVG) fusion protein remained associated with the cells and was not secreted into the culture media, the FVII-Fc target protein secreted into the culture media is expected to be free of any significant CMP-TPB(gE)-TMR(VSVG) fusion protein. Moreover, as noted above, densitometer scanning of the Western blot in
(338) The data indicate that: (1) co-expression of CMP-TPB(gE)-TMR(VSVG) fusion protein significantly enhances the level of FVII-Fc target protein secreted into the culture media of transfected host cells (lane 12) as compared to the level secreted into culture media of transfected host cells expressing the FVII-Fc target protein in the absence of any fusion protein (lane 10) and as compared to the level secreted into the culture media of transfected host cells that co-express the target protein and the CMP-TPB(Prot G) fusion (lane 11); (2) the transmembrane retention (TMR) domain in the CMP-TPB(gE)-TMR(VSVG) fusion protein functions to localize the fusion protein with the host cell so that no significant or detectable amount of the fusion protein is released into the culture media (see lanes 8 and 12); and (3) the culture media of transfected host cells co-expressing the FVII-Fc target and the CMP-TPB(gE)-TMR(VSVG) fusion protein does not contain a significant or detectable amount of a recombinant protein species other than the desired FVII-Fc target protein (lane 12), in contrast to the culture media of transfected host cells that co-express the FVII-Fc target protein and the CMP-TPB(Prot G) fusion protein (lane 11), where a significant level of CMP-TPB(Prot G) fusion protein is co-secreted with the target protein.
Example 13
Enhanced Levels of IL13Rα2TF-Fc Target Protein Secreted from Cells
(339) In this experiment, an IL13Rα2TF-Fc target protein was used as a representative example of an “Fc drug”. The IL13Rα2TF-Fc target protein used in this experiment was the same V5-tagged IL13Rα2TF-Fc monomer as described in Example 2 and Table 4 above.
(340)
(341)
(342) TABLE-US-00039 TABLE 29 Amino Acid Sequence of a Flag-Tagged CMP-TPB(IL13) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 138 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL CMP-TPB fusion GVPRSASIKDIKKAYRKLALQLHPDRNPDD protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG GSGGSGGAAALTCLGGFASPGPVPPSTALR ELIEELVNITQNQKAPLCNGSMVWSINLTA GMYCAALESLINVSGCSAIEKTQRMLSGFC PHKVSAGQFSSLHVRDTKIEVAQFVKDLLL HLKKLFREGQFNLEGDYKDDDDK Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 138 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 138 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 138 TPB(IL13) Domain residues 101-222 LTCLGGFASPGPVPPSTALRELIEELVNIT of SEQ ID QNQKAPLCNGSMVWSINLTAGMYCAALESL NO: 138 INVSGCSAIEKTQRMLSGFCPHKVSAGQFS SLHVRDTKIEVAQFVKDLLLHLKKLFREGQ FN Linker residues 223-225 LEG of SEQ ID NO: 138 Flag epitope residues 226-233 DYKDDDDK domain of SEQ ID NO: 138
(343)
(344) TABLE-US-00040 TABLE 30 Amino Acid Sequence of a Flag-Tagged CMP-TPB(IL13)- TMR(VSVG) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 139 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL CMP-TPB- GVPRSASIKDIKKAYRKLALQLHPDRNPDD TMR(VSVG) fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG protein GSGGSGGAAALTCLGGFASPGPVPPSTALR ELIEELVNITQNQKAPLCNGSMVWSINLTA GMYCAALESLINVSGCSAIEKTQRMLSGFC PHKVSAGQFSSLHVRDTKIEVAQFVKDLLL HLKKLFREGQFNLEGDYKDDDDKGSRDDES LFFGDTGLSKNPIELVEGWFSSWKSSIASF FFIIGLIIGLFLVLRVGIHLCIKLKHTKKR QIYTDIEMNRLGK Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 139 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 139 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 139 TPB(IL13) Domain residues 101-222 LTCLGGFASPGPVPPSTALRELIEELVNIT of SEQ ID QNQKAPLCNGSMVWSINLTAGMYCAALESL NO: 139 INVSGCSAIEKTQRMLSGFCPHKVSAGQFS SLHVRDTKIEVAQFVKDLLLHLKKLFREGQ FN Linker residues 223-225 LEG of SEQ ID NO: 139 Flag epitope residues 226-233 DYKDDDDK domain of SEQ ID NO: 139 Linker residues 234-236 GSR of SEQ ID NO: 139 TMR(VSVG) Domain residues 237-313 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 139 TKKRQIYTDIEMNRLGK
(345) HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture media of IL13Rα2TF-Fc target protein expressed alone, co-expressed with the CMP-TPB(IL13) fusion protein, or co-expressed with the CMP-TPB(IL13)-TMR(VSVG) fusion protein of this invention. Transfected cells were cultured for two days, and samples of cell cultures were harvested and analyzed by Western blot assay using an anti-V5 antibody to detect secreted V5-tagged IL13Rα2TF-Fc target protein.
(346) The results show that the co-expression of the IL13Rα2TF-Fc target protein and either fusion protein significantly enhanced the level of expressed target protein secreted into culture media as compared to the level secreted in the absence of a CMP fusion protein. As noted above, co-expression of a target protein and a CMP-TPB-TMR fusion protein of this invention leads to improved secretion of the target protein, presumably without a significant amount of the fusion protein being co-secreted with the target protein into the culture medium. See, e.g., Example 12, supra.
Example 14
CMP-TPB(gE)-TMR(VSVG) Fusion Protein Enhances the Level of Co-Expressed Factor VIII-V5-Fc Target Protein Secreted from Cells
(347) The biological importance of Factor FVIII is demonstrated in hemophilia A, a congenital bleeding disorder occurring primarily in males that results from an X-chromosome-linked deficiency of FVIII. Standard treatment is replacement therapy that involves supply of functional exogenous FVIII to the patient, which enables natural clotting to stop the bleeding. A FVIII-Fc protein (providing a Factor VIII dimer) was developed to provide a prolonged half-life of FVIII activity in hemophilia A patients (Powell et al., Blood, 119(13): 3031-3037 (2012)). A B-domain deleted FVIII-Fc protein was approved by the United States Food and Drug Administration in 2013 (ELOCTATE®; Biogen Idec).
(348) This experiment examined the effect of the Flag-tagged CMP-TPB(gE)-TMR(VSVG), described in Example 12 and Table 28 above, on the level of secretion of a V5-tagged FVIII-Fc target protein when the two proteins were co-expressed in the same host cell. The amino acid sequence of one chain of the V5-tagged FVIII-Fc target protein is shown in Table 31 below.
(349) TABLE-US-00041 TABLE 31 Amino Acid Sequence of a V5-Tagged FVIII-Fc Target Protein Monomer. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 V5-tagged FVIII- SEQ ID NO: 140 MQIELSTCFFLCLLRFCFSATRRYYLGAVE Fc target LSWDYMQSDLGELPVDARFPPRVPKSFPFN protein TSVVYKKTLFVEFTDHLFNIAKPRPPWMGL LGPTIQAEVYDTVVITLKNMASHPVSLHAV GVSYWKASEGAEYDDQTSQREKEDDKVFPG GSHTYVWQVLKENGPMASDPLCLTYSYLSH VDLVKDLNSGLIGALLVCREGSLAKEKTQT LHKFILLFAVFDEGKSWHSETKNSLMQDRD AASARAWPKMHTVNGYVNRSLPGLIGCHRK SVYWHVIGMGTTPEVHSIFLEGHTFLVRNH RQASLEISPITFLTAQTLLMDLGQFLLFCH ISSHQHDGMEAYVKVDSCPEEPQLRMKNNE EAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLA PDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTL LIIFKNQASRPYNIYPHGITDVRPLYSRRL PKGVKHLKDFPILPGEIFKYKWTVTVEDGP TKSDPRCLTRYYSSFVNMERDLASGLIGPL LICYKESVDQRGNQIMSDKRNVILFSVFDE NRSWYLTENIQRFLPNPAGVQLEDPEFQAS NIMHSINGYVFDSLQLSVCLHEVAYWYILS IGAQTDFLSVFFSGYTFKHKMVYEDTLTLF PFSGETVFMSMENPGLWILGCHNSDFRNRG MTALLKVSSCDKNTGDYYEDSYEDISAYLL SKNNAIEPRSFSQNSRHPSTRQKQFNATTI PENDIEKTDPWFAHRTPMPKIQNVSSSDLL MLLRQSPTPHGLSLSDLQEAKYETFSDDPS PGAIDSNNSLSEMTHFRPQLHHSGDMVFTP ESGLQLRLNEKLGTTAATELKKLDFKVSST SNNLISTIPSDNLAAGTDNTSSLGPPSMPV HYDSQLDTTLFGKKSSPLTESGGPLSLSEE NNDSKLLESGLMNSQESSWGKNVSSTESGR LFKGKRAHGPALLTKDNALFKVSISLLKTN KTSNNSATNRKTHIDGPSLLIENSPSVWQN ILESDTEFKKVTPLIHDRMLMDKNATALRL NHMSNKTTSSKNMEMVQQKKEGPIPPDAQN PDMSFFKMLFLPESARWIQRTHGKNSLNSG QGPSPKQLVSLGPEKSVEGQNFLSEKNKVV VGKGEFTKDVGLKEMVFPSSRNLFLTNLDN LHENNTHNQEKKIQEEIEKKETLIQENVVL PQIHTVTGTKNFMKNLFLLSTRQNVEGSYD GAYAPVLQDFRSLNDSTNRTKKHTAHFSKK GEEENLEGLGNQTKQIVEKYACTTRISPNT SQQNFVTQRSKRALKQFRLPLEETELEKRI IVDDTSTQWSKNMKHLTPSTLTQIDYNEKE KGAITQSPLSDCLTRSHSIPQANRSPLPIA KVSSFPSIRPIYLTRVLFQDNSSHLPAASY RKKDSGVQESSHFLQGAKKNNLSLAILTLE MTGDQREVGSLGTSATNSVTYKKVENTVLP KPDLPKTSGKVELLPKVHIYQKDLFPTETS NGSPGHLDLVEGSLLQGTEGAIKWNEANRP GKVPFLRVATESSAKTPSKLLDPLAWDNHY GTQIPKEEWKSQEKSPEKTAFKKKDTILSL NACESNHAIAAINEGQNKPEIEVTWAKQGR TERLCSQNPPVLKRHQREITRTTLQSDQEE IDYDDTISVEMKKEDFDIYDEDENQSPRSF QKKTRHYFIAAVERLWDYGMSSSPHVLRNR AQSGSVPQFKKVVFQEFTDGSFTQPLYRGE LNEHLGLLGPYIRAEVEDNIMVTFRNQASR PYSFYSSLISYEEDQRQGAEPRKNFVKPNE TKTYFWKVQHHMAPTKDEFDCKAWAYFSDV DLEKDVHSGLIGPLLVCHTNTLNPAHGRQV TVQEFALFFTIFDETKSWYFTENMERNCRA PCNIQMEDPTFKENYRFHAINGYIMDTLPG LVMAQDQRIRWYLLSMGSNENIHSIHFSGH VFTVRKKEEYKMALYNLYPGVFETVEMLPS KAGIWRVECLIGEHLHAGMSTLFLVYSNKC QTPLGMASGHIRDFQITASGQYGQWAPKLA RLHYSGSINAWSTKEPFSWIKVDLLAPMII HGIKTQGARQKFSSLYISQFIIMYSLDGKK WQTYRGNSTGTLMVFFGNVDSSGIKHNIFN PPIIARYIRLHPTHYSIRSTLRMELMGCDL NSCSMPLGMESKAISDAQITASSYFTNMFA TWSPSKARLHLQGRSNAWRPQVNNPKEWLQ VDFQKTMKVTGVTTQGVKSLLTSMYVKEFL ISSSQDGHQWTLFFQNGKVKVFQGNQDSFT PVVNSLDPPLLTRYLRIHPQSWVHQIALRM EVLGCEAQDLYLEGKPIPNPLLGLDSTSRP KSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK FVIII signal Residues 1-19 MQIELSTCFFLCLLRFCFS sequence of SEQ ID NO: 140 FVIII residues 20-2351 ATRRYYLGAVELSWDYMQSDLGELPVDARF of SEQ ID PPRVPKSFPFNTSVVYKKTLFVEFTDHLFN NO: 140 IAKPRPPWMGLLGPTIQAEVYDTVVITLKN MASHPVSLHAVGVSYWKASEGAEYDDQTSQ REKEDDKVFPGGSHTYVWQVLKENGPMASD PLCLTYSYLSHVDLVKDLNSGLIGALLVCR EGSLAKEKTQTLHKFILLFAVFDEGKSWHS ETKNSLMQDRDAASARAWPKMHTVNGYVNR SLPGLIGCHRKSVYWHVIGMGTTPEVHSIF LEGHTFLVRNHRQASLEISPITFLTAQTLL MDLGQFLLFCHISSHQHDGMEAYVKVDSCP EEPQLRMKNNEEAEDYDDDLTDSEMDVVRF DDDNSPSFIQIRSVAKKHPKTWVHYIAAEE EDWDYAPLVLAPDDRSYKSQYLNNGPQRIG RKYKKVRFMAYTDETFKTREAIQHESGILG PLLYGEVGDTLLIIFKNQASRPYNIYPHGI TDVRPLYSRRLPKGVKHLKDFPILPGEIFK YKWTVTVEDGPTKSDPRCLTRYYSSFVNME RDLASGLIGPLLICYKESVDQRGNQIMSDK RNVILFSVFDENRSWYLTENIQRFLPNPAG VQLEDPEFQASNIMHSINGYVFDSLQLSVC LHEVAYWYILSIGAQTDFLSVFFSGYTFKH KMVYEDTLTLFPFSGETVFMSMENPGLWIL GCHNSDFRNRGMTALLKVSSCDKNTGDYYE DSYEDISAYLLSKNNAIEPRSFSQNSRHPS TRQKQFNATTIPENDIEKTDPWFAHRTPMP KIQNVSSSDLLMLLRQSPTPHGLSLSDLQE AKYETFSDDPSPGAIDSNNSLSEMTHFRPQ LHHSGDMVFTPESGLQLRLNEKLGTTAATE LKKLDFKVSSTSNNLISTIPSDNLAAGTDN TSSLGPPSMPVHYDSQLDTTLFGKKSSPLT ESGGPLSLSEENNDSKLLESGLMNSQESSW GKNVSSTESGRLFKGKRAHGPALLTKDNAL FKVSISLLKTNKTSNNSATNRKTHIDGPSL LIENSPSVWQNILESDTEFKKVTPLIHDRM LMDKNATALRLNHMSNKTTSSKNMEMVQQK KEGPIPPDAQNPDMSFFKMLFLPESARWIQ RTHGKNSLNSGQGPSPKQLVSLGPEKSVEG QNFLSEKNKVVVGKGEFTKDVGLKEMVFPS SRNLFLTNLDNLHENNTHNQEKKIQEEIEK KETLIQENVVLPQIHTVTGTKNFMKNLFLL STRQNVEGSYDGAYAPVLQDFRSLNDSTNR TKKHTAHFSKKGEEENLEGLGNQTKQIVEK YACTTRISPNTSQQNFVTQRSKRALKQFRL PLEETELEKRIIVDDTSTQWSKNMKHLTPS TLTQIDYNEKEKGAITQSPLSDCLTRSHSI PQANRSPLPIAKVSSFPSIRPIYLTRVLFQ DNSSHLPAASYRKKDSGVQESSHFLQGAKK NNLSLAILTLEMTGDQREVGSLGTSATNSV TYKKVENTVLPKPDLPKTSGKVELLPKVHI YQKDLFPTETSNGSPGHLDLVEGSLLQGTE GAIKWNEANRPGKVPFLRVATESSAKTPSK LLDPLAWDNHYGTQIPKEEWKSQEKSPEKT AFKKKDTILSLNACESNHAIAAINEGQNKP EIEVTWAKQGRTERLCSQNPPVLKRHQREI TRTTLQSDQEEIDYDDTISVEMKKEDFDIY DEDENQSPRSFQKKTRHYFIAAVERLWDYG MSSSPHVLRNRAQSGSVPQFKKVVFQEFTD GSFTQPLYRGELNEHLGLLGPYIRAEVEDN IMVTFRNQASRPYSFYSSLISYEEDQRQGA EPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHT NTLNPAHGRQVTVQEFALFFTIFDETKSWY FTENMERNCRAPCNIQMEDPTFKENYRFHA INGYIMDTLPGLVMAQDQRIRWYLLSMGSN ENIHSIHFSGHVFTVRKKEEYKMALYNLYP GVFETVEMLPSKAGIWRVECLIGEHLHAGM STLFLVYSNKCQTPLGMASGHIRDFQITAS GQYGQWAPKLARLHYSGSINAWSTKEPFSW IKVDLLAPMIIHGIKTQGARQKFSSLYISQ FIIMYSLDGKKWQTYRGNSTGTLMVFFGNV DSSGIKHNIFNPPIIARYIRLHPTHYSIRS TLRMELMGCDLNSCSMPLGMESKAISDAQI TASSYFTNMFATWSPSKARLHLQGRSNAWR PQVNNPKEWLQVDFQKTMKVTGVTTQGVKS LLTSMYVKEFLISSSQDGHQWTLFFQNGKV KVFQGNQDSFTPVVNSLDPPLLTRYLRIHP QSWVHQIALRMEVLGCEAQDLY Linker residues 2352-2353 LE of SEQ ID NO: 140 V5 epitope residues 2354-2367 GKPIPNPLLGLDST domain of SEQ ID NO: 140 Linker residues 2368-2369 SR of SEQ ID NO: 140 Fc domain residues 2370-2600 PKSCDKTHTCPPCPAPELLGGPSVFLFPPK of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN NO: 140 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK
(350) The host HEK293 cells were transfected with expression plasmids for the FVIII-Fc target protein alone, with expression plasmids for FVIII-Fc and the CMP-TPB(gE)-TMR(VSVG) fusion protein of the invention, or with mock “empty vector” plasmids (control). The levels of target protein secretion were measured by ELISA.
(351) Referring to
(352)
(353)
Example 15
Enhancement of Levels of Secreted Anti-IL8 IgG1 Antibody
(354) The above examples showed that expression and secretion of target proteins comprising a protein of interest fused to an immunoglobulin Fc region, as a model of an “Fc drug”, were significantly enhanced when co-expressed with a cell-associated secretion-enhancing (CASE) fusion protein of the invention. This study compared secretion enhancement of an anti-IL8 monoclonal antibody target protein (anti-IL8 Mab) when co-expressed with either of two fusion proteins of the invention.
(355) The CMP-TPB(gE)-TMR(VSVG) fusion protein used in this study was the same Flag-tagged CMP-TPB(gE)-TMR(VSVG) described in Example 12 and Table 28 above Another fusion protein was prepared that was similar to the CMP-TPB(gE)-TMR(VSVG) fusion protein but comprising the transmembrane region of the p23 protein, designated “TMR(p23)”, as the TMR domain. This fusion protein was designated “CMP-TPB(gE)-TMR(p23)”. The amino acid sequence of the CMP-TPB(gE)-TMR(p23) fusion protein, which includes a Flag epitope tag, is shown in Table 32 below.
(356) TABLE-US-00042 TABLE 32 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)- TMR(p23) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 141 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL CMP-TPB-TMR(p23) GVPRSASIKDIKKAYRKLALQLHPDRNPDD fusion protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG GSGGSGGAAAGTPKTSWRRVSVGEDVSLLP APGPTGRGPTQKLLWAVEPLDGCGPLHPSW VSLMPPKQVPETVVDAACMRAPVPLAMAYA PPAPSATGGLRTDFVWQERAAVVNRSLVIH GVRETDSGLYTLSVGDIKDPARQVASVVLV VQPAPVPTPPPTPADYDEDDNDEGEDESLA GTPASGTPRLPPPPAPPRSWPSAPEVSHVR GVTVRMETPEAILFSPGETFSTNVSIHAIA HDDQTYSMDVVWLRFDVPTSCAEMRIYESC LYHPQLPECLSPADAPCAASTWTSRLAVRS YAGCSRTNPPPRCSAEAHMEPVPGLAWQAA SVNLEFRDASPQHSGLYLCVVYVNDHIHAW GHITISTAAQYRNAVVEQPLPQRGADLAEL EGDYKDDDDKGSRTRVLYFSIFSMFCLIGL ATWQVFYLRRFFKAKKLIE Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 141 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 141 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 141 TPB(gE) Domain residues 101-479 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 141 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 480-482 LEG of SEQ ID NO: 141 Flag epitope residues 483-490 DYKDDDDK domain of SEQ ID NO: 141 Linker residues 491-493 GSR of SEQ ID NO: 141 TMR(p23)Domain residues 494-529 TRVLYFSIFSMFCLIGLATWQVFYLRRFFK of SEQ ID AKKLIE NO: 141
(357) HEK293 cells were transfected with expression vector plasmids for expressing the anti-IL8 Mab target protein alone or for co-expressing the target protein and either the CMP-TPB(gE)-TMR(VSVG) fusion protein or the CMP-TPB(gE)-TMR(p23) fusion protein.
(358) Expression of the anti-IL8 Mab target protein in culture media was analyzed by ELISA with IL8 as a substrate and an anti-human IgG antibody (anti-hIgG antibody, catalog no. AP112P, Millipore) as a detecting antibody. A 96-well plate was coated with IL8 and incubated with media from cultures of cells transfected to express the anti-IL8 Mab target protein alone or co-expressing anti-IL8 Mab target protein and either the CMP-TPB(gE)-TMR(VSVG) fusion protein or the CMP-TPB(gE)-TMR(p23). Mock cultures were tested by the same ELISA as negative controls.
(359) The results are shown in the bar graphs in
Example 16
Enhancement in the Level of Secretion of a Therapeutic Anti-VEGF Antibody Target Protein Using CASE Fusion Proteins with Different TMR Domains
(360) This experiment examined the level of anti-VEGF-A monoclonal antibody secreted from a cell when co-expressed with either of two CASE fusion proteins comprising different TMR domains.
(361) The anti-VEGF-A monoclonal antibody (anti-VEGF Mab) used in this experiment was the same as described in Example 6 and Table 18 above.
(362) The anti-VEGF Mab target protein was expressed in HEK293 cells in the presence and absence of either the CMP-TPB(gE)-TMR(VSVG) fusion protein described in Example 12 and Table 28 above or the CMP-TPB(gE)-TMR(p23) fusion protein described in Example 15 and Table 32 above. Samples of the media from cell cultures were assayed for anti-VEGF-A Mab by ELISA using VEGF as a substrate. The wells of a 96-well plate were coated with recombinant purified human VEGF-A and incubated with media from cultures of cells transfected to express the anti-VEGF-A Mab target protein (“Anti-VEGF Mab”) alone or co-expressing anti-VEGF Mab target protein and either the CMP-TPB(gE)-TMR(VSVG) CASE fusion protein of the invention or the CMP-TPB(gE)-TMR(p23) CASE fusion protein of the invention.
(363) The results are shown in the bar graphs in
(364) As noted regarding the results in Example 15 above, the results here also show that selection of a transmembrane region for use as a TMR domain in a CASE fusion protein of the invention can have a significant effect on the level of enhancement of secreted target protein that is obtained. The results also indicate that the anti-VEGF-A Mab target protein that was secreted into the culture media was functional, as it retained VEGF-binding activity in the ELISA.
Example 17
Enhancement in the Level of Secretion of a Therapeutic Anti-TNFα Antibody Target Protein Using CASE Fusion Proteins with Different TMR Domains
(365) This experiment examined the level of anti-TNFα monoclonal antibody (adalimumab) secreted from a cell when co-expressed with either of two CASE fusion proteins comprising different TMR domains.
(366) The anti-TNFα monoclonal antibody (anti-TNFα Mab) was the same as that described in Example 5 and Table 17.
(367) The anti-TNFα Mab target protein was expressed in HEK293 cells in the presence and absence of the CMP-TPB(gE)-TMR(VSVG) fusion protein described in Example 12 and Table 28 or the CMP-TPB(gE)-TMR(p23) fusion protein described in Example 15 and Table 32. Samples of culture media were analyzed for anti-TNFα Mab target protein by assaying for TNFα binding in an ELISA. Wells of a 96-well plate were coated with recombinant purified human TNFα and incubated with culture media of transfected host cells expressing anti-TNFα Mab alone or culture media of transfected cells co-expressing anti-TNFα Mab and either the CMP-TPB-TMR(VSVG) fusion protein or the CMP-TPB-TMR(p23) fusion protein.
(368) The results are shown in the bar graphs in
Example 18
Further Studies of Fusion Proteins Comprising Alternative Target Protein Binding (TPB) Domains for Enhancing Expression of Target Proteins
(369) This example examined the effectiveness of various fusion proteins comprising alternative target protein binding (TPB) domains for enhancing the level of secretion of a V5 epitope-tagged IL13Rα2TF-Fc target protein into the media of cultures of transfected host cells.
(370) The V5-tagged IL13Rα2TF-Fc target protein used in this experiment was the same as described in Example 2 and Table 4 above.
(371)
(372) TABLE-US-00043 TABLE 33 Amino Acid Sequence of a Flag-Tagged CMP-TPB(Prot A) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 146 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL CMP-TPB(Prot A) GVPRSASIKDIKKAYRKLALQLHPDRNPDD fusion protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG GSGGSGGAAAADNKFNKEQQNAFYEILNMP NLNEEQRNGFIQSLKDDPSQSANVLGEAKK LNDSQAPKLEGDYKDDDDK Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 146 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 146 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 146 TPB(Prot A) residues 101-158 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF Domain of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK (from Protein A) NO: 146 Linker residues 159-161 LEG of SEQ ID NO: 146 Flag epitope residues 162-169 DYKDDDDK domain of SEQ ID NO: 146
(373)
(374) The CMP-TPB(gE)-TMR(VSVG) fusion protein used in this study was that described in Example 12 and Table 28 above, and thus included a Flag epitope tag and an Fc-binding portion of the herpes simplex type-1 glycoprotein E as its TPB domain (designated “TPB(gE)”).
(375) It is noted that the herpes simplex virus type-1 glycoprotein I (gI) forms a complex with the herpes simplex virus type-1 glycoprotein E (gE). Therefore, the gI protein or a polypeptide segment thereof is not a target protein binding domain as defined herein. However, a CMP-TPB(gI)-TMR(VSVG) fusion protein, which includes a segment of gI that binds the Fc-binding portion of gE, was constructed and used in this study to investigate whether or not the gI::gE complex formed between co-expressed CMP-TPB(gE)-TMR(VSVG) and CMP-TPB(gI)-TMR(VSVG) fusion proteins would have an effect on the performance of the CMP-TPB(gE)-TMR(VSVG) to enhance the level of secreted IL13Rα2TF-Fc target protein. See
(376) The amino acid sequence of the CMP-TPB(gI)-TMR(VSVG) fusion protein comprising a gE-binding portion of the gI protein and a Flag epitope tag is shown in Table 34 below.
(377) TABLE-US-00044 TABLE 34 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gI)- TMR(VSVG) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 149 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL CMP-TPB(gI)- GVPRSASIKDIKKAYRKLALQLHPDRNPDD TMR(VSVG) fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG protein GSGGSGGAAALVVRGPTVSLVSNSFVDAGA LGPDGVVEEDLLILGELRFVGDQVPHTTYY DGVVELWHYPMGHKCPRVVHVVTVTACPRR PAVAFALCRATDSTHSPAYPTLELNLAQQP LLRVRRATRDYAGVYVLRVWVGDAPNASLF VLGMAIAAEGTLAYNGSAHGSCDPKLLPYS APRLAPASVYQPAPNPASTPSTTTSTPSTT TSTPSTTIPAPQASTTPFPTGDPKPQLEGD YKDDDDKGSRDDESLFFGDTGLSKNPIELV EGWFSSWKSSIASFFFIIGLIIGLFLVLRV GIHLCIKLKHTKKRQIYTDIEMNRLGK Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 149 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 149 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 149 TPB(gI) Domain residues 101-326 LVVRGPTVSLVSNSFVDAGALGPDGVVEED (from gI) of SEQ ID LLILGELRFVGDQVPHTTYYDGVVELWHYP NO: 149 MGHKCPRVVHVVTVTACPRRPAVAFALCRA TDSTHSPAYPTLELNLAQQPLLRVRRATRD YAGVYVLRVWVGDAPNASLFVLGMAIAAEG TLAYNGSAHGSCDPKLLPYSAPRLAPASVY QPAPNPASTPSTTTSTPSTTTSTPSTTIPA PQASTTPFPTGDPKPQ Linker residues 327-329 LEG of SEQ ID NO: 149 Flag epitope residues 330-337 DYKDDDDK domain of SEQ ID NO: 149 Linker residues 338-340 GSR of SEQ ID NO: 149 TMR(VSVG) Domain residues 341-417 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 149 TKKRQIYTDIEMNRLGK
(378) The amino acid sequence of a CMP-TPB(IL13)-TMR(VSVG) fusion protein comprising a Flag epitope tag was that described in Example 13 and Table 30 above.
(379) The amino acid sequence of a CMP-TPB(hFcR)-TMR(VSVG) fusion protein comprising an Fc-binding region of the hFcR protein and including a Flag epitope tag is shown in Table 35 below.
(380) TABLE-US-00045 TABLE 35 Amino Acid Sequence of a Flag-Tagged CMP-TPB(hFcR)- TMR(VSVG) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 150 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL CMP-TPB (hFcR)- GVPRSASIKDIKKAYRKLALQLHPDRNPDD TMR (VSVG) PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG fusion protein GSGGSGGAAAAVITLQPPWVSVFQEETVTL HCEVLHLPGSSSTQWFLNGTATQTSTPSYR ITSASVNDSGEYRCQRGLSGRSDPIQLEIH RGWLLLQVSSRVFTEGEPLALRCHAWKDKL VYNVLYYRNGKAFKFFHWNSNLTILKTNIS HNGTYHCSGMLEGDYKDDDDKGSRDDESLF FGDTGLSKNPIELVEGWFSSWKSSIASFFF IIGLIIGLFLVLRVGIHLCIKLKHTKKRQI YTDIEMNRLGK Erdj3 signal residues 1-22 MAPQNLSTFCLLLLYLIGAVIA sequence of SEQ ID NO: 150 CMP Domain residues 23-83 GRDFYKILGVPRSASIKDIKKAYRKLALQL (from Erdj3) of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK NO: 150 R Linker residues 84-100 DIGGGSGGSGGSGGAAA of SEQ ID NO: 150 TPB(hFcR) Domain residues 101-250 AVITLQPPWVSVFQEETVTLHCEVLHLPGS (from hFcR) of SEQ ID SSTQWFLNGTATQTSTPSYRITSASVNDSG NO: 150 EYRCQRGLSGRSDPIQLEIHRGWLLLQVSS RVFTEGEPLALRCHAWKDKLVYNVLYYRNG KAFKFFHWNSNLTILKTNISHNGTYHCSGM Linker residues 251-253 LEG of SEQ ID NO: 150 Flag epitope residues 254-261 DYKDDDDK domain of SEQ ID NO: 150 Linker residues 262-264 GSR of SEQ ID NO: 150 TMR(VSVG)Domain residues 265-341 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 150 TKKRQIYTDIEMNRLGK
(381) HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture media of the IL13Rα2TF-Fc target protein expressed alone or co-expressed with each of the following fusion proteins: a CMP-TPB(Prot A) fusion protein, a CMP-TPB(gI)-TMR(VSVG) fusion protein, a CMP-TPB(gE)-TMR(VSVG), both the CMP-TPB(gI)-TMR(VSVG) and the CMP-TPB(gE)-TMR(VSVG) fusion proteins, CMP-TPB(IL13)-TMR(VSVG) fusion protein, and a CMP-TPB(hFcR)-TMR(VSVG) fusion protein. Transfected cells were cultured for two days, and samples of cell culture media were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect secreted V5-tagged IL13Rα2TF-Fc target protein.
(382)
(383) The data in
(384) As shown in lane 8 of
(385) Taking all of the results into consideration, it appears that the Fc-binding region of the gE protein is particularly useful as the TPB domain of a CASE fusion protein of the invention when the goal is to enhance the level of a target protein secreted from a cell wherein the target protein comprises an Fc region.
Example 19
Improved Activity of Fusion Proteins Incorporating a Truncated Version of gE Target Protein Binding
(386) In this experiment, two fusion proteins of the invention comprising different portions of the Fc-binding region of the gE protein as target protein binding (TPB) domains were compared for their ability to enhance the level of secretion of an IL13Rα2TF-Fc target protein.
(387) The IL13Rα2TF-Fc target protein used in this experiment was the V5-tagged IL13Rα2TF-Fc target protein described in Example 2 and Table 4 above.
(388)
(389) TABLE-US-00046 TABLE 36 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(KDELR) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 151 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(KDELR) AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR fusion protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRNLFRFLGDLSHLLAIILLLLKIWK SRSCAGISGKSQVLFAVVFTARYLDLFTNY ISLYNTCMKVVYIACSFTTVWLIYSKFKAT YDGNHDTFRVEFLVVPTAILAFLVNHDFTP LEILWTFSIYLESVAILPQLFMVSKTGEAE TITSHYLFALGVYRTLYLFNWIWRYHFEGF FDLIAIVAGLVQTVLYCDFFYLYITKVLKG KKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 151 Linker residues 25-31 GTGSGEF of SEQ ID NO: 151 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 151 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 151 TPB(gE)Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT (Fc-binding of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP region of gE) NO: 151 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 151 Flag epitope residues 445-453 DYKDDDDK domain of SEQ ID NO: 151 Linker residues 454-456 GSR of SEQ ID NO: 151 TMR(KDELR) residues 457-667 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 151 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(390)
(391) TABLE-US-00047 TABLE 37 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE′)-TMR(KDELR) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 153 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE′)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(KDELR) AAAAPEVSHVRGVTVRMETPEAILFSPGET fusion protein FSTNVSIHAIAHDDQTYSMDVVWLRFDVPT SCAEMRIYESCLYHPQLPECLSPADAPCAA STWTSRLAVRSYAGCSRTNPPPRCSAEAHM EPVPGLAWQAASVNLEFRDASPQHSGLYLC VVYVNDHIHAWGHITISTAAQYRNAVVEQP LLEGDYKDDDDKGSRNLFRFLGDLSHLLAI ILLLLKIWKSRSCAGISGKSQVLFAVVFTA RYLDLFTNYISLYNTCMKVVYIACSFTTVW LIYSKFKATYDGNHDTFRVEFLVVPTAILA FLVNHDFTPLEILWTFSIYLESVAILPQLF MVSKTGEAETITSHYLFALGVYRTLYLFNW IWRYHFEGFFDLIAIVAGLVQTVLYCDFFY LYITKVLKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 153 Linker residues 25-31 GTGSGEF of SEQ ID NO: 153 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 153 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 153 TPB(gE′) Domain residues 64-241 APEVSHVRGVTVRMETPEAILFSPGETFST (gE′ Fc binding of SEQ ID NVSIHAIAHDDQTYSMDVVWLRFDVPTSCA region) NO: 153 EMRIYESCLYHPQLPECLSPADAPCAASTW TSRLAVRSYAGCSRTNPPPRCSAEAHMEPV PGLAWQAASVNLEFRDASPQHSGLYLCVVY VNDHIHAWGHITISTAAQYRNAVVEQPL Linker residues 242-244 LEG of SEQ ID NO: 153 Flag epitope residues 245-252 DYKDDDDK domain of SEQ ID NO: 153 Linker residues 253-255 GSR of SEQ ID NO: 153 TMR(KDELR) residues 256-466 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 153 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(392) HEK293 cells were transfected with expression vector plasmids to compare levels of secretion of target protein in culture media of transfectants that expressed the target protein alone or co-expressed the target protein with the CMP-TPB(gE)-TMR(KDELR) fusion protein or the CMP-TPB(gE′)-TMR(KDELR) fusion protein. Transfected host cells were cultured for two days, and samples of transfectant culture media were harvested and analyzed by ELISA. Wells of a 96-well plate were coated with recombinant purified Protein A and incubated with culture media of transfected cells. IL13Rα2TF-Fc target protein bound to Protein A was detected using a peroxidase-conjugated goat anti-human IgG F(ab′).sub.2 antibody fragment (Jackson ImmunoResearch Laboratories, Product No. 109-036-098).
(393) The results are shown in the bar graphs in
(394) As shown in Table 36, above, the CMP-TPB(gE)-TMR(KDELR) fusion protein employed a 379 amino acid polypeptide of the gE protein as the TPB domain, whereas the CMP-TPB(gE′)-TMR(KDELR) fusion protein employed a considerably smaller, 178 amino acid polypeptide (gE′) from within the 379 amino acid polypeptide of the gE protein as the TPB domain (see Table 37). Thus, the fusion protein comprising the smaller gE polypeptide (gE′) provided a greater enhancement in the level of secretion of the co-expressed IL13Rα2TF-Fc target protein than the fusion protein comprising the larger 379 amino acid portion of gE. (Compare bar graph 4 (CMP-TPB(gE′)-TMR(KDELR) fusion protein) with bar graph 3 (CMP-TPB(gE)-TMR(KDELR) fusion protein) of
Example 20
Enhanced Expression of Secreted IL13Rα2TF-Fc Target Protein Co-Expressed with Fusion Proteins Comprising Different Target Protein Binding Domains
(395) The target protein binding (TPB) domain of a fusion protein of the invention must not only bind a target protein but also release the target protein for secretion via the cellular secretory pathway that follows after the endoplasmic reticulum (ER) to the Golgi apparatus and on to secretory vesicles. After the binding complex comprising the fusion protein and the target protein moves from the ER to the Golgi apparatus, the fusion protein is expected to dissociate from the target protein so that the target protein can be separately secreted from the cell. This dissociation may advantageously occur within the drop from approximately neutral pH from the ER (approximately pH 7-7.4) to pH 6.7 in the cis Golgi, to pH 6.3 in the medial Golgi, to pH 6.0 in the trans Golgi, and then down to pH 5.5 in the secretory vesicles that eventually fuse with the cell membrane and release the target protein. If a fusion proteins does not release the target protein within the conditions (pH or otherwise) of the secretion pathway of the host cell, the target protein will remain associated with the fusion protein and be localized wherever the fusion protein is ultimately localized within the cell via the transmembrane retention (TMR) domain. As shown in this example, however, successful target protein secretion enhancement may be achieved even using TPB domains derived from proteins requiring very harsh pH conditions (˜pH 4.2) for dissociation from a binding partner.
(396) This example examined the effect of varying the TPB domain in fusion proteins of the invention constructed using the same CMP and TMR domains, for enhancing secretion of the same target protein. Three different Fc-binding domains of three different Fc-binding proteins were used in constructing fusion proteins for co-expression in HEK293 transformants with the IL13Rα2TF-Fc target protein described previously.
(397)
(398) The amino acid sequence for the V5-tagged IL13Rα2TF-Fc target protein used in this experiment was described in in Example 2 and Table 4 above.
(399) The amino acid sequence of a CMP-TPB(gE)-TMR(KDELR) fusion protein used in this experiment was described in Example 19 and Table 36 above.
(400) Another fusion protein comprised a TPB domain comprising the Fc-binding region of the FcB6.1 protein. The FcB6.1 protein was engineered with various mutations to optimize the balance between affinity and the pH dependence of Fc-binding (Strauch et al., 2014, supra). In particular, the FcB6.1 protein bound IgG at pH 8.2 and exhibited an approximately 500-fold weaker binding at pH 5.5, where nearly complete elution of IgG was obtained when FcB6.1 was linked to chromatographic resin particles, whereas there was very little difference in Protein A binding to IgG at either pH 8.2 and pH 5.5 (Strauch et al., 2014). Accordingly, the FcB6.1 protein provided an advantageous means to purify Fc-containing proteins by affinity chromatography using much milder conditions for elution that the harsher acidic pH values required for elution from Protein A affinity columns (e.g., pH 3-pH 4), which can cause antibody and Fc-containing proteins to denature and aggregate resulting in reduced yields (Strauch et al., 2014). The amino acid sequence of a CMP-TPB(FcB6.1)-TMR(KDELR) fusion protein used in this experiment is shown in Table 38 below.
(401) TABLE-US-00048 TABLE 38 Amino Acid Sequence of a Flag-Tagged CMP-TPB(FcB6.1)- TMR(KDELR) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 154 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(FcB6.1)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(KDELR) AAAAPEEALIVVDMQRDFMPGGALPVPEGD fusion protein KIIPKVNEYIRKFKEKGALIVATRDWHPEN HISFRERGGPWPRHCVQNTPGAEFVVDLPE DAVIISKATEPDKEAYSGFEGTDLAKILRG NGVKRVYICGVATEYCVSRTAVDALKHGFE VYLLRDAVKGIKPTFEQQSFFYMSLKGIKI VQFLEGDYKDDDDKGSRNLFRFLGDLSHLL AIILLLLKIWKSRSCAGISGKSQVLFAVVF TARYLDLFTNYISLYNTCMKVVYIACSFTT VWLIYSKFKATYDGNHDTFRVEFLVVPTAI LAFLVNHDFTPLEILWTFSIYLESVAILPQ LFMVSKTGEAETITSHYLFALGVYRTLYLF NWIWRYHFEGFFDLIAIVAGLVQTVLYCDF FYLYITKVLKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 154 Linker residues 25-31 GTGSGEF of SEQ ID NO: 154 CMP sequence residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 154 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 154 TPB(FcB6.1) residues 64-243 APEEALIVVDMQRDFMPGGALPVPEGDKII Domain of SEQ ID PKVNEYIRKFKEKGALIVATRDWHPENHIS NO: 154 FRERGGPWPRHCVQNTPGAEFVVDLPEDAV IISKATEPDKEAYSGFEGTDLAKILRGNGV KRVYICGVATEYCVSRTAVDALKHGFEVYL LRDAVKGIKPTFEQQSFFYMSLKGIKIVQF Linker residues 244-246 LEG of SEQ ID NO: 154 Flag epitope residues 247-254 DYKDDDDK domain of SEQ ID NO: 154 Linker residues 255-257 GSR of SEQ ID NO: 154 TMR(KDELR) residues 258-468 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 154 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(402) Another fusion protein comprised a TPB domain comprising an Fc-binding region of the GB919 protein. The GB919 is a histidine-substituted Fc-binding mutant Protein G that was engineered to make the dissociation from bound IgG more pH sensitive in order to reduce the harsh acidic conditions (e.g., pH 3) that are normally required to elute Fc-containing proteins bound to Protein G. The mutant GB919 exhibited an Fc-binding that was more pH sensitive while increasing the affinity for IgG by a factor of 11 compared with wildtype Protein G (Watanabe et al., J. Biol. Chem., 284 (10):12373-12383 (2009)). In particular, the IgG bound to the GB919 mutant protein could be eluted at conditions more typical of using Protein A, such as pH 4.2, instead of much harsher pH, such as pH 3-3.1, required for elution from wildtype Protein G (Watanabe et al., 2009, supra). The amino acid sequence of a CMP-TPB(GB919)-TMR(KDELR) fusion protein used in this experiment is shown in Table 39 below.
(403) TABLE-US-00049 TABLE 39 Amino Acid Sequence of a Flag-Tagged CMP-TPB(GB919)- TMR(KDELR) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 155 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(GB919)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(KDELR) AAAADTYKLILNGKTLKGETTTEAVDAATA fusion protein EKVFKHYANEHGVHGHWTYDPETKTFTVTE LEGDYKDDDDKGSRNLFRFLGDLSHLLAII LLLLKIWKSRSCAGISGKSQVLFAVVFTAR YLDLFTNYISLYNTCMKVVYIACSFTTVWL IYSKFKATYDGNHDTFRVEFLVVPTAILAF LVNHDFTPLEILWTFSIYLESVAILPQLFM VSKTGEAETITSHYLFALGVYRTLYLFNWI WRYHFEGFFDLIAIVAGLVQTVLYCDFFYL YITKVLKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 155 Linker residues 25-31 GTGSGEF of SEQ ID NO: 155 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 155 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 155 TPB(GB919) residues 64-120 ADTYKLILNGKTLKGETTTEAVDAATAEKV Domain of SEQ ID FKHYANEHGVHGHWTYDPETKTFTVTE NO: 155 Linker residues 121-123 LEG of SEQ ID NO: 155 Flag epitope residues 124-131 DYKDDDDK domain of SEQ ID NO: 155 Linker residues 132-134 GSR of SEQ ID NO: 155 TMR(KDELR) residues 135-345 NLFRFLGDLSHLLAIILLLLKIWKSRSCAG Domain of SEQ ID ISGKSQVLFAVVFTARYLDLFTNYISLYNT NO: 155 CMKVVYIACSFTTVWLIYSKFKATYDGNHD TFRVEFLVVPTAILAFLVNHDFTPLEILWT FSIYLESVAILPQLFMVSKTGEAETITSHY LFALGVYRTLYLFNWIWRYHFEGFFDLIAI VAGLVQTVLYCDFFYLYITKVLKGKKLSLP A
(404) HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture media of cells expressing the IL13Rα2TF-Fc target protein alone or co-expressing the target protein and each of the three fusion proteins, i.e., CMP-TPB(gE)-TMR(KDELR), CMP-TPB(FcB6.1)-TMR(KDELR), or CMP-TPB(GB919)-TMR(KDELR). Transfected cells were cultured for two days, and samples of cell culture media were harvested and analyzed by ELISA with immobilized Protein A as a binding protein for the target protein and a peroxidase-conjugated goat anti-human IgG F(ab′).sub.2 antibody fragment (Jackson ImmunoResearch Laboratories, Product No. 109-036-098) as a detection reagent. Wells of a 96-well plate were coated with recombinant purified Protein A and incubated with culture media of transfected cells expressing IL13Rα2TF-Fc target protein alone or culture media of transfected cells co-expressing IL13Rα2TF-Fc target protein and CMP-TPB(gE)-TMR(KDELR), IL13Rα2TF-Fc target protein and CMP-TPB(FcB6.1)-TMR(KDELR), or IL13Rα2TF-Fc target protein and CMP-GB919-TMR(KDELR).
(405) The results are shown in the bar graphs in
(406) Similar to the results shown in Example 12, above, in which a CMP-TPB(gE)-TMR(VSVG) fusion protein of the invention comprising a 379 amino acid portion of the gE protein as a TPB domain (Table 28) significantly enhanced the level of secretion of a co-expressed FVII-Fc target protein, in this study, a CMP-TPB(gE)-TMR(KDELR) fusion protein of the invention comprising the same TPB(gE) domain also significantly enhanced the level of secretion of a co-expressed IL13Rα2TF-Fc target protein (bar graph 3 of
(407) The results obtained with the CMP-TPB(GB919)-TMR(KDELR) fusion protein, which comprises an Fc-binding region of the GB919 mutant protein, which was engineered to increase the pH sensitivity of Fc binding from pH 3.1 of the wildtype Protein G to pH 4.2, similar to that for the Fc-binding domain of Protein A (Watanabe et al., 2009, supra), provided an enhanced level of secretion of the co-expressed IL13Rα2TF-Fc target protein that was approximately twice the level of enhancement provided by a CMP-TPB(FcB6.1)-TMR(KDELR) fusion (compare bar graph 5 with bar graph 4 of
Example 21
Variation of TMR Domains for a Cell-Associated Secretion-Enhancing (CASE) Fusion Protein
(408) While not intending to be bound by any particular scientific theory regarding its mechanism of action, a cell-associated secretion-enhancing (CASE) fusion protein of the invention comprising a chaperone machinery polypeptide (CMP) domain is envisaged as binding at its target protein binding (TPB) domain to a nascent target protein in the endoplasmic reticulum (ER) to form a binding complex, recruiting the binding complex into the Hsp70 chaperone system of the host cell by means of its CMP domain, and releasing the bound target protein within the Golgi apparatus or secretory vesicles for secretion from the host cell while remaining associated with the host cell by means of its transmembrane retention (TMR) domain.
(409) In this example, 19 different fusion proteins comprising different transmembrane regions derived from various cell-associated proteins were examined and compared for the ability to enhance the level of secretion of the IL13Rα2TF-Fc target protein. The structural formats of the fusion proteins used in this example are diagrammed in
(410)
(411)
(412)
(413) The amino acid sequence for the V5-tagged IL13Rα2TF-Fc target protein used in this experiment was described in Example 2 and Table 4 above.
(414) The amino acid sequence of the CMP-TPB(gE)-TMR(CD4) fusion protein (No. 3) is shown in Table 40 below.
(415) TABLE-US-00050 TABLE 40 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(CD4) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 156 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(CD4) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRQPMALIVLGGVAGLLLFIGLGIFF CVRCRHRRRQAFRMSQIKRLLSEKKTCQCP HRFQKTCSPI Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 156 Linker residues 25-31 GTGSGEF of SEQ ID NO: 156 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 156 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 156 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 156 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 156 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 156 Linker residues 454-456 GSR of SEQ ID NO: 156 TMR(CD4) Domain residues 457-520 QPMALIVLGGVAGLLLFIGLGIFFURCRH of SEQ ID RRKAERMSQIKRLLSEKKICQCPHBFQKT NO: 156 CSPI
(416) The amino acid sequence of the CMP-TPB(gE)-TMR(Integrin) fusion protein (No. 4) is shown in Table 41 below.
(417) TABLE-US-00051 TABLE 41 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(Integrin) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 157 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(Integrin) AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR fusion protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRPVPVWVIILAVLAGLLLLAVLVFV MYRMGFEKRVRPPQEEQEREQLQPHENGEG NSET Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 157 Linker residues 25-31 GTGSGEF of SEQ ID NO: 157 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 157 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 157 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 157 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 157 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 157 Linker residues 454-456 GSR of SEQ ID NO: 157 TMR(Integrin) residues 457-514 PVPVWVIILAVLAGLLLLAVLVFVMYRMGF Domain of SEQ ID FKRVRPPQEEOEREOLQPHENGEGNSET NO: 157
(418) The amino acid sequence of the CMP-TPB(gE)-TMR(UGT1) fusion protein (No. 5) is shown in Table 42 below.
(419) TABLE-US-00052 TABLE 42 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(UGT1) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 158 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(UGT1) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRLDVIGFLLAVVLTVAFITFKCCAY GYRKCLGKKGRVKKAHKSKTH Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 158 Linker residues 25-31 GTGSGEF of SEQ ID NO: 158 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID NO: domain of Erdj4) 158 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 158 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID NO: QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP 158 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 158 Flag epitope residues 445-453 DYKDDDDK domain of SEQ ID NO: 158 Linker residues 454-456 GSR of SEQ ID NO: 158 TRM(UGT1) Domain residues 457-501 LDVIGFLLAVVLTVAFITFKCCAYGYRKCL of SEQ ID GKKGRVKKAHKSKTH NO: 158
(420) The amino acid sequence of the CMP-TPB(gE)-TMR(truncated KDELR) fusion protein (No. 6) is shown in Table 43 below.
(421) TABLE-US-00053 TABLE 43 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(truncated KDELR) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 159 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(truncated AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR KDELR) fusion GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK protein QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRDLIAIVAGLVQTVLYCDFFYLYIT KVLKGKKLSLPA Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 159 Linker residues 25-31 GTGSGEF of SEQ ID NO: 159 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 159 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 159 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 159 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 159 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 159 Linker residues 454-456 GSR of SEQ ID NO: 159 TMR(truncated residues 457-492 DLIAIVAGLVQTVLYCDFFYLYITKVLKGK KDELR) Domain of SEQ ID KLSLPA NO: 159
(422) The amino acid sequence of the CMP-TPB(gE)-TMR(p23) fusion protein (No. 7) is shown in Table 44 below.
(423) TABLE-US-00054 TABLE 44 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(p23) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 160 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(p23) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRTRVLYFSIFSMFCLIGLATWQVFY LRRFFKAKKLIE Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 160 Linker residues 25-31 GTGSGEF of SEQ ID NO: 160 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 160 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 160 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 160 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 160 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 160 Linker residues 454-456 GSR of SEQ ID NO: 160 TMR(p23) Domain residues 457-492 TRVLYFSIFSMFCLIGLATWQVFYLRRFFK of SEQ ID AKKLIE NO: 160
(424) The amino acid sequence of the CMP-TPB(gE)-TMR(p24) fusion protein (No. 8) is shown in Table 45 below.
(425) TABLE-US-00055 TABLE 45 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(p24) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 161 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(p24) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRSRVVLWSFFEALVLVAMTLGQIYY LKRFFEVRRVV Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 161 Linker residues 25-31 GTGSGEF of SEQ ID NO: 161 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 161 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 161 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 161 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 161 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 161 Linker residues 454-456 GSR of SEQ ID NO: 161 TMR(p24) Domain residues 457-491 SRVVLWSFFEALVLVAMTLGQIYYLKRFFE of SEQ ID VRRVV NO: 161
(426) The amino acid sequence of the CMP-TPB(gE)-TMR(LAMP2) fusion protein (No. 9) is shown in Table 46 below.
(427) TABLE-US-00056 TABLE 46 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(LAMP2) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 162 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(LAMP2) AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR fusion protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRTILIPIIVGAGLSGLIIVIVIAYV IGRRKSYAGYQTL Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 162 Linker residues 25-31 GTGSGEF of SEQ ID NO: 162 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 162 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 162 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 162 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 162 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 162 Linker residues 454-456 GSR of SEQ ID NO: 162 TMR(LAMP2) residues 457-493 TILIPIIVGAGLSGLIIVIVIAYVIGRRKS Domain of SEQ ID YAGYQTL NO: 162
(428) The amino acid sequence of the CMP-TPB(gE)-TMR(LIMP2 truncated C-terminal TMR) fusion protein (No. 10) is shown in Table 47 below.
(429) TABLE-US-00057 TABLE 47 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(LIMP2 truncated C-terminal TMR) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 163 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(LIMP2 AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR truncated C- GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK terminal TMR) QVPETVVDAACMRAPVPLAMAYAPPAPSAT fusion protein GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRTLIITNIPYIIMALGVFFGLVFTW LACKGQGSMDEGTADERAPLIRT Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 163 Linker residues 25-31 GTGSGEF of SEQ ID NO: 163 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 163 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 163 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 163 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 163 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 163 Linker residues 454-456 GSR of SEQ ID NO: 163 TMR(LIMP2 residues 457-503 TLIITNIPYIIMALGVFFGLVFTWLACKGQ truncated C- of SEQ ID GSMDEGTADERAPLIRT terminal TMR) NO: 163 Domain
(430) The amino acid sequence of the CMP-TPB(gE)-TMR(CDM6PR) fusion protein (No. 11) is shown in Table 48 below.
(431) TABLE-US-00058 TABLE 48 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(CDM6PR) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 164 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(CDM6PR) AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR fusion protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRSHLSVGSILLVTFASLVAVYVVGG FLYQRLVVGAKGMEQFPHLAFWQDLGNLVA DGCDFVCRSKPRNVPAAYRGVGDDQLGEES EERDDHLLPM Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 164 Linker residues 25-31 GTGSGEF of SEQ ID NO: 164 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 164 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 164 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 164 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 164 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 164 Linker residues 454-456 GSR of SEQ ID NO: 164 TMR(CDM6PR) residues 457-5550 SHLSVGSILLVTFASLVAVYVVGGFLYQRL Domain of SEQ ID VVGAKGMEQFPHLAFWQDLGNLVADGCDFV NO: 164 CRSKPRNVPAAYRGVGDDQLGEESEERDDH LLPM
(432) The amino acid sequence of the CMP-TPB(gE)-TMR(VSVG) fusion protein (No. 12) is shown in Table 49 below.
(433) TABLE-US-00059 TABLE 49 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(VSVG) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 165 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(VSVG) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRDDESLFFGDTGLSKNPIELVEGWF SSWKSSIASFFFIIGLIIGLFLVLRVGIHL CIKLKHTKKRQIYTDIEMNRLGK Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 165 Linker residues 25-31 GTGSGEF of SEQ ID NO: 165 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 165 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 165 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 165 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 165 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 165 Linker residues 454-456 GSR of SEQ ID NO: 165 TMR(VSVG) Domain residues 457-533 DDESLFFGDTGLSKNPIELVEGWFSSWKSS of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH NO: 165 TKKRQIYTDIEMNRLGK
(434) The amino acid sequence of the CMP-TPB(gE)-TMR(CNX) fusion protein (No. 13) is shown in Table 50 below.
(435) TABLE-US-00060 TABLE 50 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(CNX) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 166 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(CNX) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRPERMTPFSAIGLELWSMTSDIFFD NFIICADRRIVDDWANDGWGLKKAADGAAE PGVVGQMIEAAEERPWLWVVYILTVALPVF LVILFCCSGKKQTSGMEYKKTDAPQPDVKE EEEEKEEEKDKGDEEEEGEEKLEEKQKSDA EEDGGTVSQEEEDRKPKAEEDEILNRSPRN RKPRRE Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 166 Linker residues 25-31 GTGSGEF of SEQ ID NO: 166 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 166 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 166 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 166 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 166 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 166 Linker residues 454-456 GSR of SEQ ID NO: 166 TMR(CNX) Domain residues 457-636 PFRMTPFSAIGLELWSMTSDIFFDNFIICA of SEQ ID DRRIVDDWANDGWGLKKAADGAAEPGVVGQ NO: 166 MIEAAEERPWLWVVYILTVALPVFLVILFC CSGKKQTSGMFYKKTDAPQPDVKEEEEEKE EEKDKGDEEEEGEEKLEEKQKSDAEEDGGT VSQEEEDRKPKAEEDEILNRSPRNRKPRRE
(436) The amino acid sequence of the CMP-TPB(gE)-TMR(truncated CNX) fusion protein (No. 14) is shown in the Table 51 below.
(437) TABLE-US-00061 TABLE 51 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)- TMR(truncated CNX) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 167 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(truncated AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR CNX) fusion GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK protein QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRPFRMTPFSAIGLELWSMTSDIFFD NFIICADRRIVDDWANDGWGLKKAADGAAE PGVVGQMIEAAEERPWLWVVYILTVALPVF LVILFCCSG Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 167 Linker residues 25-31 GTGSGEF of SEQ ID NO: 167 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 167 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 167 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 167 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 167 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 167 Linker residues 454-456 GSR of SEQ ID NO: 167 TMR(truncated residues 457-549 PFRMTPFSAIGLELWSMTSDIFFDNFIICA CNX) Domain of SEQ ID DRRIVDDWANDGWGLKKAADGAAEPGVVGQ NO: 167 MIEAAEERPWLWVVYILTVALPVFLVILFC CSG
(438) The amino acid sequence of the CMP-TPB(gE)-TMR(gE) fusion protein (No. 15) is shown in Table 52 below.
(439) TABLE-US-00062 TABLE 52 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(gE) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 168 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(gE) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRPTHPHVGAPPHAPPTHGALRLGAV MGAALLLSALGLSVWACMTCWRRRAWRAVK SRASGKGPTYIRVADSELYADWSSDSEGER DQVPWLAPPERPDSPSTNGSGFEILSPTAP SVYPRSDGHQSRRQLTTFGSGRPDRRYSQA SDSSVFW Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 168 Linker residues 25-31 GTGSGEF of SEQ ID NO: 168 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 168 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 168 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 168 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 168 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 168 Linker residues 454-456 GSR of SEQ ID NO: 168 TMR(gE) Domain residues 457-607 PTHPHVGAPPHAPPTHGALRLGAVMGAALL of SEQ ID LSALGLSVWACMTCWRRRAWRAVKSRASGK NO: 168 GPTYIRVADSELYADWSSDSEGERDQVPWL APPERPDSPSTNGSGFEILSPTAPSVYPRS DGHQSRRQLTTFGSGRPDRRYSQASDSSVF W
(440) The amino acid sequence of the CMP-TPB(gE)-TMR(ERGIC53) fusion protein (No. 16) is shown in the Table 53 below.
(441) TABLE-US-00063 TABLE 53 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR(ERGIC53) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 169 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(ERGIC53) AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR fusion protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRLSTVHFIIFVVVQTVLFIGYIMYR SQQEAAAKKFF Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 169 Linker residues 25-31 GTGSGEF of SEQ ID NO: 169 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 169 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 169 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 169 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 169 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 169 Linker residues 454-456 GSR of SEQ ID NO: 169 TMR(ERGIC53) residues 457-491 LSTVHFIIFVVVQTVLFIGYIMYRSQQEAA Domain of SEQ ID AKKFF NO: 169
(442) The amino acid sequence of the CMP-TPB(gE)-TMR(gp84) fusion protein (No. 17) is shown in Table 54 below.
(443) TABLE-US-00064 TABLE 54 Amino Acid Sequence of a Flag-Tagged CMP-TPB(gE)-TMR (gp84) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged CMP- SEQ ID NO: 170 MALWMRLLPLLALLALWGPDPAAAGTGSGE TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(gp84) fusion AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR protein GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRLGGVLYLISLCVSLPASFARRRRL GRWQE Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 170 Linker residues 25-31 GTGSGEF of SEQ ID NO: 170 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 170 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 170 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO 170 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 170 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 170 Linker residues 454-456 GSR of SEQ ID NO: 170 TMR(gp84) Domain residues 457-485 LGGVLYLISLCVSLPASFARRRRLGRWQE of SEQ ID NO: 170
(444) The amino acid sequence of the TMR(gp73)-CMP-TPB(gE) fusion protein (No. 18) is shown in Table 55 below.
(445) TABLE-US-00065 TABLE 55 Amino Acid Sequence of a Flag-Tagged TMR(gp73)-CMP-TPB(gE) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 171 MMGLGNGRRSMKSPPLVLAALVACIIVLGF TMR(gp73)-CMP- NYWIAGTGSGEFIKKAFHKLAMKYDIGGGG TPB(gE) fusion SGGGGSGGGGSAAAGTPKTSWRRVSVGEDV protein SLLPAPGPTGRGPTQKLLWAVEPLDGCGPL HPSWVSLMPPKQVPETVVDAACMRAPVPLA MAYAPPAPSATGGLRTDFVWQERAAVVNRS LVIHGVRETDSGLYTLSVGDIKDPARQVAS VVLVVQPAPVPTPPPTPADYDEDDNDEGED ESLAGTPASGTPRLPPPPAPPRSWPSAPEV SHVRGVTVRMETPEAILFSPGETFSTNVSI HAIAHDDQTYSMDVVWLRFDVPTSCAEMRI YESCLYHPQLPECLSPADAPCAASTWTSRL AVRSYAGCSRTNPPPRCSAEAHMEPVPGLA WQAASVNLEFRDASPQHSGLYLCVVYVNDH IHAWGHITISTAAQYRNAVVEQPLPQRGAD LAELEGDYKDDDDK TMR(Gp73) Domain residues 1-35 MMGLGNGRRSMKSPPLVLAALVACIIVLGF of SEQ ID NYWIA NO: 171 Linker residues 36-42 GTGSGEF of SEQ ID NO: 171 CMP Domain residues 43-54 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 171 Linker residues 55-74 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 171 TPB(gE) Domain residues 75-453 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 171 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 454-456 LEG of SEQ ID NO: 171 Flag epitope residues 457-464 DYKDDDDK domain ref SEQ ID NO: 171
(446) The amino acid sequence of the TMR(truncated N-terminal LIMP2)-CMP-TPB(gE) fusion protein (No. 19) is shown in Table 56 below.
(447) TABLE-US-00066 TABLE 56 Amino Acid Sequence of a Flag-Tagged TMR(truncated N-terminal LIMP2)-CMP-TPB(gE) Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 172 MGRCCFYTAGTLSLLLLVTSVTLLVARVFG TMR(truncated N- TGSGEFIKKAFHKLAMKYDIGGGGSGGGGS terminal LIMP2)- GGGGSAAAGTPKTSWRRVSVGEDVSLLPAP CMP-TPB(gE) GPTGRGPTQKLLWAVEPLDGCGPLHPSWVS fusion protein LMPPKQVPETVVDAACMRAPVPLAMAYAPP APSATGGLRTDFVWQERAAVVNRSLVIHGV RETDSGLYTLSVGDIKDPARQVASVVLVVQ PAPVPTPPPTPADYDEDDNDEGEDESLAGT PASGTPRLPPPPAPPRSWPSAPEVSHVRGV TVRMETPEAILFSPGETFSTNVSIHAIAHD DQTYSMDVVWLRFDVPTSCAEMRIYESCLY HPQLPECLSPADAPCAASTWTSRLAVRSYA GCSRTNPPPRCSAEAHMEPVPGLAWQAASV NLEFRDASPQHSGLYLCVVYVNDHIHAWGH ITISTAAQYRNAVVEQPLPQRGADLAELEG DYKDDDDK TMR(truncated N- residues 1-29 MGRCCFYTAGTLSLLLLVTSVTLLVARV terminal LIMP2) of SEQ ID Domain NO: 172 Linker residues 30-36 GTGSGEF of SEQ ID NO: 172 CMP Domain residues 37-48 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 172 Linker residues 49-68 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 172 TPB(gE) Domain residues 69-447 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 172 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 448-450 LEG of SEQ ID NO: 172 Flag epitope residues 451-458 DYKDDDDK domain of SEQ ID NO: 172
(448) The amino acid sequence of the CMP-TPB(gE)-TMR(KDELR) fusion protein (No. 20) is described in the Table 36 above (Example 19).
(449) The amino acid sequence of TMR(truncated N-terminal LIMP2)-CMP-TPB(gE)-TMR (truncated C-terminal LIMP2) fusion protein (No. 21) is shown in Table 57 below.
(450) TABLE-US-00067 TABLE 57 Amino Acid Sequence of a Flag-Tagged TMR(truncated N-terminal LIMP2)-CMP-TPB(gE)-TMR(truncated C-terminal LIMP2) Fusion Protein Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 173 MGRCCFYTAGTLSLLLLVTSVTLLVARVFG TMR(truncated N- TGSGEFIKKAFHKLAMKYDIGGGGSGGGGS terminal LIMP2)- GGGGSAAAGTPKTSWRRVSVGEDVSLLPAP CMP-TPB(gE)-TMR GPTGRGPTQKLLWAVEPLDGCGPLHPSWVS (truncated C- LMPPKQVPETVVDAACMRAPVPLAMAYAPP terminal APSATGGLRTDFVWQERAAVVNRSLVIHGV LIMP2)fusion RETDSGLYTLSVGDIKDPARQVASVVLVVQ protein PAPVPTPPPTPADYDEDDNDEGEDESLAGT PASGTPRLPPPPAPPRSWPSAPEVSHVRGV TVRMETPEAILFSPGETFSTNVSIHAIAHD DQTYSMDVVWLRFDVPTSCAEMRIYESCLY HPQLPECLSPADAPCAASTWTSRLAVRSYA GCSRTNPPPRCSAEAHMEPVPGLAWQAASV NLEFRDASPQHSGLYLCVVYVNDHIHAWGH ITISTAAQYRNAVVEQPLPQRGADLAELEG DYKDDDDKGSRTLIITNIPYIIMALGVFFG LVFTWLACKGQGSMDEGTADERAPLIRT TMR(truncated N- residues 1-29 MCBCCFYTAGTLSLLLLVTSVTLLVARVF terminal LIMP2) of SEQ ID Domain NO: 173 Linker residues 30-36 GTGSGEF of SEQ ID NO: 173 CMP Domain residues 37-48 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 173 Linker residues 49-68 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 173 TPB(gE) Domain residues 69-447 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 173 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 448-450 LEG of SEQ ID NO: 173 Flag epitope residues 451-458 DYKDDDDK domain of SEQ ID NO: 173 Linker residues 459-461 GSR of SEQ ID NO: 173 TMR(truncated C- residues 462-508 TLIITNIPYIIMALGVFFGLVFTWLACKGQ terminal LIMP2) of SEQ ID GSMDEGTADERAPLIRT Domain NO: 173
(451) HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture media of IL13Rα2TF-Fc target protein. The relative amounts of secreted target protein expressed alone or co-expressed with one of the 17 different fusion proteins described above were measured by ELISA. Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by ELISA with Protein A as a binding protein for the target and peroxidase conjugated goat anti-human IgG F(ab′).sub.2 Fragment (Jackson ImmunoResearch Laboratories, 109-036-098) as the detecting reagent. 3,3′,5,5′-Tetramethylbenzidine (TMB) was used as a substrate for peroxidase and quantified on a microplate reader at 450 nm.
(452) The results are shown in the bar graphs in
(453) Each of the bar graphs in
(454) 1: Mock culture. Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein and were used as a negative control
(455) 2: IL13Rα2TF-Fc (target protein expressed in the absence of any fusion protein; positive control)
(456) 3: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(CD40)
(457) 4: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(Integrin)
(458) 5: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(UGT1)
(459) 6: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(KDELR truncated TMR)
(460) 7: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(p23)
(461) 8: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(p24)
(462) 9: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(LAMP2)
(463) 10: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(LIMP2 C-terminal TM region)
(464) 11: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(CDM6PR)
(465) 12: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(VSVG)
(466) 13: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(CNX)
(467) 14: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(CNX truncated TMR)
(468) 15: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(gE)
(469) 16: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(ERGIC53)
(470) 17: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(Gp84)
(471) 18: IL13Rα2TF-Fc+TMR(Gp73)-CMP-TPB(gE)
(472) 19: IL13Rα2TF-Fc+TMR(LIMP2 N-terminal TM region)-CMP-TPB(gE)
(473) 20: IL13Rα2TF-Fc+CMP-TPB(gE)-TMR(KDELR)
(474) 21: IL13Rα2TF-Fc+TMR(LIMP2 N-terminal TM region)-CMP-TPB(gE)-TMR(LIMP2 C-terminal TM region)
(475) Bar graphs 3, 7, 8, 9, 10, 11, 12, 15, 17, and 20 show a significant enhancement in the level of secreted IL13Rα2TF-Fc target protein when co-expressed in transfected host cells with a fusion protein that comprises an N-proximal CMP domain linked to an Fc-binding target protein binding (TPB) domain, which in turn was linked to a C-terminal transmembrane retention (TMR) domain comprising a transmembrane region of a Type I transmembrane protein compared to the level of secretion of the target protein expressed alone (bar graph 2). The exceptional results indicated in bar graph 20 may be contrasted with the results illustrated in bar graph 6, which correspond to the unexceptional secretion of target protein co-expressed with fusion protein no. 6, which was similar to construct no. 20 but had a drastically truncated KDELR transmembrane retention domain (cf. Table 36, SEQ ID NO:151, and Table 43, SEQ ID NO:159). A general diagram for a construct encoding this set of fusion proteins is shown in
(476) Bar graphs 5, 13, 14, and 16 indicate that no significant amount of the IL13Rα2TF-Fc target protein was secreted into culture medium of transfected host cells co-expressing the target protein and a fusion protein that comprised a transmembrane retention (TMR) domain comprising a transmembrane region from proteins known to reside in the endoplasmic reticulum (ER). Bar graph 5 shows the result when the IL13Rα2TF-Fc target protein was co-expressed with a fusion protein in which the TMR domain comprised a transmembrane region of human UDP-glucuronosyltransferase, which is a ubiquitous ER protein (Laakkonen et al., Mol. Pharmacol., 77: 931-939 (2010). For bar graph 13, the TMR domain of the co-expressed fusion protein comprised a transmembrane region of calnexin, which is also known to reside in the ER membrane. As shown in bar graph 14, a fusion protein comprising the amino terminal half of the same calnexin transmembrane region that was used in the fusion protein for bar graph 13 provided no improvement in the secretion of the co-expressed IL13Rα2TF-Fc target protein. Moreover, as shown in bar graph 16 of
(477) Bar graph 18 of
(478) Bar graph 21 of
Example 22
Importance of the TMR Domain on the Export of Target Protein from the Endoplasmic Reticulum (ER)
(479) Example 21 shows the importance of selecting a TMR domains that does not interfere with the procession of the fusion protein/target protein complex from the ER to the Golgi apparatus. In this example, the TMR domain of a CMP-TPB(gE)-TMR(VSVG) was engineered to contain a known ER retention sequence (dilysine motif) at its C-terminus to determine the effect of the ER retention of the fusion protein on the level of secreted target protein. The V5-tagged IL13Rα2TF-Fc target protein used in this experiment was the same as described in Example 2 and Table 4 above.
(480)
(481) The second fusion protein construct shown in
(482) The amino acid sequence of the Flag-tagged CMP-TPB(gE)-TMR(VSVG) with KK motif” fusion protein is shown in Table 58 below.
(483) TABLE-US-00068 TABLE 58 Amino Acid Sequence of a “Flag-Tagged CMP-TPB(gE)-TM1 with KK motif” Fusion Protein. Encoded Protein or Region (N- to C- Sequence Amino Acid Sequence terminal) Identifier 123456789012345678901234567890 Flag-tagged SEQ ID NO: 174 MALWMRLLPLLALLALWGPDPAAAGTGSGE CMP-TPB(gE)- FIKKAFHKLAMKYDIGGGGSGGGGSGGGGS TMR(VSVG) with AAAGTPKTSWRRVSVGEDVSLLPAPGPTGR KK motif fusion GPTQKLLWAVEPLDGCGPLHPSWVSLMPPK protein QVPETVVDAACMRAPVPLAMAYAPPAPSAT GGLRTDFVWQERAAVVNRSLVIHGVRETDS GLYTLSVGDIKDPARQVASVVLVVQPAPVP TPPPTPADYDEDDNDEGEDESLAGTPASGT PRLPPPPAPPRSWPSAPEVSHVRGVTVRME TPEAILFSPGETFSTNVSIHAIAHDDQTYS MDVVWLRFDVPTSCAEMRIYESCLYHPQLP ECLSPADAPCAASTWTSRLAVRSYAGCSRT NPPPRCSAEAHMEPVPGLAWQAASVNLEFR DASPQHSGLYLCVVYVNDHIHAWGHITIST AAQYRNAVVEQPLPQRGADLAELEGDYKDD DDKGSRDDESLFFGDTGLSKNPIELVEGWF SSWKSSIASFFFIIGLIIGLFLVLRVGIHL CIKLKHTKKRQIYTDIEMNRLGKKTC Human insulin residues 1-24 MALWMRLLPLLALLALWGPDPAAA signal sequence of SEQ ID NO: 174 Linker residues 25-31 GTGSGEF of SEQ ID NO: 174 CMP Domain residues 32-43 IKKAFHKLAMKY (peptide from J of SEQ ID domain of Erdj4) NO: 174 Linker residues 44-63 DIGGGGSGGGGSGGGGSAAA of SEQ ID NO: 174 TPB(gE) Domain residues 64-442 GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP NO: 174 ETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIHGVRETDSGLY TLSVGDIKDPARQVASVVLVVQPAPVPTPP PTPADYDEDDNDEGEDESLAGTPASGTPRL PPPPAPPRSWPSAPEVSHVRGVTVRMETPE AILFSPGETFSTNVSIHAIAHDDQTYSMDV VWLRFDVPTSCAEMRIYESCLYHPQLPECL SPADAPCAASTWTSRLAVRSYAGCSRTNPP PRCSAEAHMEPVPGLAWQAASVNLEFRDAS PQHSGLYLCVVYVNDHIHAWGHITISTAAQ YRNAVVEQPLPQRGADLAE Linker residues 443-445 LEG of SEQ ID NO: 174 Flag epitope residues 446-453 DYKDDDDK domain of SEQ ID NO: 174 Linker residues 454-456 GSR of SEQ ID NO: 174 TMR Domain residues 457-536 DDESLFFGDTGLSKNPIELVEGWFSSWKSS (VSVG) with KK of SEQ ID IASFFFIIGLIIGLFLVLRVGIHLCIKLKH motif NO: 174 TKKRQIYTDIEMNRLGKKTC
(484) HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture media of IL13Rα2TF-Fc target protein expressed alone, IL13Rα2TF-Fc target protein co-expressed with the CMP-TPB(gE)-TMR(VSVG) fusion protein, or target protein co-expressed with the CMP-TPB(gE)-TMR(VSVG) with KK motif fusion protein. Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by ELISA with Protein A as a binding protein for the target protein and peroxidase conjugated goat anti-Human IgG F(ab′).sub.2 Fragment (Jackson ImmunoResearch Laboratories, 109-036-098) for detection of immobilized target. Wells of a 96-well plate were coated with recombinant Protein A and incubated with culture media of transfected cells expressing IL13Rα2TF-Fc target protein alone, culture media of transfected cells co-expressing the target protein and the CMP-TPB(gE)-TMR(VSVG) fusion protein, or culture media of transfected cells co-expressing the target protein and the CMP-TPB(gE)-TMR(VSVG) with KK motif fusion protein. The captured target protein was then detected using the F(ab′)2 fragment reagent.
(485)
(486) The results show that the presence of the dilysine ER retention signal abolished the secretion enhancing activity of the fusion protein. The results are consistent with those shown in Example 10 for a CASE fusion protein of the invention comprising the same TPD and TMR domains, but lacking a CMP domain. These results indicate that for a fusion protein of the invention to enhance secretion of a co-expressed target protein, the TMR domain of the fusion protein must be able to function and associate with the membrane of the intracellular secretory pathway without being retained in the ER. Accordingly, as a general principle, a transmembrane region useful as a TMR domain in a cell-associated secretion-enhancing fusion protein of the invention should not comprise a C-terminal dilysine (KK) motif or any other signal or sequence known to localize a transmembrane protein in the ER.
(487) All patents, applications, and publications cited in the above text are incorporated herein by reference.
(488) Other variations and embodiments of the invention described herein will now be apparent to those of skill in the art without departing from the disclosure of the invention or the claims below.